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Abstract  
c-Kit, a receptor tyrosine kinase, interacts with Stem Cell Factor (SCF), mediating cell 
differentiation, function, and survival. c-Kit is critical for the development and maintenance 
of beta-cell function in both rodents and humans. The mutation of c-Kit at W locus (c-KitWv/+) 
in mice results in an early onset of diabetes. However, the underlying mechanisms by which 
c-Kit deficiency leads to beta-cell failure are unknown. Therefore, studying SCF/c-Kit 
downstream signaling pathways is essential to understanding the precise mechanism by 
which c-Kit regulates beta-cell survival and function in vivo. 
We identified that dysregulated Akt/Glycogen synthase kinase 3β (Gsk3β)/cyclin D1 
pathway, downstream of c-Kit, is responsible for reduced beta-cell proliferation, leading to a 
severe loss of beta-cell mass in c-KitWv/+ mice. An up-regulation of Fas-mediated caspase-
dependent apoptotic machinery is also associated with beta-cell death in c-KitWv/+ mouse 
islets. The loss of functional Fas (lpr mutation) reversed beta-cell apoptosis and dysfunction 
in c-KitWv/+;Faslpr/lpr double mutant mice, demonstrating that a balance between c-Kit and Fas 
signaling is critical for beta-cell survival and function. To further delineate the primary 
functional role of c-Kit in beta-cells, we developed a transgenic (c-KitβTg) mouse model 
with beta-cell specific c-KIT overexpression. c-KitβTg mice exhibited increased beta-cell 
mass with improved insulin secretion, which is mediated by up-regulation of 
Akt/Gsk3β/cyclin D1 pathway. c-KIT overexpression in beta-cells not only protected islet 
function from 4 weeks of high-fat-diet (HFD) challenge, but also recused the onset of 
diabetes observed in c-KitWv/+ mice. We also found that c-Kit signaling plays a critical role in 
islet vascularization. c-Kit mediates VEGF-A production via the Akt/mTOR pathway in vivo. 
c-KIT overexpression in beta-cells rescued the islet vascular defects in c-KitWv/+ mice. 
However, under long-term HFD challenge, c-KitβTg mouse islets displayed dilated vessels 
with reduced beta-cell mass and increased beta-cell apoptosis. The observed beta-cell failure 
was likely associate with expanded islet vasculature causing increased islet inflammatory 
response. 
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In conclusion, this series of studies represent an integrated in vitro and in vivo approach 
aimed at unraveling the cellular mechanisms by which SCF/c-Kit regulates beta-cell survival 
and function.  
Keywords 
c-Kit, Stem Cell Factor, diabetes, pancreas, islet, beta-cell survival and insulin secretory 
function, islet vasculature, glucose metabolism 
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1.1 Significance of the study 
The incidence of diabetes mellitus is rising globally. One major cause behind the 
progression of diabetes is the decline in pancreatic beta-cell mass and function. 
Repopulating insulin-producing cell-based therapy remains a highly promising 
therapeutic modality that could provide the solution for treating diabetes. Donor islet 
availability is limited, so a greater understanding of how cellular machinery maintains 
islet function and survival is needed. c-Kit, a receptor tyrosine kinase (RTK), plays an 
important role in mediating islet cell neogenesis, proliferation, differentiation, and 
function. The objective of this work is to determine the intracellular mechanisms of c-Kit 
and its ligand, Stem Cell Factor (SCF), in regulating beta-cell survival and function in 
both physiological and pathological settings. The resulting data from this work will 
contribute to new and more physiologically relevant cell replacement therapies for 
treating diabetes.  
1.2 Pancreas and islet of Langerhans 
1.2.1 Pancreas 
The pancreas is a glandular organ that consists of two major functional compartments: 
exocrine and endocrine. The exocrine pancreas constitutes almost 99% of the total 
pancreatic mass and is comprised of acinar cells and ducts. Acinar cells release pancreatic 
juices containing protease, lipases, and amylases to assist in the digestion and absorption 
of nutrients in the small intestine. The pancreatic ducts join to the common bile duct, 
which transports the pancreatic juices to the duodenum. The endocrine pancreas is 
comprised of the islets of Langerhans, and account for only 1-2% of the total pancreatic 
mass. Islets possess a remarkable architecture and varying levels of cellular organization 
across different species. In rodents, five primary endocrine cell types are found within 
islets: insulin-producing beta-cells are the major endocrine cell population in the core of 
islets (60-80%), and are surrounded by the glucagon-secreting alpha-cells (15-20%). The 
remaining 5% of endocrine cells are somatostatin-secreting delta-cells, pancreatic 
polypeptide-secreting F-cells, and ghrelin-secreting epsilon-cells, which appear as single 
cells or in small groups that are scattered within islets. The levels of glucose in the blood 
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are rapidly and precisely regulated by hormone production from islets [1, 2]. Thus, islet 
dysfunction is central to the development of hyperglycemia, and multiple efforts have 
been made to improve islet survival and function.  
1.2.2 Pancreas development in rodents 
The development of the pancreas is conserved among species, and the mouse model has 
been a powerful research tool for examining pancreatic organogenesis. In rodents, the 
pancreas begins to develop from the mid-gut endoderm on embryonic day e8.5 [3, 4]. 
The ‘primary transition’ commences when the dorsal bud develops in proximity to the 
notochord at e9.5, and the ventral bud grows as the pancreatic epithelium evaginations 
derivate at e10.25. The twisting of the gut tube brings the dorsal and ventral buds 
together in close proximity, which leads to projections of the epithelium invading into 
surrounding mesenchyme at approximately e12.5 [3]. The first wave of the pancreatic 
endocrine differentiation begins during the primary transition. Endocrine cells that co-
express both glucagon and insulin are first visible at e9.5 in the dorsal pancreas. Ghrelin- 
and somatostatin-expressing cells begin to appear between e9.5 and e12.5 at the tip of the 
dorsal pancreas, and a few pancreatic polypeptide-expressing cells clustered in the ventral 
pancreas are seen at e11.5 [3]. Following the primary transition, the pancreatic epithelium 
undergoes a massive wave of expansion and differentiation, marking the ‘secondary 
transition’. During this transition, the pancreatic primordium branches off, differentiates, 
and commits to an endocrine or exocrine pancreatic lineage. This indicates the second 
wave of the pancreatic endocrine cell differentiation, with the majority differentiating 
into beta-cells or alpha-cells. This is followed by the expansion and maturation of 
epsilon-cells, delta-cells, and F-cells [3]. Mature islet aggregates with capillaries form 
during the third transition, and the endocrine pancreas continues to mature, expand, and 
remodel until the end of the third postnatal week [1, 3-5]. 
1.2.3 Morphogenesis signals in islet development 
The morphogenesis of the pancreas relies on inductive signals from the notochord. 
Specifically, growth factor activin-β and fibroblast growth factor-2 from the notochord 
repress expression of the sonic hedgehog (Shh) morphogen in the primitive gut endoderm 
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[6]. Inhibition of Shh signaling promotes pancreatic and duodenal homeobox 1 (Pdx-1) 
expression at e8.5, marking the onset of the pancreas development [7]. Following Pdx-1 
expression, Pancreas transcription factor (Ptf1a) and Homeobox transcription factor 
(Hlxb9) appear, which are required for ventral and dorsal pancreas formation, 
respectively. The initial step that specifies pancreatic endocrine cell fate occurs with the 
expression of the bHLH transcription factor Neurogenin 3 (Ngn3) at e9-9.5 [8]. Mice 
lacking Ngn3 expression failed to develop any endocrine cells [9]. Ngn3-expressing islet 
progenitors adopt the pancreatic endocrine cell fate with a specific combinations of 
lineage-determining transcription factors. In brief, alpha-cell fate is primarily specified by 
the appearance of aristaless related homebox, and subsequent expression of brain 4, V-
maf musculoaponeurotic fibrosarcoma oncogene homolog B, and paired box protein 6 
(Pax6) [8]. In contrast, beta-cell phenotype is determined by transient expression of 
paired box protein (Pax4), which is followed by the appearance of V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), NK2 homeobox 2 (Nkx 
2.2), NK6 homeobox 1 (Nkx 6.1), Pax6, and Pdx-1 [8]. Many transcription factors, such 
as Pdx-1 and Pax6, appear to serve dual functions in determining the specification of 
endocrine cell lineage and in maintaining the phenotype and function of islet cells. Thus, 
loss of these transcriptional regulators correlates with defective pancreatic endocrine cells 
growth and function, and later corresponding manifestation of impaired glucose 
homeostasis. 
1.2.4 Vasculature in the pancreas and the pancreatic islets 
Blood vessels play an important role in pancreatic development. During the primary 
transition, most of the vessels in the early budding pancreas are not perfused; this 
provides non-nutrient cues to the developing pancreas. There is emerging evidence 
showing that the maintenance of Pdx-1, induction of Ptf1A, and subsequent pancreatic 
budding depends on signals from embryonic aortic endothelial cells [4, 10-12]. Blood 
vessels also appear to provide nutrient cues to trigger pancreatic growth from e14.5-15 
onward [12]. Blood perfusion in vessels is coordinated with rapid pancreas branching and 
endocrine cell differentiation during the second transition. The capillary network also 
plays an important role in islet survival and function. The vasculature in the endocrine 
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pancreas is five-fold denser than in the exocrine pancreas [13]. Likewise, islets receive 
10% of total pancreatic blood flow, and their vessels are approximately ten times more 
fenestrated than the exocrine pancreas [14]. The denser capillary networks correlate with 
high vascular endothelial growth factor (VEGF) production from beta-cells. Beta-cells 
exclusively express the soluble, diffusible splice-forms of VEGF-A 120, VEGF-A 164, 
and VEGF-A 188. VEGF-A 164 (the predominant form) has the highest bioavailability 
and biological potency [5, 8, 15]. As demonstrated in mouse models, VEGF-A acts as a 
messenger to maintain the intimate connection between islet endocrine cells and blood 
vessels. The dense islet capillary network supplies beta-cells with a nutrient filled 
environment necessary for survival and function. In return, constitutive release of VEGF-
A by beta-cells promotes endothelial cell recruitment and maintains the integrity of islet 
vasculature. Overall, the efficient communication between blood and beta-cells is 
essential for the precise glucose sensing and systemic circulation of pancreatic hormone 
[16]. Thus, disturbance of VEGF-A signaling can lead to abnormal vasculature in islets, 
and ultimately affects beta-cell survival and function resulting in impaired glucose 
homeostasis. 
1.2.5 Pancreatic beta-cell mass 
Pancreatic beta-cell mass is determined by neogenesis, proliferation of pre-existing beta-
cells, and apoptosis [17]. In rodent pancreatic development, the major expansion of beta-
cells occurs during secondary transition and involves a rapid daily doubling of the beta-
cell population. Neogenesis accounts for almost 80% of new beta-cells formed, whereas 
only a fraction (10-20%) of beta-cell growth is attributed to beta-cell proliferation [17]. 
Newly formed islet clusters appear adjacent to or are embedded in the ducts, suggesting 
that the islet cell precursors are a subpopulation found within the ducts or harboured in 
the ducts [17]. In contrast to gestational stages in rodents, beta-cell mass expansion only 
occurs at a rate of 2-3% per day [17], consisting of a transient surge in beta-cell 
neogenesis within the first week, and proliferation after the first week of birth in neonatal 
rodent pancreas [17]. Loss of some beta-cell mass due to apoptosis is seen around 
weaning age during the postnatal remodelling period. In the adult rodent pancreas, the 
mitotic rate of beta-cells slows down due to the limited proliferative capacity of the 
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terminally differentiated endocrine cells. The turnover rate is less than 0.25% beyond 3 
months of age [17, 18]. Interestingly, beta-cells retain a remarkable degree of plasticity in 
response to a variety of stresses, including pregnancy, obesity, and insulin resistance. 
Under these scenarios, a robust beta-cell mass compensation is seen in an attempt to 
maintain insulin production and subsequent euglycemia. However, the underlying 
mechanism(s) by which beta-cells maintain their own survival and proliferation is (are) 
not fully determined.  
1.2.6 Pancreatic beta-cell insulin secretion  
The Insulin genes in rodents form a two-gene system in which Insulin I was retroposed 
from the partially processed mRNA of Insulin II. These two Insulin genes are located on 
different chromosomes, with Insulin I on chromosome 7, and Insulin II on chromosome 
19 in mice [19]. This is in contrast to humans, in which one copy of the INSULIN gene 
was found on chromosome 11 [19]. Preproinsulin gene I (Insulin I) is a rodent specific 
retrogene that contains only one intron homologous to the first intron of Preproinsulin 
gene II (Insulin II). Insulin II is an ortholog to the INSULIN gene in humans that has three 
exons and two introns. Insulin production involves multiple intermediate steps. 
Preproinsulin is a large precursor translational product of either Insulin I or Insulin II, and 
it contains the N-terminal signal peptide, B chain, C-peptide, and A chain. Preproinsulin 
is rapidly cleaved to proinsulin by signal peptidases, which remove the signal peptide 
from its N-terminus. The modification of proinsulin to insulin is a relatively slow 
process, which comprises both the conversion of proinsulin to insulin in the Golgi 
apparatus, and the sorting out of insulin polypeptides on their way from the rough 
endoplasmic reticulum (ER) to the storage secretory granules [19]. Mechanically, 
proinsulin together with the proteolytic enzymes is stored in trans Golgi vesicles 
surrounded by a cisternae membrane that contains the adenosine triphosphate (ATP)-
dependent proton pump. As ATP increases due to glucose metabolism in beta-cells, the 
proton pump transports H+ into the trans Golgi vesicles. The acidic proteolytic enzymes 
are activated, and the C-peptide is cleaved from the A and B chains of insulin [20]. 
Mature insulin and cleaved C-peptides are then packaged into secretory granules for 
release into circulation.  
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Insulin is exclusively secreted by beta-cells in response to changes in blood glucose 
levels [21]. In rodents, insulin secretion occurs along a biphasic time course [22]. The 
first phase lasts approximately 10 minutes, peaking 5 minutes following glucose 
stimulation. The second phase is characterized by a prolonged slow release, which lasts 
until the blood glucose level returns to normal. Glucose transporter 2 (Glut2) is involved 
in metabolic glucose sensing by mediating glucose transport into rodent beta-cells. 
Subsequently, glucose is phosphorylated by the rate-limiting enzyme glucokinase, and is 
further metabolized to produce ATP via the mitochondrial tricarboxylic acid cycle in the 
mitochondria. Increased ATP: adenosine diphosphate ratio causes the closure of ATP-
sensitive potassium channels. The increasing concentration of intracellular potassium 
ions in beta-cells leads to beta-cell depolarization, which triggers calcium influx from 
opened voltage-gated calcium channels. There is emerging evidence showing that the 
first phase of insulin secretion depends on the rapid and marked elevation of intracellular 
calcium level in beta-cells, and corresponds to the release of insulin granules from a 
readily releasable pool within 5 minutes of glucose stimulation. The second phase of 
insulin secretion requires paracrine signals other than the intracellular calcium rise, 
including the amplification of glucose and insulin that may serve to replenish the pool of 
granules that are releasable at the prevailing intracellular calcium level. 
1.3 Diabetes mellitus and current therapies 
Diabetes mellitus is a chronic metabolic disease that occurs when the body is either 
unable to sufficiently produce or properly use insulin. It is widely recognized as an 
epidemic in Canada. There are currently more than 9 millions Canadians living with 
diabetes or prediabetes [23]. The prevalence of diabetes translates into a huge economical 
burden for Canadian society. It is estimated that the total health care costs associated with 
diabetes is expected to increase to over 8 billion dollars annually by the year 2016 [23]. 
There are two major forms of diabetes. It is estimated that 5% to 10% of diabetic 
Canadians have type 1 diabetes mellitus (T1D), while 90% to 95% have type 2 diabetes 
mellitus (T2D) [23]. T1D, once known as ‘juvenile diabetes’ or ‘insulin dependent 
diabetes’, is characterized by an absolute deficiency of beta-cells due to an autoimmune 
attack, resulting in an insufficient supply of insulin that is unable to maintain euglycemia 
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[23]. In contrast, T2D, also referred to as ‘non-insulin-dependent diabetes’, is a metabolic 
disorder that occurs when there is insufficient insulin production to compensate for 
growing systemic insulin resistance [23]. The high secretory demand in overt 
hyperglycemia results in progressive deterioration of beta-cell function and induction of 
beta-cell apoptosis. Thus, beta-cell failure is regarded as the primary cause of both forms 
of diabetes.  
1.3.1 Type 1 diabetes mellitus 
T1D is an autoimmune disorder, meaning patients often exhibit features reflective of an 
immunological contribution to the disease. In most cases, genetic predisposition 
associated with the immune system plays a huge role in the onset of T1D. The region of 
the human leukocyte antigen (HLA) complex in T1D patients and non-obese diabetic 
mice is highly linked to T1D susceptibility. The majority of T1D patients carry HLA-
DR3 and HLA-DR4, with around 30% being DR3/DR4 heterozygous [24]. Beyond the 
HLA, the variable number of tandem repeats (VNTR) located upstream of the Insulin 
gene is the second most susceptible region to T1D. Short VNTR confers high risk for 
T1D [25]. Other non-HLA genes associated with T1D are cytotoxic T lymphocyte (CTL) 
associated-4 and PTPN22. CTL associated-4 encodes a molecule that plays a regulatory 
role in T-cell functionality [26], and the PTPN22 phosphatase is thought to influence 
immune responsiveness [27]. The genes that confer a risk to T1D may also play an 
important role in beta-cell death.  
Mechanistically, beta-cells develop specific autoantigens expressed as peptide-major 
histocompatibility complexes. This portends the development of activated CTLs and 
autoreactive helper T-cells (including CD8+ and CD4+ T-cells) capable of destroying 
beta-cells. Beta-cells can be selectively killed by the immune system via multiple 
pathways including: 1) activation of death receptor, 2) perforin and granzyme B released 
by CD8+ T cells, and 3) interleukin-1 β (IL-1β). Activation of death receptors including 
Fas and tumor necrosis factor alpha (TNFα) receptors has also been implicated in beta-
cell destruction in T1D [28]. While Fas receptor (Fas) expression is negligible in healthy 
islets, up-regulated Fas expression on beta-cells could be triggered by exposure to 
cytokine IL-1β. Extrinsic caspase 8 apoptotic pathway is mediated by the interaction 
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between Fas and Fas ligand (FasL), which contributes to beta-cell destruction in the 
progression of T1D. Perforin and granzyme B represent an alternative pathway of beta-
cell apoptosis in T1D [28]. Perforin released by CTLs are able to integrate into the beta-
cell membrane forming pores for granzyme B infiltration. Granzyme B is able to enter 
the cell and cleave multiple apoptotic proteins, including Bid, to activate apoptosis [29]. 
Additionally, IL-1β is detectable in islets, and confers another avenue in mediating beta-
cell destruction in T1D. In rodent models, injection of recombinant IL-1β induced 
transient hyperglycemia, and high doses of IL-1β accelerated the onset of diabetes [30]. 
Furthermore, neutralization of IL-1β was able to delay and reduce diabetes in non-obese 
diabetic (NOD) mice [31].  
1.3.2 Type 2 diabetes mellitus 
T2D is characterized by beta-cell failure, hyperinsulinemia, and hyperlipidemia. There is 
emerging evidence showing that T2D stems from interactions between genetic 
predisposition and environment, including obesity. Genetically, calpain-10, a member of 
a ubiquitously expressed family of cysteine proteases, is associated with a high risk of 
T2D. About 30% of the T2D population is associated with this locus [32]. Obesity is 
associated with peripheral insulin resistance and systemic inflammation. In obese people, 
increased beta-cell mass and insulin secretion is required to compensate for the metabolic 
demand. A failure of this compensatory increase results in beta-cell dysfunction and 
insulin resistance, and eventually a loss of beta-cell mass during the course of T2D. 
Compared to weight-matched control subjects, a 40-60% loss of beta-cell mass is also 
found in T2D subjects, and at least 40% of the beta-cell mass is reduced in pre-diabetic 
patients [33]. Multiple proposed pathogenic mechanisms are responsible for beta-cell 
failure during the progression of T2D, including: 1) glucose toxicity, 2) beta-cell 
exhaustion, 3) lipotoxicity, and 4) pro-inflammatory cytokine. Glucose toxicity implies a 
direct effect of elevated blood glucose levels, which impairs beta-cell health via various 
mechanisms, such as Fas-mediated beta-cell apoptosis [34], toxic reactive oxygen species 
production from mitochondria [35], or induction of the pro-apoptotic protein TXNIP [36] 
and Bcl family members [37]. Beta-cell exhaustion is another proposed mechanism based 
on an indirect effect of hyperglycemia to impair beta-cell function by causing a 
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nonsustainable compensatory increase in insulin secretion. Increased beta-cell workload 
could result in an increase of misfolded protein production, and activation of the unfolded 
protein response in the ER and Golgi apparatus [38, 39]. Subsequently, an accumulation 
of these misfolded proteins can trigger beta-cell failure in T2D. There has been interest in 
examining excess fatty acids such as palmitate, as they may have toxic effects on beta-
cell function and viability via the generation of ceramide and reactive oxygen species. 
Indeed, previous studies have demonstrated that palmitate is able to trigger beta-cell 
apoptosis via activation of caspase-mediated mitochondrial dysfunction and reduction of 
Bcl pro-survival proteins. Moreover, palmitate negatively impacts proinsulin’s 
conversion to mature insulin by an induced calcium-dependent degradation of 
carboxypeptidase E [38]. Furthermore, palmitate has been demonstrated to impair the 
secretory pathways by partially depleting ER calcium stores [39]. Finally, considerable 
data supports that pro-inflammatory cytokines and immune cell infiltration of the islet are 
potential underlying mechanisms contributing to beta-cell failure in T2D. An elevated 
production of IL-1β can be detected in islets exposed to high glucose levels and 
hyperlipidemia. The induced local islet inflammation recruits subsequent islet infiltration 
by macrophages to promote beta-cell apoptosis [40]. There is emerging evidence that 
cytokines, such as IL-1β and TNFα, promote the production of NO, leading to depleted 
calcium influx into the ER, which in turn promotes ER stress mediated beta-cell 
apoptosis [41]. 
1.3.3 High-fat diet induced diabetes in C57BL/6J mice 
Obesity represents a major risk factor, and often precedes the onset of T2D. In diabetes 
research, syndromes resembling T2D have been identified in obese C57BL/6J mice. 
Several genetic factors contained in the C57BL/6J background allow these mice to 
develop diabetes in a manner analogous to most cases of T2D in humans through dietary 
manipulation [42]. C57BL/6J mice fed with food enriched in fat spontaneously developed 
obesity along with hyperinsulinemia, hyperglycemia, and hypertension. However, lean 
C57BL/6J mice remain euglycemic when fed a normal diet. Noticeable weight gain is 
observed after 2 weeks of high-fat diet (HFD), and hyperglycemia usually develops 
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within 4 weeks of HFD [43], and the full manifestation of diet-induced diabetes develops 
after 16 weeks of HFD, with 20-30% weight gain, compared to normal diet-fed mice. 
1.3.4 Diagnosis of diabetes and current therapies 
Blood tests are used to diagnose diabetes and prediabetes, and the amount of glucose in 
the blood is measured in mmol/L. There are different tests that can be used for a  
diagnosis, including 1) a glycated hemoglobin (A1C) test; 2) fasting and/or random 
plasma glucose tests; or 3) an oral glucose tolerance test. The hemoglobin A1C (HbA1c) 
is a form of hemoglobin that is formed in a non-enzymatic glycation pathway by its 
exposure to plasma glucose. It is an indication of the average plasma glucose 
concentration over prlonged periods of time (the past 3 months). If a patient has test 
results of HbA1c ≥6.5%, fasting plasma glucose ≥7.0 mmol/L, or 2-hour plasma glucose 
in a 75g oral glucose tolerance test ≥11.1 mmol/L, they are diagnosed with diabetes.  
T1D patients require lifelong intensive insulin therapy. Most of them require two or more 
daily injections of insulin. In contrast, patients with T2D are usually obese, and therefore 
the first line of treatment includes diet modification and physical activity, with the end 
goal of weight management. If the blood glucose levels remain high, medications that 
increase peripheral insulin sensitivity and secretion are usually advised.  Over a decade 
ago, the Edmonton Islet Transplantation Protocol created a new era of therapeutic 
promise for treating T1D diabetic patients with islet cell replacement. The success of this 
protocol was driven by a low risk of morbidity and hypoglycemia, normalization of 
glycosylated hemoglobin values, and sustained freedom from the need for exogenous 
insulin [44-46]. Unfortunately, many problems accompanied this success, including the 
shortage of cadaver islets and gradual loss of function and/or viability of transplanted 
islets due to immunosuppressive drug toxicity [45, 46]. These obstacles have limited islet 
cell replacement therapy for wide scale application [46]. For these reasons, an 
extraordinary amount of research is currently underway to search factors that promote 
beta-cell development and maintain beta-cell function and survival in the pancreas. One 
such factor currently being researched is c-Kit. Accumulating evidence from recent 
studies and the present work has demonstrated the prominent role of c-Kit in the 
formation of the islet of Langerhans. More importantly, c-Kit is a marker and 
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maintenance factor for putative pancreatic stem/progenitor cells, and activation of c-Kit 
signaling modulates beta-cell survival and function in normal and diabetic settings. 
1.4 c-Kit and Stem Cell Factor 
1.4.1 Structure of c-Kit and Stem Cell Factor 
c-Kit is a cellular homologue of the v-Kit oncogene, found to be encoded by the W locus 
on chromosome 4 (4q11-21) in humans, and on chromosome 5 in rodents [47]. c-Kit is a 
member of the type III group of RTKs. The receptor structure and sequence within the 
kinase domain of c-Kit is closely related to Platelet-Derived Growth Factor Receptor 
(PDGFR), macrophage colony-stimulating factor receptor, and Fms-like tyrosine kinase 3 
[48-51]. Structurally, c-Kit is characterized by the presence of an extracellular region 
comprised of five Ig-like domains, a single spanning transmembrane region, and a 
cytoplasmic region containing a hydrophilic kinase insert domain (Figure 1-1A). The 
specificity of c-Kit for binding Stem Cell Factor (SCF) depends on the concave surface of 
the ligand-binding pocket formed by the first three domains. The fourth and fifth domains 
play a critical role in c-Kit monomer positioning and dimerization [52]. The intracellular 
portion of c-Kit constitutes a juxtamembrane domain with an ATP-binding region, a 
phosphotransferase region split into two domains by a kinase insert, and a COOH-
terminal tail. Most of the phosphorylation sites are located in the cytoplasmic region and 
are important in the transduction of intracellular activation signals. 
Production of c-Kit is regulated at the mRNA level in both humans and rodents. 
Transcriptional regulation gives rise to two main isoforms, distinguished by the presence 
or absence of an in-frame insertion of a four amino acid sequence, Gly-Asn-Asn-Lys 
(GNNK), in the extracellular compartment [53-55]. Both isoforms of c-Kit are co-
expressed in most tissues, with the dominant form lacking the GNNK (GNNK(-)) 
isoform [56]. Although receptor affinity to SCF is identical between both isoforms, there 
is a profound difference in the kinetics of receptor phosphorylation and signal 
transduction in the different isoform types. For instance, the GNNK(-) isoform of c-Kit 
displays rapid receptor phosphorylation, internalization, and degradation compared to the 
GNNK(+) isoform. Upon c-Kit phosphorylation, activation of both the extracellular 
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signal-regulated kinases (ERK) and phosphoinositide 3-kinase (PI3K) pathways are 
stronger in GNNK(-) expressing cells, as opposed to cells expressing the GNNK(+) 
isoform [57, 58]. 
SCF is a ligand for c-Kit and is a product of the Sl locus, mapped to chromosome 12 in 
humans and 10 in rodents [59]. There are six known SCF transcripts in humans, and four 
in rodents. Two alternative transcripts (220 and 248) are predominantly expressed (Figure 
1-1B). Both transcripts encode for membrane-bound SCF (mSCF), constituting an 
extracellular domain, a transmembrane domain, and an intracellular region. In humans, 
SCF 248 contains a proteolytic cleavage site at exon 6, possibly accelerating the 
production of soluble SCF (sSCF) 165 by posttranscriptional modification. In contrast, 
both SCF 220 and 248 can be cleaved at exon 7 to generate the soluble from of SCF in 
rodents [60, 61]. Dimerization in mSCF makes it more biologically active than the 
monomeric form [16], but most sSCF proteins exist as monomers under physiological 
conditions [62]. Both mSCF and sSCF are considered biologically active, but with 
differential effects on c-Kit signal transduction in target cells [63, 64]. It is now apparent 
that mSCF results in persistent activation and a prolonged c-Kit lifespan, whereas sSCF 
induces transient receptor activation and enhances receptor degradation.  
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Figure 1-1. Structure of c-Kit and Stem Cell Factor (SCF). 
(A) c-Kit has extracellular, transmembrane, and intracellular regions. The 
extracellular region consists of five Ig-like domains. The transmembrane region 
keeps c-Kit attached to the cell membrane. The intracellular region contains two 
kinase domains split into two parts by the kinase insert domain. (B) The soluble SCF 
165 is generated by cleavage of membrane-bound SCF (220 or 248). The primary 
proteolytic cleavage sites are indicated by the arrows. 
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1.4.2 SCF/c-Kit signaling pathways  
Receptor activation: c-Kit exists as a monomer on the cell membrane and SCF drives the 
formation of c-Kit homodimerization by binding to the first three Ig-like domains of the 
c-Kit monomers [65]. The subsequent interaction between Ig-like domain 4 and domain 5 
in adjacent c-Kit monomers further stabilizes c-Kit dimerization, allowing for positioning 
and efficient trans-phosphorylation of cytoplasmic kinases [66-68]. The juxtamembrane 
domain plays a critical role in regulating c-Kit activity [69]. SCF stimulation promotes 
the release of the juxtamembrane domain from the activation loop, enabling catalytic 
function of the tyrosine kinase to convey its downstream signaling transduction [70, 71].  
Molecular signal transduction: To date, nine tyrosine phosphorylation sites have been 
identified in c-Kit (Figure 1-1A). Trans-phosphorylation proceeds on the tyrosine kinase 
residues, which act as docking sites for signaling molecules containing the v-src avian 
sarcoma (Src) homology 2 domain and phosphotyrosine-binding domain. c-Kit 
phosphorylated at Y721 and Y900 activates the PI3K pathway, resulting in cell survival 
and proliferation (Figure 1-2) [72-74]. Phosphorylation of c-Kit at Y703 and Y936 
activates the mitogen-activated protein (MAP) kinase pathway (Figure 1-2) [75]. The 
MAP kinases can act on transcription factors to affect gene transcription and proliferation 
[65]. c-Kit phosphorylation at Y568, Y570, and Y936 activates the Src pathway, which is 
associated with cell adhesion and cell motility (Figure 1-2) [76, 77].  Src also converges 
with the PI3K and MAP kinase pathways, as well as the janus kinase and signal 
transducers and activators of transcription (JAK/STAT) pathway [65, 78, 79]. The 
phospholipase c-gamma (PLC-γ) pathway can interact with tyrosine kinase residue Y730 
of c-Kit [80], and was found to be important for suppressing cellular apoptosis (Figure 1-
2) [81, 82]. There is also evidence indicating that SCF/c-Kit signaling pathways are not 
simple linear reactions. Indeed, integrated inputs from different pathways determine the 
biological consequences in different cellular contexts. This is accomplished by c-Kit 
cross-talking with other receptors, including erythropoietin receptor or interleukin 
receptors, to recruit common signaling molecules, such as PI3K, MAP kinase, 
JAK/STAT, and PLCγ, so that multiple physiological responses may be amplified [83-
87].  
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Receptor down-regulation: A tight regulation of c-Kit signaling is crucial for proper 
cellular functions. Attenuation of c-Kit signaling can be achieved by several routes, 
including receptor internalization, tyrosine dephosphorylation, and kinase domain 
inactivation by serine phosphorylation. Phosphorylation at sites Y568 and Y936 and 
association with the E3 ubiquitin ligase c-Cbl is required for c-Kit internalization [76, 88, 
89]. Studies have demonstrated that suppression of cytokine signaling proteins SOCS1 
and SOCS6 negatively regulate c-Kit signaling by endocytosis and subsequent lysosomal 
degradation [90, 91]. In addition, negative feedback regulation contributes to c-Kit down-
regulation: stimulation of ligand binding to c-Kit increases protein kinase C activity, 
which negatively regulates kinase activity by phosphorylating serine residues S741 and 
S746 of c-Kit. This results in shedding of the c-Kit extracellular domain from the cell 
surface [65, 92-95]. Furthermore, the adaptor protein, Lnk, preferentially binds to 
phosphorylated Y567 in the c-Kit juxtamembrane domain, mediating inhibition of c-Kit 
activity [96]. c-Kit signaling can also be regulated by tyrosine phosphatases, including 
SHP-1, even in the absence of SCF [97].     
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Figure 1-2. c-Kit signaling pathways. 
The MAPK pathway (blue) regulates gene transcription and proliferation. PI3K 
signaling (green) plays an important role in cellular proliferation, survival and 
adhesion. PLCγ and JAK/Stat pathways (orange) are implicated in proliferation and 
differentiation. Shp-1, c-Cbl, SOCs and PKC signal (brown) are involved c-Kit 
down-regulation. sSCF: soluble Stem Cell Factor; mSCF: membrane-bound Stem 
Cell Factor.  
20 
 
1.4.3 SCF/c-Kit function in organ development 
c-Kit-mediated signal transduction governs proliferation, survival, and adhesion in 
hematopoietic stem cells (HSCs), mast cells, and dendrite cells. The mechanism involved 
in this phenomenon is suppression of cell apoptosis through either activation of anti-
apoptotic genes, such as Bcl-2, or inactivation of pro-apoptotic genes, such as Bad via the 
PI3K pathway. SCF functions as a chemotactic factor for HSCs [98]. Cell adhesion, a 
process SCF is known to play a role in, is required for the maintenance of cells in their 
microenvironment [99]. sSCF promotes mast cell proliferation, whereas mSCF binds 
directly to c-Kit, and in mast cells increases the expression of proteins involved in cell-
matrix attachment [100, 101]. Animal studies using Sl and W mutant mice demonstrate 
that defective SCF/c-Kit signaling results in deformity of erythrocytes, megakaryocytes, 
and mast cells, illustrating that these cells are dependent on c-Kit for their proliferation, 
survival, and function [102]. 
c-Kit and SCF play an indispensable role in the pigmentation of the epidermis and hair of 
mammals. Mice with a heterozygotic mutation in SCF or c-Kit exhibited a lack of hair 
pigmentation associated with loss of melanocytes [103]. In contrast, overexpression of 
epidermal SCF leads to hyperpigmentation in mice, and constitutively activated c-Kit 
results in uncontrolled proliferation of melanocytes, promoting melanogenesis and 
migration of pigment cells [104, 105]. SCF/c-Kit activity is essential in enabling 
melanocyte-lineage cell migration from the neural crest into developing mature hair 
follicles in rodents [106, 107]. Furthermore, c-Kit-activated Src family kinases regulate 
the microphthalmia-associated transcription factor to govern the proliferation, survival, 
and maturation of melanocytes [108, 109].   
Expression and functional studies have shown that SCF/c-Kit is essential for germ cell 
development during both the fetal and postnatal periods of life. Humans with a mutation 
in SCF suffer from idiopathic male infertility [110]. Elevation of c-Kit expression is 
linked to the commitment of germ cell differentiation in rodents. Both Sl and W mutant 
mice show defective c-Kit signaling, which is associated with germ cell apoptosis and the 
corresponding degree of sterility [111]. Activation of the PI3K and MAP kinase 
pathways by stimulation of SCF has been found to promote germ cell proliferation [74, 
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112, 113]. Other studies have demonstrated that phosphorylation of Src family kinases, 
by the juxtamembrane kinase of c-Kit, regulates primitive germ cell migration [114]. In 
addition, downstream of c-Kit, the PLCγ pathway has been implicated in meiosis of 
fertilized eggs [115, 116], and the ERK cascade has been shown to act as a regulator of 
gene transcription involved in the maturation and proliferation of primitive germ cells 
[112, 114]. 
The physiological relevance of SCF and c-Kit has been characterized in mice with 
various naturally occurring mutations in the Sl and W loci. The loss-of-function mutations 
in these receptor/ligand-defective mice result in defective signaling pathways and 
underline the complexity of rodent phenotypes. Given the fact that SCF and c-Kit are 
expressed in a wide variety of normal tissues, it is not surprising that SCF/c-Kit 
interactions play a crucial role in hematopoiesis, pigmentation, and gametogenesis, as 
well as in the gastrointestinal tract, cardiovascular system, and neuronal network [117]. 
Recent studies suggest that c-Kit function may be linked to regulation of pancreatic 
endocrine cell development, particularly beta-cell maturation, proliferation and function, 
which will be highlighted in the following sections. 
1.5 c-Kit function in the pancreas 
1.5.1 c-Kit in the developing rodent pancreas 
c-Kit expression was first detected in RINm5F rat insulinoma cell lines and fetal rat islets 
[118]. Subsequent immunohistochemistry studies revealed the localization of c-Kit to 
pancreatic ducts [119], and mRNA expression of the c-Kit gene was enriched in the e13 
embryonic rat pancreata [120], suggesting that c-Kit expression is important for proper 
development of the pancreas. One cell-lineage tracing study utilizing LacZ murine 
embryos showed that c-Kit expression is detectable in a subpopulation of endocrine and 
epithelial cells [121]. The abundant c-Kit expression in early rodent pancreas 
development demonstrates that c-Kit might be involved in maintaining the endocrine cell 
precursor pool in fetal rodents. This statement was further supported by findings from our 
laboratory. We characterized dynamic changes of c-Kit expression in rodent pancreata 
during transition from the prenatal to postnatal period, and revealed that c-Kit was 
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localized to the ductal region and in newly formed islet endocrine cell clusters at e18, and 
progressively decreased during postnatal life [122]. These observations suggested that 
decreased c-Kit expression correlated with islet endocrine cell maturation. More recently, 
the presence of two distinct putative stem cell like populations, expressing either c-Kit or 
Sca-1, another stem cell antigen, in the developing rodent pancreas was characterized. 
Flow cytometry analysis revealed that the isolated c-Kit+ cell population co-expressed 
markers of islet differentiation including Pdx-1 and Ngn3, but an isolated Sca-1+ cell 
population lacked these markers [123]. This data indicates that c-Kit could be used a 
marker to identify putative islet precursor cells, thus playing a significant role in pancreas 
morphogenesis, particularly in the developing rodent endocrine pancreas. Interestingly, a 
report from Bernex et al. has documented pancreatic endocrine cells present in 
WvLacZ/WvLacZ mouse embryos with a null allele of c-Kit. Findings from this study 
suggested c-Kit might not be required for the determination and specification of 
pancreatic endocrine cells [124]. However, it is worth noting that PDGFR is also 
expressed in islets of Langerhans, which might represent a possible redundant RTK 
signaling pathway that compensates for the absence of c-Kit expression. 
1.5.2 SCF/c-Kit in islet cell differentiation  
Accumulating evidence has shown that c-Kit plays an important role in pancreatic 
morphogenesis and islet maturation. c-Kit-mediated islet differentiation was 
demonstrated across multiple species in vitro. It was demonstrated that stimulation of c-
Kit promotes gene transcription [121] and proliferation in the INS-1 rat insulinoma cell 
line [125, 126]. Furthermore, exogenous SCF induced differentiation of human 
pancreatic carcinoma epithelial-like cell lines (PANC-1) into islet-like clusters [127]. In 
isolated primary rodent islet cultures, Oberg-Welsh et al. demonstrated that rat fetal islet 
clusters treated with SCF show augmented insulin and total DNA content [119]. The rat 
islet epithelial monolayer that expanded on collagen I contained an increased number of 
proliferating c-Kit-expressing cells, with constant expression of Pdx-1, Ngn3, Pax4, and 
multiple undifferentiated cell markers, including octamer-binding transcription factor-4, 
and α-fetoprotein [128]. Differentiation of these monolayers was greatly enhanced when 
cultured on laminin-rich matrigel. Islet-like clusters were formed and cells secreted 
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insulin in response to glucose [128]. It was found that SCF released from 
microencapsulated monolayered Sertoli cells significantly accelerated differentiation and 
maturation of neonatal porcine islets. Increased early islet differentiation markers and co-
localization with c-Kit and insulin was found in these porcine islets, demonstrating that 
the c-Kit positive subpopulation represents islet precursors that can stimulate 
differentiation of porcine insulin producing cells in vitro [129]. Our group showed that 
SCF mediates the differentiation of c-Kit-expressing immature endocrine progenitors in 
the human fetal pancreas, and phosphorylated Akt may have a functional role 
downstream of c-Kit signaling in mediating their maturation [130]. Furthermore, c-Kit 
activation results in cellular proliferation via suppression of cell apoptosis in human fetal 
islet epithelia [131]. Conversely, silencing c-Kit mRNA disrupts islet differentiation in 
cells of the human fetal pancreas [131], highlighting the importance of c-Kit signaling in 
mediating early beta-cell differentiation and survival. 
1.5.3 c-Kit in the regenerating pancreas 
Although there is no consensus about the identity and origin of pancreatic 
stem/progenitor cells, c-Kit-expressing cells exhibit many stem cell-like features in the 
regenerating pancreas. Our group showed that following pancreatic duct ligation, 
pancreatic islets, exocrine acini, and ductal complexes regrew, indicating that c-Kit-
expressing proliferating pancreatic progenitors may be a putative source for islet 
regeneration in rodents [132]. Our study revealed that c-Kit is expressed in the periphery 
of islets and co-localizes with ductal/progenitor markers cytokeratin 20 and Pdx-1 in the 
ligated rat pancreas 3 days post-ligation [133]. c-Kit-expressing cells in ligated regions 
displayed a high proliferative capacity, suggesting that beta-cell neogenesis may arise 
from these ductal progenitor cells. c-Kit has also been found to participate in islet 
regeneration in a streptozotocin-induced diabetic model. A few remaining beta-cells that 
express c-Kit have high proliferative capacity following streptozotocin-induced beta-cell 
damage, suggesting that these cells are involved in the regenerative process [134]. A 
similar study was reported in an acute pancreatitis rat model in which extensive 
pancreatic cellular damage was induced by cerulean and resulted in beta-cell 
replenishment due to replication of these highly proliferative pre-existing c-Kit 
24 
 
expressing beta-cells [135]. c-Kit-expressing cells from other cell sources may also be 
involved in beta-cell regeneration. Hess et al. showed that transplanted bone marrow-
derived c-Kit-expressing cells initiate islet regeneration in streptozotocin-treated non-
obese diabetic/severe combined immune deficient (NOD/SCID) recipient mice. Rapid 
engraftment of these GFP-tagged c-Kit+ bone marrow-derived cells to the damaged 
ductal and islet regions stimulated endogenous islet neogenesis [136]. Using multipotent 
stromal cells expressing surface markers (ALDHhighc-Kit+CD113+CD34+) to treat the 
streptozotocin-treated NOD/SCID mice nearly restored glucose homeostasis, with 
formation of beta-cell clusters adjacent to the ductal epithelium [137]. By transferring 
these purified multipotent stromal cells from umbilical cord blood into the recipient 
NOD/SCID mice, hyperglycemia was reversed in the animals. Intriguingly, multipotent 
stromal cells purified from umbilical cord blood were able to augment endogenous beta-
cell proliferation and revascularization [138]. 
1.5.4 c-Kit in pancreatic disease 
Despite the necessity of c-Kit in the pancreas, it has also been identified to be a proto-
oncogene [47]. Indeed, inappropriate expression of c-Kit or SCF has led to a wide range 
of pancreatic diseases ranging from pancreatitis (acute and chronic) to pancreatic cancer 
[117, 139, 140]. Chronic pancreatitis is characterized by chronic inflammation, fibrosis, 
and loss of pancreatic function [141]. The immune response in chronic pancreatitis is 
very powerful and contributes to a large portion of chronic pancreatitis pathophysiology. 
Indeed, increased mast cell presence correlates with inflammation and fibrosis in chronic 
pancreatitis [142]. It has been reported that SCF/c-Kit interactions have an influential 
effect on mast cells. During chronic pancreatitis, c-Kit expression is increased on mast 
cells near affected ducts, and weak immunoreactivity of c-Kit is observed on acini and 
islets [142]. c-Kit expression is also found in ducts during chronic pancreatitis, consistent 
with other studies that have shown increased ductal c-Kit expression after pancreatic 
ductal ligation in rodents [133]. Therefore, it can be concluded that c-Kit plays various 
important roles dependent upon the cell type in which it is expressed.  
Pancreatic cancer is among the most lethal and least common of the human cancers 
[143]. Diabetes and chronic pancreatitis have been linked to pancreatic cancer, yet 
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smoking was shown to be responsible for 20-25% of pancreatic cancers. While cancer 
etiology is varied, SCF/c-Kit interactions play a role in promoting pancreatic cancer cell 
line proliferation, invasion, and differentiation into endocrine hormone producing cells 
[127, 144]. Other cell line experiments showed that hypoxia-inducible factor 1-alpha, a 
protein expressed under hypoxic conditions that can indicate tumor survival and 
proliferation, was influenced by c-Kit activity in pancreatic cancer cells independent of 
the oxygen level [145].  c-Kit is also present on neoplastic cells in the pancreas, as well 
as throughout the duct of the cancerous pancreas [146], indicating that SCF/c-Kit 
interactions have profound implications on pancreatic cancer cell proliferation and 
invasiveness. Therefore, the development of c-Kit inhibitors has been useful for the 
management of cancers by inhibiting proliferation as well as inducing apoptosis of cancer 
cells [147, 148].  
1.6 Rationales, objectives and hypotheses  
1.6.1 Overall objective and hypothesis  
The overall objective is to understand the physiological role of c-Kit on beta-cells in 
vivo, and we hypothesize that activation of c-Kit and its downstream PI3K/Akt signaling 
pathway plays a critical role in determining beta-cell survival and function under normal 
and diabetic pathophysiological conditions. 
1.6.2 Beta-cell survival and function in c-KitWv/+ mice 
The first reported evidence, in vivo, linking c-Kit activity with beta-cell survival and 
function utilized mice carrying the mutation, viable dominant spotting (Wv)[149]. The Wv 
point mutation refers to a threonine to methionine substitution at the first catalytic region 
of the c-Kit cytoplasmic kinase domain, greatly diminishing its kinase activity without 
altering the binding site to SCF. As a result, the autophosphorylation activity of c-Kit Wv 
mutant monomers is only ~10-20% of that observed in normal c-Kit monomers. More 
importantly, c-Kit Wv mutant monomer can act in a trans-dominant manner to prevent 
tyrosine phosphorylation of normal c-Kit by dimerization, reflected by ~60% reduction in 
c-Kit transduction activity [150]. Phenotypic analysis of c-KitWv/+ mice showed high 
fasting plasma glucose and impaired glucose tolerance between 4 to 8 weeks of age. 
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Absence of insulin resistance in peripheral tissue was found, indicating that the 
development of a diabetic phenotype was due to a loss of beta-cell mass, along with a 
reduced proliferative capacity in c-KitWv/+ mice. Islet morphology and Pdx-1 expression 
was altered in c-KitWv/+ pancreatic islets when compared to controls. In addition, these 
mice demonstrated a significant reduction in plasma insulin levels 35 minutes after 
glucose stimulation, and isolated islets exhibited marked insulin secretory defects in 
response to glucose load [149]. Overall, beta-cell dysfunction emerges as the 
physiological defect, leading to early onset diabetes in c-KitWv/+ mice, specifically in 
males. Interestingly, the female c-KitWv/+ mice did not show the impaired glucose 
metabolism until 40 weeks of age [149]. The complex intracellular pathways downstream 
of c-Kit have been well studied in other cellular contexts, but such information is largely 
unknown in the context of beta-cell biology in vivo. Therefore, the first objective of this 
work was to identify the responsible intracellular machinery that had the most influence 
on beta-cell proliferation and function in c-KitWv/+ male mice (Chapter 3). We 
hypothesized that the dysregulated Akt/Gsk3β pathway contributes to severe loss of 
beta-cell mass and impaired beta-cell function in c-KitWv/+ mice. 
1.6.3 Beta-cell apoptosis in c-KitWv/+ mice 
Beta-cell mass reflects a dynamic balance between cell proliferation and apoptosis. The 
increase in beta-cell apoptosis and decrease in beta-cell proliferation, followed by loss of 
beta-cell mass and eventual beta-cell failure, is a hallmark of diabetes. A high rate of 
apoptosis was detected in the beta-cell population of c-KitWv/+ mice. However, our current 
understanding of apoptotic pathways induced by the c-Kit Wv mutation in beta-cells is 
lacking. One attractive candidate is Fas, also known as APO-1 or CD95, which belongs 
to the tumor necrosis superfamily. The gene coding Fas is located near the lpr locus of 
chromosome 19 in rodents [151]. The lpr mutation leads to the production of non-
functional truncated Fas mRNA due to an early transposable element, similar to an 
endogenous retrovirus inserted into intron 2 [151]. Thus, the Faslpr/lpr mouse model is an 
excellent system to study the effect of a deficiency in Fas signaling in any given tissue. 
FasL-binding and subsequent activation of Fas leads to programmed cell death in many 
systems. Experimental data from several studies showed that, at least in T1D models, that 
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Fas/FasL interaction has been implicated in beta-cell death. In transgenic mice expressing 
FasL on beta-cells, extensive beta-cell destruction was associated with autoimmune 
attack, whereas Fas-negative NOD mice with lpr mutation failed to develop T1D [151], 
and are resistant to adoptive transfer of diabetogenic NOD spleen cells [152]. More 
experiments using NOD-gld/+ mice, which have reduced FasL expression, also 
demonstrated that beta-cell apoptosis is possibly mediated by FasL-positive T-
lymphocytes on activation of Fas. In addition, Fas deficient (lpr/lpr) NOD/SCID were 
protected from diabetes induced by adoptive transfer of diabetogenic T-cells [153]. 
Taking this further, more studies using dominant negative Fas mutation beta-cell specific 
NOD mice [154] and administration of FasL antibody treatment found that it prevented 
early onset of autoimmune diabetes [155], and prolonged survival and engraftment of 
NOD islets in diabetic NOD mice [156]. A conditional knockout of Fas improved beta-
cell insulin releasing function [157]. Accumulating evidence demonstrates that Fas 
signaling contributes to cell apoptosis, which is accompanied by the absence of c-Kit 
signaling in melanocytes [158], gametes [159], oocytes [160], and HSCs [161], thus 
leaving an open question as described in Chapter 4. The second objective of this work 
was to assess the balance between c-Kit and Fas signaling on beta-cell survival and 
function using c-KitWv/+ and c-KitWv/+;Faslpr/lpr mice, and in vitro rat insulinoma INS-1 
cells. We hypothesized that loss of c-Kit signaling leads to activation of Fas-mediated 
beta-cell loss in c-KitWv/+ mice, but that the Fas lpr mutation in c-KitWv/+ mice would 
protect beta-cells from apoptosis, and improve beta-cell insulin release in the c-KitWv/+ 
mouse model. 
1.6.4 c-Kit directly affects beta-cell function  
Homozygous c-Kit null mutant mice display relatively normal islet morphology, but they 
die shortly after birth and are not available for further functional studies [124]. We 
recently characterized c-KitWv/+ mice with a loss of beta-cell function resulting in early-
onset of diabetes [149]. However, the c-KitWv/+ mice model may not be sufficient to 
reveal whether c-Kit plays a primary or secondary role in beta-cell survival and function, 
because the global c-Kit mutation may raise unknown confounding effects from other 
tissue. Thus, we further generated a novel transgenic mouse model containing beta-cell 
28 
 
specific overexpression of c-KIT (c-KitβTg mice). Using this novel c-KitβTg mouse 
model, the third objective of this work was to delineate the physiological role of c-Kit in 
normal, and HFD-induced diabetic and c-KitWv/+ mice. This work is described in Chapter 
5. It is hypothesized that elevated beta-cell c-Kit expression can improve beta-cell 
function and survival in normal and HFD-induced diabetic c-KitβTg mice, and c-KIT 
overexpression in beta-cells could reverse the onset of diabetes in c-KitWv/+ mice. 
1.6.5 VEGF-A and islet vasculature in c-Kit mutant and transgenic 
mouse 
The formation of microvascular networks in the islet relies on vascular endothelial 
growth factors (VEGFs), a group of receptor tyrosine kinase signaling proteins able to 
stimulate vasculogenesis and angiogenesis through binding to three functionally distinct 
VEGF receptors 1-3. Beta-cells express high levels of VEGFs, in particular VEGF-A that 
binds to and activates VEGF receptors 2 present on the neighboring endothelial cells. 
This attracts endothelial cells and stimulates their proliferation and growth. By deleting 
VEGF-A in the pancreas, the fenestration of islet capillaries, required for fine-tuning of 
blood glucose regulation, is severely impaired [162]. This is further supported by studies 
using transgenic mice with beta-cell-specific loss of VEGF-A, driven by the rat insulin 
promoter (RIP)-Cre system. The substantial loss of islet vasculature results in severely 
impaired development of islet capillaries and beta-cell dysfunction [163, 164]. The causal 
link between c-Kit and VEGF-A production has been documented previously in multiple 
cancer pathologies: in lung cancer cells, SCF was shown to induce VEGF expression, and 
this was associated with increased PI3K signaling and hypoxia-inducible factor 1-alpha 
transcription, and the effect was blocked by inhibition of c-Kit [165]. Likewise, in 
neuroblastoma cells, inhibition of c-Kit resulted in a significant reduction in VEGF 
expression, which led to significant decreases in tumor vasculogenesis and angiogenesis 
[166]. In a pancreatic islet cancer model, treatment with both SU5416 (VEGFR inhibitor) 
and Gleevec (c-Kit inhibitor) significantly repressed tumor growth [167]. Therefore, the 
fourth objective was to assess the role of SCF/c-Kit signaling on islet microvasculature, 
and its subsequent effect on islet function and glucose homeostasis in vivo under both 
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normal and diabetic conditions (Chapter 6). It is hypothesized that c-Kit-dependent 
regulation of VEGF-A is critical for islet vasculature and beta-cell survival.   
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2 Summary of materials and methods for Chapters 3, 4, 5 and 6 
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2.1 Mouse models 
The crossbreeding strategies used to generate the mouse models used throughout this 
thesis are detailed below. Mice were maintained in an environment of constant 
temperature (20°C) and were exposed to regular 12-hour day, 12-hour night cycles. All 
mice were fed ad libitum with a normal diet (5% vol./vol. fat; Harlan Tekard, 
Indianapolis, IN, USA), unless specified. Male mice were used in the following studies 
due to male mice having a more severe diabetic phenotype as compared to females. The 
animal experimental protocol used in the following studies was approved by the 
University of Western Ontario Animal Use Subcommittee, in accordance with the 
guidelines of the Canadian Council of Animal Care (Appendix 1 and 2). 
2.1.1 Mouse models used in Chapter 3 
Generation of the c-KitWv/+ mouse model: Paired c-Kit Wv heterozygous mutant (c-
KitWv/+) mice on a C57BL/6J background obtained from the Jackson Laboratory (stock 
no. 000049, Jackson Laboratory, Bar Harbor, ME, USA) were bred (Figure 2-1). Mice 
were genotyped by their distinct differences in fur pigmentation as described previously 
[1]. Homozygous mutant (c-KitWv/Wv) mice are severely anemic and infertile and do not 
survive for a long time after maturity. Since sufficient c-KitWv/Wv male mice could not be 
obtained, they were excluded them from this study [1]. Thus, this study focused on c-
Kit+/+ and c-KitWv/+ male mice at 8 weeks of age. 
Treatment with Gsk3β inhibitor: At 6 weeks of age, both c-Kit+/+ and c-KitWv/+ male mice 
were intraperitoneally injected with either 1-Azakenpaullone (1-AKP, Calbiochem, 
Etobicoke, ON, Canada) at 2 mg/kg or with saline, every other day for 2 weeks, to 
establish four experimental groups including: c-Kit+/+/saline, c-Kit+/+/1-AKP, c-
KitWv/+/saline, and c-KitWv/+/1-AKP mice (Figure 2-2). 
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Figure 2-1. Breeding schematic for c-KitWv/+ mice. 
C57BL/6J/KitWv/+ (stock no. 000049) from the Jackson laboratory were crossed to 
obtain three mouse genotypes. The study focused on male c-Kit+/+ and c-KitWv/+ mice 
as highlighted above. 
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Figure 2-2. Experimental design of 1-AKP treatments for c-KitWv/+ mice. 
6-week-old male c-Kit+/+ mice or c-KitWv/+ mice received either i.p. injections of 
saline or 1-AKP for two weeks. Four experimental groups including, c-Kit+/+/saline, 
c-KitWv/+/saline, c-Kit+/+/1-AKP, and c-KitWv/+/1-AKP mice were established. 
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2.1.2 Mouse models used in Chapter 4 
c-KitWv/+ and Faslpr/lpr mice with a C57BL/6J background were obtained from the Jackson 
Laboratory (stock no. 000049 for C57BL/6J/KitWv/+; stock no. 000482 for B6.MRL-
Faslpr/lpr; the Jackson Laboratory) and cross-bred to generate six genotypes including: c-
Kit+/+;Fas+/+, c-KitWv/+;Fas+/+, c-KitWv/+;Faslpr/lpr, c-Kit+/+;Faslpr/+, c-KitWv/+;Faslpr/+, and 
c-Kit+/+;Faslpr/lpr mice (Figure 2-3). This study focused on three groups: c-Kit+/+;Fas+/+, 
c-KitWv/+;Fas+/+, and c-KitWv/+;Faslpr/lpr mice. Male mice at 8 weeks of age were used for 
this study. The c-Kit Wv mutation was distinguished by fur pigmentation: black for c-
Kit+/+ and piebaldism for c-KitWv/+ [1]. The Fas (lpr) mutation was identified by 
genotyping using PCR with DNA isolated from tails (Appendix 3).  
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Figure 2-3. Breeding schematic for c-KitWv/+;Faslpr/lpr double mutant mice. 
C57BL/6J/KitWv/+ (stock no. 000049) and B6.MRL-Faslpr/lpr (stock no. 000482) mice 
from the Jackson Laboratory were crossed to obtain c-KitWv/+;Faslpr/+ and c-
Kit+/+;Faslpr/+ mice. Crossbreeding these mice resulted in six mouse genotypes. This 
study focused on three groups including, c-Kit+/+;Fas+/+, c-KitWv/+;Fas+/+, and c-
KitWv/+;Faslpr/lpr mice as highlighted above. 
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2.1.3 Mouse models used in Chapter 5 
Generation of the c-KitβTg mouse model: the human c-KIT cDNA (2.9 kbp) followed by 
IRES2 linked with enhanced green fluorescent protein (eGFP) sequence was inserted into 
the pKS/RIP plasmid to generate the transgene. Transgenic mice (c-KitβTg) were 
generated using C57BL/6J embryos and identified by PCR first using primers globin5 
and c-Kit, and further confirmed by a second set of primers eGFP3 and globin3 
(Appendix 3) [2, 3]. Five RIP-c-Kit transgenic founders were obtained (Dr. Siu-Pok Yee, 
University of Connecticut), and bred with C57BL/6J mice (the Jackson Laboratory) to 
establish the independent mouse lines. Initial characterization revealed that they display a 
similar, if not identical, pattern of transgene expression and phenotype, which eliminated 
any positional effects due to the location of transgene integration. We therefore used 
offspring from two independent transgenic lines for subsequent detailed analyses. Male 
mice were used in this study. 
Generation of HFD-induced diabetes in c-KitβTg and wild type (WT) littermates: the 
HFD study was conducted starting at 6 weeks of age, and male c-KitβTg and WT 
littermates were fed with HFD containing 60 kcal % fat (D12492, Research Diets, New 
Brunswick, NJ, USA) for 4 weeks. 
Generation of the c-KitβTg;Wv mouse model: the c-KitβTg;Wv mouse model was 
generated by crossbreeding c-KitβTg with c-KitWv/+ mice, which would yield mice with 
four different genotypes including: wild type (WT); c-KitWv/+; c-KitβTg; c-KitβTg;c-
KitWv/+ (c-KitβTg;Wv) mice (Figure 2-4). The c-Kit Wv allele was identified by its 
characteristic fur pigmentation (Figure 2-1) [1], and c-KitβTg allele was determined by 
PCR (Appendix 3). Male mice at 8 weeks of age were used for this study.  
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Figure 2-4. Breeding schematic for c-KitβTg;Wv mice. 
C57BL/6J/KitWv/+ mice (stock no. 000049) from the Jackson Laboratory and c-
KitβTg mice were crossed to obtain four experimental groups including: c-Kit+/+, c-
KitWv/+, c-KitβTg, and c-KitβTg;Wv mice. 
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2.1.4 Mouse models used in Chapter 6 
Generation of the c-KitβTg;Wv mouse model: c-KitβTg with c-KitWv/+ mice were crossed 
to obtain mice with listed all 4 different genotypes including: WT, c-KitβTg, c-KitWv/+, 
and c-KitβTg;Wv mice, as described in 2.1.3 section (Figure 2-4). Male mice at 8 weeks 
of age were used for this study. 
The long-term HFD treatment for c-KitβTg mice: c-KitβTg male mice and their age-
matched WT littermates were generated as described in section 2.1.3. A HFD study was 
performed using HFD (D12492, Research Diets) starting at 6 weeks of age in both c-
KitβTg and WT mice for 20-22 weeks (labelled as experimental groups: c-KitβTg-HFD 
and WT-HFD). In parallel, age-matched c-KitβTg and WT mice under normal diet were 
also examined. 
2.2 DNA extraction and PCR genotyping  
Genotyping was performed on all mice at weaning (21 days after birth). In brief, 2 mm of 
tail was obtained and placed into Eppendorf tubes for DNA extraction, with the exception 
of c-KitWv/+ mice. Each tail sample was digested by 50 µL of base solution (25 mM 
NaOH; 0.2 mM EDTA), and placed on heat block at 95 oC for 30 minutes following by 
an hour cooldown at room temperature. Fifty µL of 40 mM Tris HCl (pH 5.5) was added 
to each digested sample, and centrifuged at 13,000 rpm x g for 1 minute. One µL of 
aliquot was taken for PCR. PCR was performed with a mixture of primer sequences listed 
in Appendix 3 using a thermocycler (Biometra GmbH, Goettingen, Germany) as follows: 
94 oC for 30 seconds (melting temperature), 59 oC for 1 minute (annealing temperature), 
and 72 oC for 1 minute (primer extension phase), for 25-35 cycles depending on the 
primers. The PCR products were separated on 2% agarose gel, stained with 1 µg/mL 
ethidium bromide, and visualized under UV light (Appendix 3). 
2.3 Body weight, food intake, and in vivo metabolic studies 
Body weight, blood glucose level, and intraperitoneal glucose (IPGTT) and insulin 
tolerance tests (IPITT) were performed on the listed mouse models [1]. Food intake was 
monitored. In brief, a known amount of a diet is given to the animal. After 7 days, the 
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food was reweighed and the amount consumed was calculated by measuring the 
difference. Blood glucose levels were examined under the non-fasting, as well as after 4-
hour or 16-hour (overnight) fasting with ad libitum water access. For IPGTT and IPITT, 
an intraperitoneal injection of glucose (D-(+)-glucose; dextrose; Sigma, St. Louis, MO, 
USA) at a dosage of 2 mg/g of body weight or human insulin (Humalin, Eli Lilly, 
Toronto, ON, Canada) at 1 U/kg of body weight was administrated. Blood glucose levels 
were examined at 0, 15, 30, 60, and 120 minutes following injection, and area under the 
curve (AUC) was used to quantify glucose or insulin responsiveness. The data is shown 
with units of ([mmol/L] x minutes) [1].  
2.4 In vivo and ex vivo glucose stimulated insulin secretion assay  
For in vivo glucose stimulated insulin secretion (GSIS), mouse blood samples were 
collected from the tail vein following 4 hours of fasting (0 minute), and at 5 and 35 
minutes after glucose loading [1]. Plasma samples were immediately obtained by 
centrifuging at 3000 rpm x g for 10 minutes and stored at -20oC.  
For ex vivo GSIS, islets from each experimental group were isolated. In brief, the bile 
duct was clamped closed to the duodenum. The pancreas was inflated via an intraductal 
collagenase V (1 mg/mL, Sigma) injection through the common bile duct (3 mL) [4]. The 
inflated pancreas was carefully excised and moved into a falcon tube with 3 mL of cold 
dissociation buffer (Hank’s balanced salt solution with HEPES, 0.6% g/mL). The excised 
pancreas was digested at 37 oC in a water bath for 20-30 minutes. Freshly isolated islets 
were hand-picked and incubated with an oxygenated Krebs-Ringer bicarbonate HEPES 
plus 0.5% BSA buffer containing 2.2 mmol/L or 22 mmol/L glucose for 1 hour. Media 
and islets were collected and stored at –20 oC for measuring insulin secretion and content 
by ELISA.  
2.5 Insulin ELISA analyses 
Insulin secretion and content was measured using an ultrasensitive (mouse) insulin 
ELISA (ALPCO, Salem, NH, USA) with a sensitivity of 0.15 ng/mL, according to the 
manufacturer’s instruction [1]. Plasma insulin levels were expressed as ng/mL. A static 
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glucose stimulation index in isolated islets was calculated by dividing the insulin output 
from the high glucose (22 mM) incubation by the insulin output during the low glucose 
(2.2 mM) incubation. Insulin content in the islets was expressed as ng/µg of DNA. DNA 
content of the islets was determined along with insulin content using a Multiskan 
spectrum microplate spectrophotometer (Thermo Electron Corp., Waltham, MA, USA) 
[1]. 
2.6 Cell culture and treatment 
2.6.1 Treatment with Gsk3β inhibitor on isolated islets in Chapter 3 
Islets were isolated from c-Kit+/+ and c-KitWv/+ male mice at 8 weeks of age (isolation 
procedure is described in section 2.4).  Isolated islets were cultured in RPMI-1640 
medium (Gibco, Burlington, ON, Canada), supplemented with sodium bicarbonate (0.2% 
g/mL), Soybean trypsin inhibitor (10% mg/mL), fetal bovine serum (10% mL/mL), 
Penicillin-Streptomycin (1% mL/mL), and Fungizone (1% mL/mL) with or without 1-
AKP (10 µM, Calbiochem) for 24 hours [5]. Islets were harvested for protein and 
quantitative RT-PCR (qRT-PCR) analyses. 
2.6.2 INS-1 cell culture in Chapter 4 and 5 
Rat insulinoma (INS-1 832/13 cells, a gift from Dr. Christopher Newgard, Duke 
University Medical Center, USA) were cultured in RPMI-1640 medium (Gibco), 
containing sodium bicarbonate (0.2% g/mL), fetal bovine serum (10% mL/mL), HEPES 
(2.5% mL/mL), sodium pyruvate (1% mL/mL), and β-mercaptoethanol (0.4% µL/mL) 
under a humidified condition of 95% air and 5% carbon dioxide at 37 °C. Medium was 
replaced every other day until cells reached near 80% confluence. 
Treatment with human SCF: INS-1 cells were starved in serum-free RPMI-1640 plus 1% 
BSA medium (Gibco) for 3 hours. Cell cultures were then treated with either SCF vehicle 
(10 mM acetic acid) as a control, SCF (50 ng/mL, ID labs, London, ON, Canada), or SCF 
plus wortmannin (100 nM, Sigma) for 24 hours [6]. 
c-Kit and Fas siRNA transfection of INS-1 cell lines: INS-1 cells were transfected for 48 
hours with either control siRNA (sc-37007, proprietary sequence), c-Kit (rat) siRNA (sc-
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63363) with or without a p53 inhibitor, pifithrin-alpha (PFT-α, 5 µM, Sigma), or 
combined c-Kit (rat) siRNA and Fas (rat) siRNA (sc-270241) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) using an siRNA transfection protocol described by the 
manufacturer (Santa Cruz Biotechnology) [6]. The sequence for c-Kit (rat) and Fas (rat) 
siRNAs are listed (Appendix 4). Transfection efficiency was monitored using 
fluorescein-conjugated control siRNA (sc-36869, Santa Cruz Biotechnology), with 
approximately 60-70% of the cells being transfected. 
At the end of the culture period, cells were harvested and prepared for qRT-PCR analyses, 
immunofluorescence staining, and protein extraction for western blot. Cell apoptosis was 
examined using the Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay. Cell viability was examined using the (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay and cell proliferation was examined using the 
Ki67 staining [7]. 
2.7 Immunofluorescence and morphometric analyses 
Pancreata from all mouse models used in this thesis were fixed in 4% paraformaldehyde 
overnight at 4 °C followed by a standard protocol of dehydration and paraffin 
embedding. Pancreatic tissue sections (4 µm thick) were prepared and double-stained 
with primary antibodies of appropriate dilutions as listed in Appendix 5. Secondary 
antibodies, fluorescein isothiocyanate (FITC, anti-mouse; anti-rabbit; or anti-guinea pig) 
and TexRed (anti mouse; anti-rabbit; or anti-guinea pig) (Jackson ImmunoResearch, 
West Grove, PA, USA) were used. Nuclei were counterstained with 4’-6’-diamidino-2-
phenylindol (DAPI) (Sigma) and were blue in color. To determine the specificity of the 
antibodies used in this thesis, the pancreatic sections were processed with the omission of 
primary or secondary antibodies, and tests resulted in a negative staining reaction [8]. 
Double-immunolabeled images were captured using a Leica DMIRE2 fluorescence 
microscope with Openlab image (Improvision, Lexington, MA, USA), or with Image Pro 
Plus (Media Cybernetics, Rockville, MD, USA).  
Quantitative evaluation for islet number, islet size, alpha-cell, and beta-cell mass was 
performed using computer-assisted image analysis [1]. Islet number (density) was 
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obtained from total islet counts divided by the total area of the pancreas. Islet size was 
measured and grouped into different size classes, then expressed as a percentage of the 
total number of islet. Alpha-cell positive areas were identified by glucagon-staining, 
whereas beta-cell positive areas were identified by insulin-staining on the pancreatic 
sections. Alpha-cell or beta-cell mass was calculated by multiplying relative glucagon-
positive or insulin-positive area over the total pancreas area by pancreas weight and 
expressed as mg.  
The beta-cell proliferation, apoptosis, and expression of different transcription factors 
were determined by double immunofluorescence staining and cell counting (Appendix 5). 
MafA+ staining on pancreatic islets was determined by immunohistochemical staining 
using the streptavidin-biotin horseradish peroxidase complex and developed with 
aminoethyl carbazole substrate kit (Invitrogen, Burlington, ON, Canada). In brief, 12 
random islets from the head, middle, and tail of the pancreata per pancreatic section were 
chosen, with a minimum of 5 pancreata per experimental group was analyzed [1]. 
In Chapter 6, the pancreatic endocrine and exocrine vasculature was analyzed. The 
capillaries were labeled by platelet endothelial cell adhesion molecule-1 (PECAM-1) on 
the pancreatic sections (Appendix 5). Islet capillary density, capillary area per islet, 
average islet capillary size and diameter, exocrine capillary density, and exocrine 
capillary area were measured [9-11]. Islet capillary density was calculated by dividing the 
total number of capillaries over the islet area. Capillary area per islet was determined as a 
ratio of the total islet capillary area to the islet area. Average islet capillary size was 
determined by dividing the total islet capillary area over the number of islet capillaries. 
Average islet capillary diameter was determined by dividing the sum of individual islet 
capillary diameter (the maximum inner diameter of the capillary lumen) over the number 
of islet capillaries. Exocrine capillary density was determined by dividing the number of 
capillaries over the pancreatic exocrine area, and exocrine capillary area was determined 
as a ratio of the exocrine capillary area to the pancreatic exocrine area. A minimum of 5 
pancreata per age per experimental group with at least 12 random islets was analyzed.  
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2.8 Protein extraction and western blot analyses 
Proteins from mouse pancreata and isolated islets were extracted by homogenization in a 
Nonidet-P40 lysis buffer (Nonidet-P40, phenylmethylsulfonyl fluoride, sodium 
orthovanadate, Sigma; and complete inhibitor cocktail tablet, Roche) [1]. Samples were 
then centrifuged at 12,000 rpm x g for 20 minutes at 4 oC. The resulting supernatant was 
collected and frozen at -80 oC until use. The protein concentration was measured by a 
protein assay using Bradford dye (BioRad Laboratories; Mississauga, ON, Canada), with 
bovine serum albumin (fraction V) as the standard. 
Equal amounts of lysate were separated by 5%, 7.5% or 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose 
membrane (Bio-Rad Laboratories). The membrane was then incubated with primary 
antibodies (Appendix 6), and a goat anti- mouse or rabbit IgG secondary antibody 
conjugated to horseradish peroxidase (Cell Signaling Technology, Danvers, MA, USA). 
The blot was probed with antibodies against total proteins or housekeeping proteins for a 
sample loading control (Appendix 6). The membrane was then incubated with 
chemiluminescence reagents (Perkin Elmer, Wellesley, MA, USA). The protein bands 
were visualized on BioMax MR Film (Kodak, Rochester, NY, USA), or were imaged by 
Versadoc Imaging System (Bio-Rad Laboratories). Densitometric quantification of bands 
at sub-saturation levels was analyzed by Syngenetool gel analysis software (Syngene, 
Cambridge, UK) and normalized to the loading controls, or was quantified by Image Lab 
(Bio-Rad laboratories).  
2.9 RNA extraction and real-time RT-PCR analyses 
RNA was extracted from isolated islets of mouse pancreata using RNAqueous-4 PCR kit 
(Ambion, Austin TX, USA), according to the manufacturer’s instruction. The extraction 
procedure includes a DNase I treatment step, which eliminates any potential DNA 
contamination [1]. The RNA quality was verified by 1% agarose gel electrophoresis 
using ethidium bromide staining. Sequences of PCR primers are listed in Appendix 7. For 
each reverse transcription reaction (RT), 2 µg of DNA-free RNA from isolated islets 
were incubated with random hexamers/oligo-(dT) primers and superscript reverse 
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transcriptase (Invitrogen) to generate the complementary DNA (cDNA). The qRT-PCR 
analyses were performed using 0.1 µg of cDNA with iQ SYBR Green Supermix kit on 
Chromo4 qRT-PCR system (Bio-Rad Laboratories). Controls were performed by 
omitting reverse transcriptase, cDNA, or DNA polymerase and showed no reaction 
bands. Relative expression of mRNA were calculated using the arithmetic formula “2-ΔΔ
CT”, where ΔCT is the difference between the threshold cycle of a given target cDNA and 
18S rRNA subunit cDNA, with at least five repeats per experimental group. The melting 
curve was used to indicate if the qRT-PCR assay had any amplified target sequence with 
an excellent specificity. 
2.10 Statistical analyses 
Data are expressed as means ± SEM. Statistical significance was determined by unpaired 
student’s t-test, if comparing only two groups, or a one-way ANOVA followed by least 
significant difference (LSD) post-hoc test if there was more than two groups. Differences 
were considered to be statistically significant when p<0.05.  
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Chapter 3  
3 Inhibition of Gsk3β activity improves beta-cell function in c-
KitWv/+ mice2 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
2
 This chapter has been modified and adapted from the following manuscript: 
v Feng ZC, Donnelly L, Li J, Krishnamurthy M, Riopel M, Wang R. (2012) Inhibition of Gsk3β 
activity improves beta-cell function in c-KitWv/+ male mice. Lab Invest. 92:543-555. 
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3.1 Introduction 
Recent studies by our lab and others demonstrated that c-Kit and its ligand, SCF, are 
important in pancreatic beta-cell survival and maturation [1-8]. Stimulation of c-Kit by 
SCF leads to dimerization of c-Kit and subsequent auto phosphorylation of intrinsic 
tyrosine kinases. Moreover, c-Kit activation mediates multiple intracellular pathways, 
including the PI3K pathway for modulation of gene transcription, proliferation, 
differentiation, metabolic homeostasis and cell survival [9-12]. PI3K is, a common 
signaling pathway, required for the regulation of glucose and preproinsulin gene 
expression as well as the nuclear translocation of Pdx-1, a transcription factor to regulate 
beta-cell function [13]. Our previous in vitro studies of human fetal islets demonstrated 
that increased c-KIT activity leads to enhanced PDX-1 and insulin expression, and cell 
proliferation via the activation of the PI3K/AKT pathway [14, 15]. Recently, our in vivo 
study using c-KitWv/+ male mice showed that reduced c-Kit activity correlated with 
reduced beta-cell function and proliferation, which is associated with significantly 
decreased Pdx-1 expression and glucose intolerance [6]. However, the signaling pathway 
under c-Kit including PI3K/Akt and downstream targets involved in beta-cell 
proliferation and function in vivo remain unclear. 
Gsk3, a serine/threonine kinase, consists of two highly homologous α (Gsk3α) and β 
(Gsk3β) isoforms that share overlaping physiological functions in terms of regulating a 
diverse array of cellular processes. Gsk3β is one of the substrates that are directly 
regulated by the PI3K/Akt pathway. Activation of Akt, which phosphorylates Gsk3β at 
Serine residue 9, leads to inactivation of Gsk3β [16-18]. Unphosphorylated Gsk3β can 
directly phosphorylate downstream substrates, and modulate their activity [19]. Apart 
from the function from which it derives its name (i.e., suppressing glycogen synthesis by 
phosphorylating glycogen synthase), studies have shown that Gsk3β is involved in 
mediating cell cycle, motility, and apoptosis [19], and that Gsk3β dysregulation is linked 
to several prevalent pathological diseases including Alzheimer’s disease, cancer, and 
diabetes [19]. Indeed, mice with beta-cell-specific overexpression of Gsk3β displayed 
glucose intolerence due to reduced beta-cell mass and proliferation [20]. Furthermore, 
isolated adult human and rat islets incubated with Gsk3β inhibitors demonstrated a 
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significant increase in islet cell proliferation [21]. This evidence was further confirmed 
by mice with beta-cell specific ablation of Gsk3β [22]. Although the beneficial effect of 
Gsk3β inhibition has been demonstrated in islet biology, the physiological role of Gsk3β 
under disrupted c-Kit signaling in beta-cell has yet to be investigated. 
In order to understand the intracellular mechanisms that relate c-Kit to physiological 
changes in beta-cells in c-KitWv/+ mice [6], we proposed to examine whether beta-cell 
dysfunction in c-KitWv/+ mice is associated with down-regulation of the phospho-
Akt/Gsk3β pathway. Furthermore, 1-AKP, a specific organic inhibitor that prevents 
Gsk3β phosphorylation of multiple downstream substrates by competitively binding at its 
ATP-binding site [23], was used to investigate whether inhibition of Gsk3β could 
improve beta-cell proliferation and function, delaying the onset of diabetes in c-KitWv/+ 
mice. Here, we report that decreased beta-cell proliferation and function in c-KitWv/+ mice 
was associated with dysregulated Akt and Gsk3β phosphorylation as well as cyclin D1 
protein levels. Treating c-KitWv/+ mice with 1-AKP delayed onset of diabetes, maintained 
beta-cell mass and enhanced beta-cell function. This study demonstrates a functional role 
for c-Kit in mediating glucose homeostasis and beta-cell function via the Akt/Gsk3β axis 
in c-KitWv/+ mice. 
3.2 Materials and methods  
Mouse model: in this study, c-Kit+/+ and c-KitWv/+ mice were bred and genotyped by 
differences in fur pigmentation as detailed in section 2.1.1. Mice were kept until 8 weeks 
of age with normal diet at which point, metabolic studies, and subsequent islet 
morphological studies, islet qRT-PCR, and pancreatic and islet protein analyses were 
performed. Only male mice were used for this study [6]. 
In vivo and in vitro treatment with Gsk3β inhibitor: to investigate whether inhibition of 
Gsk3β activity could prevent early onset of diabetes in c-KitWv/+ mice at 8 weeks of age 
[6], both c-Kit+/+ and c-KitWv/+ 6-week-old mice were treated with either 1-AKP at 2 
mg/kg or saline injections intraperitoneally every other day for 2 weeks to establish four 
experimental groups: c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline and c-KitWv/+/1-
AKP, as detailed in section 2.1.1 [24, 25]. To examine whether administrating the Gsk3β 
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inhibitor to isolated c-KitWv/+ mouse islets could improve islet beta-cell function, islets 
were isolated from c-Kit+/+ and c-KitWv/+ mice at 8 weeks of age and cultured with or 
without 1-AKP (10 µM) for 24 hours, as detailed in section 2.6.1 [21].  
Metabolic studies: body weight was measured weekly while fasting (4-hour) blood 
glucose levels, IPGTT and IPITT analyses were performed on c-Kit+/+/saline, c-Kit+/+/1-
AKP, c-KitWv/+/saline and c-KitWv/+/1-AKP mice at 8 weeks of age (after 2 weeks of 1-
AKP treatment), as detailed in section 2.3.  
In vivo, ex vivo GSIS studies, and insulin ELISA analyses: in vivo GSIS, and ex vivo 
GSIS on isolated islets, were performed on c-Kit+/+ and c-KitWv/+ mice at 8 weeks of age, 
as detailed in sections 2.4 and 2.5. 
Immunofluorescence and morphometric analyses: pancreatic tissue sections from mice at 
8 weeks of age were prepared and double-stained with appropriate antibodies listed in 
Appendix 5. Islet number, islet size, alpha and beta-cell mass were measured. Cell 
proliferation (Ki67+ labeling), cyclin D1 and Pdx-1 positive staining in beta-cell nuclear 
was quantified, and the average percent of Ki67+/insulin+, cyclin D1+/insulin+, and Pdx-
1+/insulin+ cells was calculated. MafA+ staining on pancreatic islets was determined by 
immunohistochemical staining, as detailed in section 2.7. 
Protein extraction and western blot analyses: protein levels of phospho-AktS473, 
phospho-AktT308 total-Akt, phospho-Gsk3βS9, phospho-Gsk3βY216, total-Gsk3β, β-
catenin, cyclin D1 and Pdx-1 and corresponding housekeeping proteins including 
calnexin and β-actin in pancreata and isolated islets from c-Kit+/+ and c-KitWv/+ mice at 8 
weeks of age with or without 1-AKP were analyzed (Appendix 6), as detailed in section 
2.8. 
RNA extraction and real-time RT-PCR analyses: RNA was extracted from isolated islets 
of c-Kit+/+ and c-KitWv/+ mice with or without 1-AKP at 8 weeks of age. mRNA 
expression of Ccnd1 (cyclin D1), Ins I (Ιnsulin I), Ins II (Ιnsulin II), MafA, Pdx-1 was 
measured and normalized to 18S rRNA (Appendix 7), as detailed in section 2.9.   
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3.3 Results 
3.3.1 Reduction of phospho-Akt, phospho-Gsk3β and cyclin D1 in c-
KitWv/+ mice 
Our recent study has demonstrated that mice with mutated c-Kit develop early onset of 
diabetes with a loss of beta-cell mass and proliferation, suggesting that c-Kit plays a 
critical role in beta-cell proliferation and function [6]. Moreover, experiments in isolated 
human fetal islet-epithelial cells revealed that the PI3K/Akt pathway is significantly up-
regulated upon exogenous SCF stimulation [14, 15]. Here, we showed that both whole 
pancreatic tissue and isolated islets from c-KitWv/+ mice displayed a significant reduction 
in phosphorylated Akt at S473 (Figure 3-1A), but not at T308 (Figure 3-2A). In parallel, 
decreased protein levels of phosphorylated Gsk3β at S9 was observed in c-KitWv/+ mice 
when compared to c-Kit+/+ mice (Figure 3-1B), but not at Y216 (Figure 3-2B). No 
alteration in cyclin D1 protein levels was observed in total pancreatic tissue extract. 
However, a significant reduction in cyclin D1 protein expression was noted in isolated 
islets of c-KitWv/+ mice (Figure 3-3A) along with a 60% reduction in the proportion of 
cyclin D1+/insulin+ cells when compared to c-Kit+/+ mice (Figure 3-3B and C).  
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Figure 3-1. Down-regulation of phospho-Akt/Gsk3β signaling in the pancreata 
and isolated islets from c-KitWv/+ mice. 
Western blot analyses of S473-phosphorylated (P) and total (T) Akt (A), S9-(P) and 
total (T) Gsk3β (B) protein levels in the pancreata and isolated islets of c-Kit+/+ and 
c-KitWv/+ mice at 8 weeks of age. Representative blots are shown. Data (A and B) are 
normalized to total protein and expressed as mean ± SEM (n=11 pancreata; n=3 
isolated islets), *p<0.05 analyzed by unpaired student’s t-test.  
 
71 
 
 
  
72 
 
  
Figure 3-2. Western blot analyses of phospho-AktT308, and phospho-Gsk3βY216 
protein levels in isolated islets from c-KitWv/+ mice. 
T308-phosphorylated (P) and total (T) Akt (A), Y216-(P) and total (T) Gsk3β (B) 
protein levels in isolated islets of c-Kit+/+ and c-KitWv/+ mice at 8 weeks of age. 
Representative blots are shown. Data (A and B) are normalized to total protein and 
expressed as mean ± SEM (n=3), analyzed by unpaired student’s t-test. 
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Figure 3-3. Decreased cyclin D1 protein levels in isolated islets of c-KitWv/+ mice. 
(A) Western blot analysis of cyclin D1 in the pancreata and isolated islets of c-Kit+/+ 
and c-KitWv/+ mice at 8 weeks of age. Representative blots are shown. Data are 
normalized to loading control calnexin and expressed as mean ± SEM (n=4 
pancreas; n=6 isolated islets), **p<0.01 analyzed by unpaired student’s t-test. (B) 
Double immunofluorescence staining for cyclin D1 (green), insulin (red) of c-Kit+/+ 
and c-KitWv/+ mice pancreatic section at 8 weeks of age. Nuclear counter stained by 
DAPI (blue). Scale bar 20  µm (inset: 10  µm). Arrows indicate cyclin D1/insulin 
double-positive cells. (C) The percentage of cyclin D1+ cells in beta-cells of c-Kit+/+ 
and c-KitWv/+ mice at 8 weeks of age. Data are expressed as mean percent positive 
cells over insulin+ cells ± SEM (n=6), *p<0.05 analyzed by unpaired student’s t-test. 
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3.3.2 Inhibition of Gsk3β activity prevents early onset of diabetes in c-
KitWv/+ mice 
c-Kit+/+ and c-KitWv/+ mice that received saline or 1-AKP treatment revealed no 
significant change in body weight at 8 weeks of age (Figure 3-4A). However, fasting 
blood glucose levels in c-KitWv/+/1-AKP mice showed a significant improvement when 
compared to c-KitWv/+/saline group (Figure 3-4B) and reached similar fasting blood 
glucose levels of c-Kit+/+/saline and c-Kit+/+/1-AKP groups (Figure 3-4B). These 
improvements in glucose metabolism were further confirmed by glucose tolerance tests 
(Figure 3-4C). c-KitWv/+/1-AKP mice showed similar glucose tolerance capacity to both c-
Kit+/+/saline and c-Kit+/+/1-AKP groups, along with significant decreases in AUC when 
the IPGTT was performed (Figure 3-4C). Insulin tolerance tests revealed no significant 
differences between the four experimental groups (Figure 3-4D).  
Furthermore, the effects of Gsk3β inhibition on insulin secretion were examined by the 
GSIS assay in vivo and on isolated islets. No significant differences were found in basal 
plasma insulin levels between the four experimental groups. However, 5 minutes after 
glucose stimulation, an increase in plasma insulin release was noted in c-KitWv/+/1-AKP 
mice when compared to c-KitWv/+/saline and c-Kit+/+/saline groups (Figure 3-5A).  There 
was a further increase in plasma insulin secretion at 35 minutes following stimulation in 
both 1-AKP treated groups (Figure 3-5A). To further confirm if these changes in insulin 
secretion upon glucose stimulation are observed in isolated islets, in vitro GSIS was 
performed using isolated islets from all experimental groups. Insulin secretion in 
response to 22 mM glucose was significantly increased in the islets of c-KitWv/+/1-AKP 
mice, showing a 2-fold increase in insulin secretion compared to c-KitWv/+/saline group 
(Figure 3-5B).  
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Figure 3-4. Effect of Gsk3β inhibitor on glucose homeostasis of c-KitWv/+/1-AKP 
mice. 
Body weight (A) and fasting blood glucose (B) of c-Kit+/+/saline, c-Kit+/+/1-AKP, c-
KitWv/+/saline and c-KitWv/+/1-AKP groups. IPGTT (C), and IPITT (D) in c-
Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline, and c-KitWv/+/1-AKP groups. Glucose 
responsiveness of the corresponding experimental groups is shown as a measurement 
of AUC of the IPGTT or IPITT graphs with units of (mmol/L x  minutes). Data (A-D) 
are expressed as mean ± SEM (n=6–8), *p<0.05, **p<0.01, ***p<0.001 analyzed by 
one-way ANOVA followed by LSD post-hoc test. 
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Figure 3-5. Effect of Gsk3β inhibitor on beta-cell function of c-KitWv/+/1-AKP 
mice.  
(A) In vivo GSIS of c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline and c-KitWv/+/1-
AKP groups. c-KitWv/+/1-AKP group demonstrated an increase in plasma insulin 
release after glucose loading (n=3–8), *p<0.05, **p<0.01, ***p< 0.001 analyzed by 
one-way ANOVA followed by LSD post-hoc test. (B) Insulin secretion is improved 
in isolated islets from c-KitWv/+/1-AKP mice in response to 22  mM glucose challenge; 
data are expressed as fold change normalized to basal (2.2  mM glucose) secretion as 
mean ± SEM (n=4–5), *p<0.05, **p<0.01 analyzed by one-way ANOVA followed 
by LSD post-hoc test. 
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3.3.3 Inhibition of Gsk3β activity preserves beta-cell mass in c-KitWv/+ 
mice 
Our in vivo metabolic data suggests that inhibition of Gsk3β activity in c-KitWv/+ mice 
could prevent early onset of diabetes. There was no observed difference in pancreatic 
weight between all experimental groups (data not shown). Morphometric analyses were 
performed to examine the effects of the Gsk3β inhibitor on islet number and size as well 
as alpha and beta-cell mass in c-Kit+/+ and c-KitWv/+ mice with or without 1-AKP 
treatments. A significant increase in the number of pancreatic islets was noted in c-
KitWv/+/1-AKP mice (Figure 3-6A), with a significant increase in the number of small 
islets (<500 µm2) when compared to c-KitWv/+/saline group (Figure 3-6B). Moreover, the 
number of large islets (>10000 µm2) was only slightly increased in c-KitWv/+/1-AKP mice 
when compared to c-KitWv/+/saline group, while both c-Kit+/+/saline and c-Kit+/+/1-AKP 
groups had the most number of large islets (Figure 3-6B). Furthermore, beta-cell mass in 
c-KitWv/+/1-AKP mice also increased by 24% when compared to c-KitWv/+/saline group 
(Figure 3-6D), however it only reached 80-90% of the beta-cell mass of c-Kit+/+/saline 
and c-Kit+/+/1-AKP groups (Figure 3-6D). Increased beta-cell mass was also correlated 
with increased expression of Insulin I and II genes in the islets of 1-AKP treated c-
Kit+/+and c-KitWv/+ mice (Figure 3-6E). No alterations were detected in alpha-cell mass 
among any of the four experimental groups (Figure 3-6C).  
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Figure 3-6. Effect of Gsk3β inhibitor on pancreatic morphology of c-KitWv/+/1-
AKP mice. 
Morphometric analyses of islet number (A), islet size (B), alpha-cell mass (C) and 
beta-cell mass (D) in c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline, and c-
KitWv/+/1-AKP groups. (E) qRT-PCR analyses of insulin I and II mRNA in isolated 
islets of c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline and c-KitWv/+/1-AKP mice. 
Data (A-E) are expressed as mean ± SEM (n=5-8), *p<0.05, **p<0.01, ***p<0.001 
analyzed by one-way ANOVA followed by LSD post-hoc test. 
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3.3.4 Inhibition of Gsk3β activity preserves β-catenin, cyclin D1, Pdx-1, 
and MafA expression and increases the proliferative capacity of 
beta-cells of c-KitWv/+ mice 
The effect of Gsk3β inhibition on downstream signaling mediators of β-catenin protein 
levels in the islets of c-KitWv/+/1-AKP mice was significantly higher when compared to c-
KitWv/+/saline group (Figure 3-7A). However, this protein levels only reached 78% of 
both c-Kit+/+/saline and c-Kit+/+/1-AKP groups (Figure 3-7A). c-KitWv/+/saline group 
showed a significantly lower level of islet β-catenin protein than that of c-Kit+/+/1-AKP 
and c-Kit+/+/saline groups (Figure 3-7A). In addition, c-Kit+/+/1-AKP mice showed 
slightly increased β-catenin protein levels in islet protein extracts but did not reach 
statistical significance when compared to c-Kit+/+/saline group (Figure 3-7A). The 
protein levels of β-catenin were also significantly higher in isolated islets from c-KitWv/+ 
mice, when treated with 1-AKP for 24 hours, compared to non-treated c-Kit+/+ and c-
KitWv/+ islets (Figure 3-7A). These increases in islet β-catenin corresponded with 
significantly elevated islet cyclin D1 protein levels in c-KitWv/+/1-AKP mice and c-KitWv/+ 
islets cultured with 1-AKP when compared to c-KitWv/+/saline mice and untreated isolated 
c-KitWv/+ islets, respectively (Figure 3-7B). These findings were further corroborated 
using qRT-PCR and double immunofluorescence, which revealed a significantly 
increased Ccnd1 mRNA (Figure 3-7C) and a higher number of cyclin D1+/insulin+ cells 
in c-KitWv/+/1-AKP mice (vs. c-KitWv/+/saline group, Figure 3-7D). Quantitative RT-PCR 
analyses of Pdx-1 and MafA showed significantly increased mRNA levels in the islets of 
both 1-AKP treated c-Kit+/+and c-KitWv/+ mice (Figure 3-8A). Double 
immunofluorescence demonstrated a significant increase in the number of Pdx-1+ cells in 
beta-cells of c-KitWv/+/1-AKP mice (vs. c-KitWv/+/saline group, Figure 3-8B). Increased 
MafA staining intensity was also observed in c-KitWv/+/1-AKP mouse beta-cells (Figure 
3-8D). These results were further supported by western blot analysis and showed 
significantly higher Pdx-1 protein levels in c-KitWv/+ islets from either 1-AKP injected 
mice or 1-AKP incubation when compared to c-KitWv/+/saline mice and c-KitWv/+ islets 
without 1-AKP treatment, respectively (Figure 3-8C). Furthermore, increased cyclin D1 
expression (Figure 3-7B and C and D) was correlated with a significant increase in Ki67 
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immunoreactivity in beta-cells of c-KitWv/+/1-AKP mice (vs. c-KitWv/+/saline group, Figure 
3-9).  
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Figure 3-7. Inhibition of Gsk3β maintains β-catenin and cyclin D1 level in c-
KitWv/+/1-AKP mouse islets. 
Western blot analyses of β-catenin (A) and cyclin D1 (B) protein levels in isolated 
islets from 8-week-old c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline and c-
KitWv/+/1-AKP mice (left column) and isolated islets from 8-week-old c-Kit+/+ and c-
KitWv/+ mice cultured with or without 1-AKP treatment for 24  hours (right column). 
Representative blots are shown. Data (A and B) are normalized to β-actin. qRT-PCR 
analysis of Ccnd1 mRNA in isolated islets (C) and the number of nuclear cyclin D1+ 
cells in beta-cells (D) of c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline, and c-
KitWv/+/1-AKP mice. Data (A-D) are expressed as mean ± SEM (n=5–8), *p<0.05, 
**p<0.01, ***p<0.001 analyzed by one-way ANOVA followed by LSD post-hoc 
test. 
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Figure 3-8. Inhibition of Gsk3β results in increased Pdx-1 and MafA expression 
in c-KitWv/+/1-AKP mice. 
qRT-PCR analyses of Pdx-1 and MafA mRNA in isolated islets (A) and the number 
of Pdx-1+ cells (B) in beta-cells of c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline 
and c-KitWv/+/1-AKP mice. (C) Western blot analysis of Pdx-1 protein levels in 
isolated islets from 8-week-old c-Kit+/+/saline, c-Kit+/+/1-AKP, c-KitWv/+/saline and 
c-KitWv/+/1-AKP mice (left column) and isolated islets from 8-week-old c-Kit+/+ and 
c-KitWv/+ mice cultured with or without 1-AKP treatment for 24  hours (right column). 
(D) An increased MafA staining intensity was observed in the islet of c-KitWv/+/1-
AKP mice when compared to c-KitWv/+/saline treated mice. No counterstaining was 
applied and nuclei are white transparent. Scale bar 25 µm. Data (A-C) are expressed 
mean ± SEM (n=5–8) *p<0.05, **p<0.01, ***p<0.001 analyzed by one-way 
ANOVA followed by LSD post-hoc test. 
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Figure 3-9. Inhibition of Gsk3β results in increased beta-cell proliferation in c-
KitWv/+/1-AKP mice. 
(A) Double immunofluorescence staining of Ki67 (green) with insulin (red) and 
nuclear stained with DAPI (blue). Arrows indicate Ki67/insulin double-positive cells. 
Scale bar 20  µm. (B) Percentage of Ki67+ cells in beta-cells of c-Kit+/+/saline, c-
Kit+/+/1-AKP, c-KitWv/+/saline and c-KitWv/+/1-AKP mice. Data are expressed mean ± 
SEM (n=5–8) *p<0.05, **p<0.01, ***p<0.001 analyzed by one-way ANOVA 
followed by LSD post-hoc test. 
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Figure 3-10. A proposed model involving c-Kit/Akt/Gsk3β signaling pathways in 
beta-cell survival and function in c-KitWv/+ mice. 
(A) Mutating the c-Kit receptor (grey star) at the Wv locus lead to a down-regulation 
of the PI3K/Akt pathway via reduced phosphorylation of Akt at S473, which resulted 
in enhanced active Gsk3β  and increased inhibition of Pdx-1 and cyclin D1 
expression. (B) Direct inhibition of active Gsk3β with 1-AKP preserved β-catenin 
protein levels, along with maintained cyclin D1 and Pdx-1 expression that allowed 
improvement of beta-cell proliferation and function and prevented the onset of 
diabetes in c-KitWv/+ mice. sSCF: soluble Stem Cell Factor; mSCF: membrane-bound 
Stem Cell Factor. Green arrow: positive signaling; red arrow: negative signaling. 
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3.4 Discussion 
The present study demonstrates that diabetic c-KitWv/+ mice displayed reduced levels of 
phospho-Akt at residue S473 and phospho-Gsk3β at residue S9 in both pancreatic and 
isolated islet protein extracts. These mice also possess decreased cyclin D1 expression in 
their beta-cells. When treated with 1-AKP, c-KitWv/+ mice demonstrated significant 
improvements in fasting glucose, glucose tolerance and insulin secretion along with 
increased beta-cell mass and proliferation. These results indicate that the Akt/Gsk3β 
pathway downstream of c-Kit is predominantly involved in regulating beta-cell 
proliferation and function in c-KitWv/+ mice and that inhibition of Gsk3β activation can 
significantly improve glucose tolerance and beta-cell function (Figure 3-10). 
The PI3K pathway is one of the major downstream pathways of c-Kit that triggers a 
variety of pro-survival signaling events, such as cell survival, cell growth, and cell cycle 
entry via Akt phosphorylation [14, 26]. Akt, a serine/threonine protein kinase, exerts its 
effects after being phosphorylated by PI3K at two regulatory residues: T308 in the 
activation segment, and S473 in the hydrophobic motif of the kinase domain [27]. In this 
study, we showed decreased protein levels of phospho-Akt at S473, but not at T308 in c-
KitWv/+ mice when compared to controls. c-KitWv/+ mice are heterozygous for the c-Kit Wv 
mutation caused by substitution of a threonine to methionine at amino acid 660 in the 
kinase domains of the c-Kit gene [28], and this loss-of-function mutation leads to down-
regulation, but not abolition of c-Kit activity. Previous research has demonstrated that 
Akt monophosphorylation on T308 showed only 10% kinase activity compared to 100% 
when Akt was doubly phosphorylated on S473 and T308 [27], suggesting that S473 
phosphorylation is required for maximal kinase activity of Akt [27]. Therefore, our 
results demonstrate that c-KitWv/+ mice showed significant down-regulation of the 
primary Akt phosphorylation site required conferring maximal activity, S473. 
It is well documented that Gsk3β is the target of many important signaling molecules 
[29]. In particular, Akt blocks the catalytic activity of the kinase, and activates 
downstream signals repressed by active Gsk3β [26]. In this study, we observed reduced 
Gsk3β phosphorylation and cyclin D1 protein levels in islets of c-KitWv/+ mice, which is 
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consistent with the role of cyclin D1 as essential for postnatal beta-cell growth [30]. 
Active Gsk3β promotes destabilization of cyclin D1 and thus cell cycle arrest, which is 
associated with Akt inactivation [31]. Taken together, our results suggest that Akt/Gsk3β 
axis dysregulation from the c-Kit Wv mutation contributed to loss of beta-cell mass and 
function, which may have been responsible for the early onset of diabetes observed in c-
KitWv/+ mice reported previously [6]. 
It has been previously shown that Gsk3β is involved in differentiation and proliferation of 
numerous tissue types including beta-cells [21, 22]. Tanabe et al. showed that genetic 
ablation of Gsk3β in Irs-/- mice preserved beta-cell function and prevented the onset of 
diabetes [32]. Moreover, mice with beta-cell-specific ablation of Gsk3β were resistant to 
HFD-induced diabetes [22]. These studies suggest that endogenous Gsk3β activity is 
involved in a highly specialized feedback inhibition mechanism with the insulin receptor, 
which primarily signals via the PI3K/Akt pathway. In this study, c-KitWv/+ mice received 
treatment of a Gsk3β inhibitor for 2 weeks and showed significant improvements in 
glucose tolerance and beta-cell function when compared to saline-treated c-KitWv/+ 
controls, which showed diabetic symptoms. In addition, no significant differences in 
insulin tolerance were observed between the experimental groups suggesting that this 
improvement in glucose tolerance and beta-cell function was not due to enhanced 
peripheral insulin sensitivity, but primarily to improved beta-cell proliferation and 
function in c-KitWv/+ mice received 1-AKP treatment.  
Our morphological analyses revealed that improved glucose tolerance and insulin 
secretion was associated with preservation of beta-cell mass and an increase in islet 
number in c-KitWv/+/1-AKP mice. The most notable change was a significant increase in 
the percentage of small islets (<500 µm2), with a relative increase in the number of large 
islets (>10000 µm2), suggesting that inhibition of Gsk3β activity is associated with an 
increase in beta-cell neogenesis and proliferation. β-catenin and cyclin D1 are two 
potential targets of Gsk3β, and have been implicated in beta-cell growth [30, 33]. 
Preserved beta-cell mass in c-KitWv/+/1-AKP group was accompanied by increased beta-
cell proliferation (Ki67), and maintained β-catenin and cyclin D1 protein levels, which 
closely matched those in c-Kit+/+ group. This is in agreement with the role of β-catenin in 
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up-regulating cyclin D1 expression to promote beta-cell expansion [33, 34]. These results 
suggest that Akt/Gsk3β axis-mediated β-catenin activation in islets may regulate beta-cell 
growth and function in c-KitWv/+ mice [1-8, 35]. 
The critically important pancreatic transcription factor, Pdx-1 has been shown to regulate 
beta-cell survival, function and pancreatic development [9-12, 36, 37]. Previous studies 
have also demonstrated that reduction of Pdx-1 impairs islet insulin secretion [13, 38, 
39], while, a partial reduction in Pdx-1 has a major effect on beta-cell survival with 
reductions in BclXL and Bcl2 expression [14, 37, 40]. Using c-KitWv/+ mice, we observed 
a significant reduction in Pdx-1 expression (~50% of c-Kit+/+ controls) along with 
impaired beta-cell function [6], and an up-regulation in the Fas associated cell death 
pathway (see Chapter 4). In this study, Pdx-1 mRNA and protein levels were maintained 
upon Gsk3β inhibition. Previous studies in isolated mouse islets have shown that Pdx-1 is 
negatively regulated in a Gsk3β-dependent manner [16-18, 41]. In addition, inhibition of 
Gsk3β by activated Akt could ameliorate Pdx-1 phosphorylation leading to a 
consequential delay of its degradation, which suggests that Pdx-1 accumulation in beta-
cells may be regulated by the Akt/Gsk3β axis [19, 42]. Further in vivo studies have 
demonstrated that Gsk3β ablation in mouse beta-cells lead to increased Pdx-1 protein 
levels [19, 22, 32]. In addition, a significant up-regulation of MafA mRNA expression in 
c-KitWv/+/1-AKP mouse islets was observed. Overexpression of MafA in neonatal rat beta-
cells led to enhanced glucose-responsive insulin secretion and beta-cell maturation [19, 
43]. Taken together, the findings of the present study showed that Akt/Gsk3β signaling, 
downstream of c-Kit, is not only required for beta-cell proliferation. By modulating Pdx-
1 and MafA expression, this signalling pathway is likely essential for beta-cell function 
and differentiation. 
This study demonstrates that the Gsk3β inhibitor, 1-AKP, predominantly improved beta-
cell proliferation and function, and had no significant effects in peripheral tissues, like 
muscle or liver insulin sensitivity. However, previous studies have shown that treatment 
of Gsk3β inhibitors improved glucose homeostasis by ameliorating muscle and liver 
insulin resistance in non-insulin dependent obese animal models [20, 44-46]. The c-Kit 
Wv point mutation primarily causes defect in melanocytic, hematopoietic, and endocrine 
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cell lineages, with no apparent muscle and liver dysfunction [6, 21, 28, 47]. This is in 
contrast to non-insulin dependent diabetic animal models, such as ZDF rat and ob mice 
that have primary defects in muscle and liver insulin stimulated peripheral glucose 
transport activity [22, 44-46]. Thus, we speculate that the effect of Gsk3β inhibition is 
highly tissue-specific depends on functional defects in specific cell types among different 
mouse models.  
In summary, this study elucidates a novel link between c-Kit and the Akt/Gsk3β/cyclin 
D1 signaling pathways and their effects on beta-cell proliferation and function in vivo.  
Our results suggest that dysregulated Akt/Gsk3β/cyclin D1 downstream from the c-Kit 
Wv mutation is the possible signaling mechanism that contributes to the loss of beta-cell 
mass and function in c-KitWv/+ mice reported in our previous publication [6]. 
Furthermore, chronic inhibition of Gsk3β in c-KitWv/+ mice resulted in increased β-
catenin, cyclin D1, and Pdx-1 protein levels, suggesting that regulation of downstream 
signaling increased beta-cell proliferative capacity, mass, as well as later improved 
glucose tolerance, and helped prevent early onset of diabetes. Taken together, the 
findings of present study emphasizes that understanding the complex intracellular 
pathways that affect beta-cell proliferation and function in vivo, which c-Kit regulates, 
will enable the development of more successful treatment protocols for diabetes.  
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Chapter 4  
4 Down-regulation of Fas activity rescues early onset of 
diabetes in c-KitWv/+ mice3 
  
                                                
3
 This chapter has been modified and adapted from the following manuscript: 
v Feng ZC, Riopel M, Li J, Donnelly L, Wang R. (2013) Improved beta-cell proliferation and 
function in c-KitWv/+;Faslpr/lpr double mutant mice. Am J Physiol Endocrinol Metab. 304:E557-
E565. 
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4.1 Introduction 
The prevalence of diabetes has been increasing at an alarming rate. During the 
progression of diabetes, pancreatic beta-cells are often lost because the delicate balance 
between beta-cell proliferation and death is disrupted [1-4]. Our previous studies showed 
that c-KitWv/+ mice, which contain a point mutation in the kinase region (Wv) of c-Kit, 
exhibit severe beta-cell mass loss that was associated with a significant down-regulation 
of the PI3K/Gsk3β/cyclin D1 signaling [5, 6] and this affects beta-cell proliferation. 
However, the underlying mechanisms involved in c-Kit-mediated effects on beta-cell 
apoptosis have yet to be determined in c-KitWv/+ mice. 
Fas belongs to the tumor necrosis factor family and requires the FasL for activation. 
Fas/FasL interactions result in activation of Fas-associated death domains and cleavage 
of caspase 8, which triggers apoptotic pathway. In diabetes, beta-cells constitutively 
express Fas [7-11]. Fas/FasL interactions were suggested to be one of the major 
mechanisms leading to beta-cell apoptosis in T cell-mediated autoimmune diabetes [12-
14]. In addition, cytokine-induced up-regulation of the Fas apoptotic pathway is also 
involved in glucotoxicity and subsequent increases in beta-cell death [15]; meanwhile, 
deletion of FAS protects human islet amyloid polypeptide deposition-mediated beta-cell 
apoptosis [16]. In vivo studies have demonstrated that non-obese diabetic mice with non-
functional Fas (global lpr/lpr mutation) show protection against diabetes [13, 14], and 
transgenic mice with beta-cell specific knockout of Fas exhibit increased beta-cell insulin 
secretion function [2]. 
There have been numerous studies in hematopoietic cells, melanocytes and germ cells 
indicating that Fas-mediated cell apoptosis can be prevented by up-regulation of SCF/c-
Kit interactions [17, 18]. Conversely, in cells with deficient c-Kit signaling, down-
regulation of Fas can rescue cell death and dysfunction [19-23]. In this study, we 
generated c-KitWv/+;Faslpr/lpr (Wv;-/-) double mutant mice to understand the inter-
relationship between c-Kit and Fas with respect to beta-cell survival and function. 
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4.2 Materials and methods 
Mouse model: In this study, two mouse models were used: 1) c-KitWv/+ mice (see detail in 
section 2.1.1, and same mouse model used in Chapter 3), and 2) c-KitWv/+;Faslpr/lpr double 
mutant mice (see detail in section 2.1.2). c-KitWv/+, c-KitWv/+;Fas+/+(Wv;+/+), and c-
KitWv/+;Faslpr/lpr(Wv;-/-) mice were the experimental groups, while c-Kit+/+ and c-
Kit+/+;Fas+/+(WT) were designated as the control groups. Genotyping was detailed in 
section 2.2. Mice were kept until 8 weeks of age with normal diet at which point, 
metabolic studies, islet morphological studies, and islet qRT-PCR, islet protein analyses 
were performed. Only male mice were used for this study. 
Metabolic studies:  Body weight, fasting (4-hour) blood glucose levels, IPGTT and IPITT 
analyses were performed on Wv;-/- mice and compared to WT and Wv;+/+ littermates at 
8 weeks of age, as detailed in section 2.3.  
In vivo, ex vivo GSIS studies, and insulin ELISA analyses: in vivo GSIS, and ex vivo 
GSIS on isolated islets, were performed from WT, Wv;+/+ and Wv;-/- mice at 8 weeks of 
age, as detailed in sections 2.4 and 2.5.  
INS-1 cell culture studies: To study the inter-balance relationship between c-Kit and Fas 
signaling on cell apoptosis, INS-1 cells were treated with SCF for 24 hours, or cultured 
for 48 hours with control siRNA, c-Kit siRNA with or without PFT-α (p53 inhibitor), or 
combined c-Kit siRNA and Fas siRNA, as detailed in section 2.6.2.  
Immunofluorescence and morphometric analyses: Pancreatic tissue sections from mice at 
8 weeks of age were prepared and double-stained with appropriate antibodies listed in 
Appendix 5. Islet number, islet size, alpha and beta-cell mass were measured. Cell 
proliferation (Ki67+ labeling), and apoptosis (TUNEL+ labeling), Fas positive staining in 
beta-cell nuclei was quantified, and the average percent of Ki67+/insulin+, 
TUNEL+/insulin+, and Fas+/insulin+ cells was calculated, as detailed in section 2.7.  
Protein extraction and western blot analyses: protein levels of Fas, FasL, c-Kit, cleaved 
caspase 3D175, total caspase 3, cleaved caspase 8D391, total caspase 8, p53, and 
corresponding housekeeping proteins including calnexin and β-actin in isolated islets 
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from mice at 8 weeks of age or in INS-1 cells were analyzed (Appendix 6), as detailed in 
section 2.8.  
RNA extraction and real-time RT-PCR analyses: RNA was extracted from isolated islets 
of WT, Wv;+/+, Wv;-/- mice at 8 weeks of age. mRNA expression of Bax, Bcl2, Cflar (c-
Flip), Kit (c-Kit), Fas, FasL, Glucagon, Insulin, MafA, NFkb1 (Nfκb1), NFkb2 (Nfκb2), 
Pdx-1, RelA, RelB, Trp53 (p53) was measured and normalized to 18S rRNA (Appendix 
7), as detailed in section 2.9. 
4.3 Results 
4.3.1 c-KitWv/+ mice show increased beta-cell apoptosis due to increased 
p53 signaling and resulting up-regulated Fas activity  
c-KitWv/+ mice had severe beta-cell loss and dysfunction, which was associated with 
Akt/Gsk3β/cyclin D1 pathway down-regulation[6]. Significantly elevated p53 mRNA 
expression and protein levels were observed in the islets of c-KitWv/+ mice when 
compared to c-Kit+/+ mice (Figure 4-1A). Fas mRNA expression was significantly 
elevated in c-KitWv/+ islets (Figure 4-1B), which was corroborated with increased Fas 
protein levels (Figure 4-1B) and Fas-expressing insulin positive cells (Figure 4-1D) 
relative to c-Kit+/+ group. However, there was no significant alteration of FasL among all 
groups (Figure 4-1C). A significant increase in beta-cell apoptosis, as indicated by 
elevated TUNEL staining in insulin-positive cells, was observed in c-KitWv/+ mice (Figure 
4-1E).  
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Figure 4-1. Up-regulation of p53 and Fas signaling in isolated islets from c-
KitWv/+ mice. 
qRT-PCR and western blot analyses of p53 (A), Fas (B), and FasL levels (C) in 
isolated islets of c-Kit+/+ and c-KitWv/+ mice at 8 weeks of age. Representative blots 
are shown. Data are normalized to loading control (calnexin). Percentage of Fas+ (D) 
and TUNEL+ (E) beta-cells in c-Kit+/+ and c-KitWv/+ mice at 8 weeks of age. Data (A-
E) are expressed as mean ± SEM (n=3-10), *p<0.05, **p<0.01 analyzed by unpaired 
student’s t-test. 
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In vitro studies on INS-1 cells were used to further understand the relationship between c-
Kit, p53, and Fas in the regulation of beta-cell survival. The expression of c-Kit and Fas 
mRNA in INS-1 cells was measured by qRT-PCR and showed relatively higher c-Kit and 
lower Fas expression in INS-1 cells when compared to normal mouse islets (Figure 4-
2A). INS-1 cells treated with exogenous SCF showed a slight reduction in p53 and a 
significant decrease in Fas protein levels, which was attenuated by the addition of a PI3K 
inhibitor, wortmannin (Figure 4-2B). However, when INS-1 cells were transfected with 
c-Kit siRNA, the protein levels of p53, Fas and cleaved caspase 3 was significantly 
elevated compared to the controls (Figure 4-3). Interestingly, cells transfected with c-Kit 
siRNA and treated with PFT-α (p53 inhibitor) or co-transfected with Fas siRNA 
displayed significantly abated protein levels of p53, Fas and cleaved caspase 3 when 
compared to c-Kit siRNA-transfected INS-1 cells (Figure 4-3). Fas protein levels were 
significantly reduced in the Fas siRNA group when compared to the control siRNA 
group (Figure 4-4A). Furthermore, INS-1 cell apoptosis was measured by TUNEL 
staining, which demonstrated a significant increase in the c-Kit siRNA group as 
compared to other experimental conditions (Figure 4-4B).    
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Figure 4-2. Increased SCF/c-Kit interaction in INS-1 cells results in decrease of 
p53 and Fas expression via the PI3K pathway. 
(A) qRT-PCR analyses of c-Kit and Fas mRNA levels, in 8-week-old c-Kit+/+ mouse 
islets, INS-1 cells, and INS-1 cells with SCF treatment cultured for 24 hours. (B) 
Western blot analyses of p53 and Fas protein levels in INS-1 cells cultured with 
serum-free medium plus 50 ng/mL SCF with and without wortmannin (Wort, PI3K 
inhibitor) for 24 hours. Representative blots are shown. Data are normalized to 
loading control (β-actin). Data (A and B) are expressed as mean ± SEM (n=3), 
*p<0.05 analyzed by one-way ANOVA followed by LSD post-hoc test. 
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Figure 4-3. Absence of c-Kit signaling induces the p53/Fas-mediated caspase-
dependent apoptotic signaling. 
Western blot analyses of c-Kit, p53, Fas, and D175-cleaved (C) and total (T) caspase 
3 protein levels in INS-1 cells transfected with c-Kit siRNA and cotreated with PFT-
α (p53 inhibitor) or Fas siRNA for 48 hours. Representative blots are shown. Data 
are normalized to total protein or loading control (calnexin or β-actin) and expressed 
as mean ± SEM (n=3–4), *p<0.05, **p<0.01, ***p<0.001 analyzed by one-way 
ANOVA followed by LSD post-hoc test. 
 
112 
 
 
  
113 
 
  
Figure 4-4. Knockdown of Fas decreases cell apoptosis. 
(A) Fas protein levels in INS-1 cells cultured with control or Fas siRNA for 48 
hours. Representative blots are shown. Data is normalized to loading control 
(calnexin) and expressed as mean ± SEM (n=4), *p<0.05 analyzed by unpaired 
student’s t-test, (B) Percentage of TUNEL positivity in INS-1 cells under all 
experimental conditions (control siRNA, c-Kit siRNA, c-Kit siRNA with PFT-α, c-
Kit siRNA with Fas siRNA). Data are expressed as mean ± SEM (n=4), *p<0.05, 
**p<0.01, ***p<0.001 analyzed by one-way ANOVA followed by LSD post-hoc 
test. Representative images of TUNEL staining (green) and DAPI (blue). Scale bar, 
10 µm. 
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4.3.2 Down-regulation of Fas in c-KitWv/+ mice leads to improved beta-
cell function 
At 8 weeks of age, there was no difference in body weight (Figure 4-5A), but fasting 
blood glucose levels were significantly lower in Wv;-/- mice compared to Wv;+/+ mice 
(Figure 4-5B), while significantly higher than their WT littermates (Figure 4-5B). Wv;-/- 
mice had significantly improved glucose tolerance demonstrated by decreased AUC 
relative to Wv;+/+ mice (Figure 4-5C). There were no significant changes observed in 
insulin tolerance among the three different groups (Figure 4-5D). In vivo GSIS analyses 
demonstrated that insulin secretion in Wv;-/- mice was significantly higher at all three 
time points (0, 5 and 35 minutes after glucose challenge) when compared to Wv;+/+ 
mice (Figure 4-6A). This was further corroborated with our observations from the ex vivo 
GSIS assay, which showed a significant increase in insulin secretion from Wv;-/- mouse 
islets after incubation in 22 mM glucose, as compared to Wv;+/+ mouse islets (Figure 4-
6B). However, the ability of Wv;-/- mice islets to respond to a 22 mM glucose challenge 
was significantly lower compared to islets from WT mice (Figure 4-6B). Insulin secretion 
from the ex vivo GSIS assay was comparable to measured insulin content, which was 
significantly higher in islets from Wv;-/- mice relative to Wv;+/+ mice (Figure 4-6C), but 
not significantly lower than WT mice (Figure 4-6C). It was noted that the effect of 
glucose on islet insulin secretion was smaller in all groups when compared to previous 
reports, which may be associated with increased sensitivity when islets are freshly 
isolated.  
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Figure 4-5. Fasting blood glucose and glucose tolerance on c-KitWv/+;Faslpr/lpr 
(Wv;-/-) mice at 8 weeks of age. 
Body weight (A), fasting blood glucose (B), IPGTT (C), and IPITT (D) of WT, 
Wv;+/+, and Wv;−/− mice at 8 weeks of age. Glucose responsiveness of the 
corresponding experimental groups is shown as a measurement of AUC of the 
IPGTT or IPITT graphs with units of (mmol/L x minutes). Data (A-D) are expressed 
as mean ± SEM (n=5-8), *p<0.05, **p<0.01, ***p<0.001 analyzed by one-way 
ANOVA followed by LSD post-hoc test. 
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Figure 4-6. GSIS and insulin content in c-KitWv/+;Faslpr/lpr(Wv;-/-) mice at 8 weeks 
of age. 
(A) In vivo GSIS of WT, Wv;+/+, and Wv;−/− mice at 8 weeks of age, (B) Ex vivo 
GSIS on isolated islets from WT, Wv;+/+, and Wv;−/− mice at 8 weeks of age. Data 
are expressed as fold change normalized to basal (2.2 mM glucose) secretion, (C) 
Insulin content in isolated islets from WT, Wv;+/+, and Wv;−/− mice at 8 weeks of 
age where data are normalized to DNA content. Data (A-C) are expressed as mean ± 
SEM (n=3-7), *p<0.05, **p<0.01 analyzed by one-way ANOVA followed by LSD 
post-hoc test. 
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4.3.3 Increased beta-cell mass and proliferation, and decreased beta-cell 
apoptosis observed in c-KitWv/+;Faslpr/lpr double mutant mice 
Islet morphology was analyzed by immunostaining (Figure 4-7A). Pancreatic weight was 
unchanged between experimental groups at 8 weeks of age (data not shown). However, 
Wv;-/- mice displayed a significant increase in islet number when compared to Wv;+/+ 
mice (Figure 4-7B), and no difference when compared to WT mice (Figure 4-7B). Alpha-
cell mass was unchanged among the experimental groups (data no shown), but Wv;-/- 
mice exhibited a doubling of beta-cell mass compared to Wv;+/+ mice (Figure 4-7C). 
Furthermore, Wv;-/- mice showed a significant increase in beta-cell proliferation, 
determined by Ki67 labeling (Figure 4-7D and F), with a 2-fold decreased in TUNEL 
positive beta-cells when compared to Wv;+/+ mice (Figure 4-7E and G).   
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Figure 4-7. Islet morphology and immunohistochemical analysis of endocrine 
cell mass, cell proliferation, and cell death in c-KitWv/+;Faslpr/lpr(Wv;-/-) mice at 8 
weeks of age. 
(A) Representative images of islet morphology by double immunofluorescence 
staining for insulin (red) and glucagon (green), and nuclei stained with DAPI (blue). 
Scale bar, 50 µm. Islet number (B), beta-cell mass (C), percentage of Ki67+ (D) and 
TUNEL+ beta-cells (E) in WT, Wv;+/+, and Wv;−/− mice at 8 weeks of age. Data  
(B-E) are expressed as mean ± SEM (n=3-6), *p<0.05, **p<0.01, ***p<0.001 
analyzed by one-way ANOVA. Representative double immunofluorescence staining 
images for Ki67 (F) and TUNEL (G) (green) with insulin (red) in islets of WT, 
Wv;+/+, and Wv;−/− mice at 8 weeks of age. Nuclei are stained with DAPI (blue). 
Arrows indicate double-labeled cells. Scale bar, 20 µm. 
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4.3.4 Down-regulation of Fas in the absence of c-Kit signaling activates 
the cFlip/NF-κB pathway, and increases islet transcription factor 
expression  
To further investigate the underlying mechanisms in Wv;-/- mice, gene expression was 
assessed in isolated islets by qRT-PCR. Analyses of insulin, glucagon, Pdx-1, and MafA 
showed significantly increased mRNA expression in Wv;-/- mice when compared to 
Wv;+/+ and WT mice (Figure 4-8A). Furthermore, the mRNA expression of cFlip, RelA, 
RelB, and NFkb2 in isolated islets of Wv;-/- mice were significantly increased as 
compared to Wv;+/+ mice (Figure 4-8B). However, no significant changes were found in 
the mRNA expression of Bax and a ratio of Bcl-2 over Bax between Wv;+/+ and Wv;-/- 
mouse islets (Figure 4-8C). Furthermore, western blot analyses showed down-regulation 
of Fas signaling, as indicated by a significant reduction of cleaved caspase 8 and 3 
protein levels in Wv;-/- mouse islets (Figure 4-9) and this was correlated with reduced 
beta-cell apoptosis in Wv;-/- mice compared to Wv;+/+ group (Figure 4-7E and G).   
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Figure 4-8. Expression of transcription factors, endocrine genes, and signaling 
molecules in c-KitWv/+;Faslpr/lpr(Wv;-/-) mice. 
(A) qRT-PCR analyses of insulin (I and II), glucagon, Pdx-1, and MafA. Fas-
mediated signaling molecules (B), and Bax and Bcl2/Bax ratio (C) in isolated islets 
of WT, Wv;+/+, and Wv;−/− mice at 8 weeks of age. Data (A-C) are expressed as 
mean ± SEM (n=4). *p<0.05, **p<0.01, ***p<0.001 analyzed by one-way ANOVA 
followed by LSD post-hoc test. 
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Figure 4-9. Expression of cleaved caspase 8 and 3 in c-KitWv/+;Faslpr/lpr (Wv;-/-) 
mice at 8 weeks of age. 
Western blot analyses of Fas levels along with cleaved (C) and total (T) caspase 8 
and 3 levels in isolated islets of WT, Wv;+/+, and Wv;−/− mice at 8 weeks of age. 
Representative blots are shown. Data are normalized to total protein or loading 
control (calnexin) and expressed as mean ± SEM (n=4). *p<0.05, **p<0.01 analyzed  
analyzed by one-way ANOVA followed by LSD post-hoc test. 
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Figure 4-10. Proposed model of c-Kit and Fas signaling that mediates beta-cell 
proliferation, function, and survival. 
The Wv mutation of c-Kit (red star) causes down-regulation of Akt phosphorylation 
with increased p53 levels and subsequent induction of Fas-mediated beta-cell 
apoptosis. Down-regulation of the Fas pathway (yellow star) by the lpr mutation in 
c-KitWv/+ mice rescues early onset of diabetes by down-regulating caspase 8 and 3 
cleavage, up-regualting beta-cell proliferation, and key islet transcription factors, 
suggesting that the interrelationship between c-Kit and Fas signaling is critical for 
the maintenance of beta-cell mass and function. sSCF: soluble Stem Cell Factor; 
mSCF: membrane-bound Stem Cell Factor; FasL: Fas ligand. Red arrow: negative 
signaling; green arrow: positive signaling. Solid line: direct regulation; Dotted line: 
indirect regulation.   
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4.4 Discussion 
In this study, we demonstrated that the loss of beta-cell mass in c-KitWv/+ mice is due to 
increased p53 and Fas levels, along with associated downstream caspase-mediated beta-
cell death in c-KitWv/+ mouse islets (Figure 4-10). Mutation of Fas (lpr) rescued early 
onset of diabetes in c-KitWv/+ mice by enhancing insulin secretory function and increasing 
beta-cell survival. This improvement was associated with down-regulation of the Fas-
mediated extrinsic apoptotic pathway, and up-regulation of the cFLIP/NF-κB pathway, as 
well as the key islet transcription factors (Pdx-1 and MafA). Therefore, the present 
findings suggest that a balance between c-Kit and Fas signaling pathway is required to 
maintain beta-cell mass and function. 
Both p53 and Fas levels were up-regulated in the islets of c-KitWv/+ mice, which was 
correlated with increased beta-cell apoptosis. It has been documented that p53 is an 
important checkpoint protein that regulates cyclin D1 expression during cell cycle 
progression in many cell types [24, 25]. Although the cellular mechanism by which c-Kit 
regulates p53 is unclear, we have previously demonstrated that decreased cyclin D1 
levels are observed in c-KitWv/+ mouse islets [6], suggesting that inhibition of cell cycle 
progression by c-Kit deficiency may be p53-dependent. Not only is p53 involved in cell 
cycle arrest, it also plays a pivotal role in cell apoptosis. Several apoptotic genes are up 
regulated by p53 [26-29], in particular, p53 induces Fas mRNA expression by binding to 
elements that are found in the promoter and first intron regions of the Fas gene [27]. 
Also, overexpression of p53 may promote trafficking of the Fas to the cell surface via the 
Golgi apparatus [30]. Thus, the elevated p53 levels observed in c-KitWv/+ mouse islets 
suggest that p53 serves as a mediator in cell cycle arrest and may induce Fas-mediated 
apoptosis in the absence of c-Kit signaling, in vivo. However, FasL levels were slightly 
increased in c-KitWv/+ mouse islets, suggesting that FasL was already present at 
sufficiently high levels, and that beta-cell apoptosis is dependent upon Fas expression in 
islets. The inter-relation between c-Kit, p53 and Fas was further examined by stimulation 
of c-Kit via up- and down-regulation assays in INS-1 cells. Activation of c-Kit by 
exogenous SCF reduced both p53 and Fas protein levels in a PI3K-dependent manner. 
When cells were transfected with c-Kit siRNA, there was up-regulation of p53 and Fas 
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protein levels, which was reversed by the addition of a p53 inhibitor or Fas siRNA 
transfection and led to reduced apoptosis. These data suggest that c-Kit plays a key role 
in regulating p53-induced Fas-mediated cell death. p53-mediated Fas up-regulation has 
been proposed by several in vitro [27, 30, 31] and rodent studies [32, 33], and is likely 
responsible for increasing beta-cell apoptosis in c-KitWv/+ mice. 
To further elucidate the physiological role of Fas in the absence of c-Kit signaling, in vivo, 
we generated Wv;-/- mice bearing both c-Kit Wv and Fas lpr mutations, and found that 
anti-apoptotic genes such as cFlip, NFκB2, and both RelA and RelB were significantly 
up-regulated in Wv;-/- mouse islets. It is well-established that Fas-mediated apoptosis 
occurs through activation of procaspase-8, the most upstream caspase in the Fas apoptotic 
pathway, while cFlip, a protease-deficient caspase homolog to caspase-8, is able to 
modulate activation of procaspase-8, and trigger pro-survival signaling [34]. Although 
previous studies have documented that caspase 8 may be involved in the activation of 
NF-κB [35], the present study suggests that the up-regulation of NF-κB is independent of 
caspase-8 activity. Our data indicate that cFlip exerts its physiological function by 
triggering the NF-κB signaling pathway, which plays an important role in regulating cell 
survival and proliferation [36]. Therefore, in Wv;-/- mouse islets, an up-regulation of 
cFlip could have enhanced NF-κB activity by increasing NF-κB-inducing kinases, 
leading to improved beta-cell function and survival. 
We further investigated the signaling pathway downstream of Fas that regulates beta-cell 
apoptosis and dysfunction in c-KitWv/+ mice. Cleaved caspase 8 and 3 levels were 
significantly increased in c-Kit siRNA-transfected INS-1 cells and c-KitWv/+ mouse islets. 
However, down-regulation of Fas in c-Kit-deficient islets resulted in significantly 
decreased cleaved caspase 8 and 3 levels when compared to controls. Previous ex vivo 
studies with human pancreatic beta-cells have shown that glucotoxicity-induced beta-cell 
apoptosis occurs via up-regulation of the Fas-mediated apoptotic pathway, which could 
be rescued by down-regulation of Fas [15, 16]. Furthermore, deletion of Fas in rodent 
pancreatic beta-cells has showed protection against FasL-induced apoptosis, and 
increased in vivo insulin secretion [2]. While much evidence has pointed to Fas as an 
important mediator of beta-cell apoptosis, downstream caspase 8 and 3 are also well 
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known for their roles as the principle executioners of beta-cells. In vivo, deletion of either 
caspase 8 or 3 in mouse beta-cells has shown to be protective against low doses of 
streptozotocin-induced cell death [37, 38]. Taken together, these results suggest that a 
loss of c-Kit signaling promotes beta-cell apoptosis and dysfunction, in part, by activation 
of the Fas-dependent apoptotic pathway.  
In this study, we demonstrated that c-Kit deficiency led to an increase in Fas expression, 
and a mutation in Fas rescued defects associated with the c-KitWv/+ mutation. The 
correlation between c-Kit and Fas signaling coincides well with previous studies, which 
suggest that PI3K/Akt signaling via c-Kit suppresses Fas-mediated extrinsic apoptotic 
signaling. However, several lines of evidence have also demonstrated that SCF-induced 
PI3K/Akt pathway signaling can inactivate proapoptotic transcriptional factor, FKHRL-1 
[8], as well as Bim, a proapoptotic member of the Bcl-2 family [10]. Therefore, our 
findings suggest that Fas-mediated apoptotic signaling is directly involved in beta-cell 
dysfunction, especially when Fas is up-regulated due to the c-Kit Wv mutation, but we 
also cannot exclude the participation of other apoptotic factors that may be regulated by 
the disrupted c-Kit/PI3K/Akt pathway. 
The biological role of Fas signaling is becoming increasingly complex. Controversial 
findings have reported both apoptotic and anti-apoptotic roles for Fas in the beta-cell in 
vivo. A previous study has reported that Fas is essential for beta-cell insulin secretory 
function, but not in the regulation of beta-cell mass [7]. Other studies have showed that 
islet-specific Fas deletion is protective against FasL- and ceramide-induced apoptosis ex 
vivo, and enhances beta-cell insulin secretion in vivo [2]. These discrepancies may be 
linked to differences in genetic backgrounds of the mouse strains used in these two 
studies. In this study, Wv;-/- mice were obtained by crossbreeding c-KitWv/+ and Faslpr/lpr 
mice both from a C57BL/6J background. Using the same mutant mouse model, previous 
studies have reported that loss of Fas function led to reduced apoptosis and improved 
function in granulosa cells, oocytes and germ cells of c-KitWv/+ mice [21, 22]. In 
agreement with these findings, we propose that a balance between c-Kit and Fas signaling 
is important for beta-cell survival and function.  
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Through analyses of INS-1 cells and c-KitWv/+;Faslpr/lpr mice, our results suggest that 
SCF/c-Kit interactions prevent Fas-mediated beta-cell apoptosis and dysfunction. This 
study advances the understanding of the relationship between c-Kit-mediated survival 
signals and Fas-mediated death signals in beta-cells, which will assist in the development 
of protocols that maintain beta-cell survival and function essential for cell-based 
therapies in the treatment of diabetes.   
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Chapter 5  
5 Critical role of c-Kit in beta-cell function: increased insulin 
secretion and protection against diabetes4  
  
                                                
4
 This chapter has been modified and adapted from the following manuscript: 
v Feng ZC*, Li J*, Turco B, Riopel M, Yee SP, Wang R. (2012) Critical role of c-Kit in beta-cell 
function: increased insulin secretion and protection against diabetes in a mouse model. 
Diabetologia 55:2214-2225. *Equal contribution 
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5.1 Introduction  
c-Kit is expressed in fetal and adult rodent pancreatic islets [1-4]. Our previous studies 
demonstrated that human and rat fetal pancreatic ductal cells expressing c-Kit display 
high proliferation and SCF expression [5-7]. Fetal rat islets treated with SCF 
demonstrates to a significant increase in insulin and DNA content [1]. Manipulation of 
islets in cell culture has further revealed that c-Kit-enriched cells can give rise to new 
beta-cells that secrete insulin in a glucose-responsive fashion [8]. However, down-
regulation of c-KIT expression in the human islet-epithelial clusters using siRNA leads to 
significantly reduced mRNA and protein levels of PDX-1 and insulin in conjunction with 
decreased cell proliferation and increased cell death [6]. These studies reveal a 
remarkable correlation between c-Kit function and enhanced beta-cell development and 
function. After pancreatic duct ligation in the rat, c-Kit is activated in ductal cells during 
islet cell neogenesis, along with increased of Pdx-1 expression [9]. Furthermore, 
increased c-Kit and Pdx-1 expression is observed in islets of streptozotocin-induced 
diabetic rat pancreata, suggesting that c-Kit is involved in beta-cell regeneration [10]. 
Homozygous c-Kit null mutant mice display relatively normal islet morphology, but they 
die shortly after birth and are not available for further functional studies [11]. We have 
previously characterized c-KitWv/+ mice, which have a point mutation in c-Kit, disrupting 
its receptor function. These mice exhibit a loss of beta-cell mass and proliferation, 
resulting in early onset of diabetes [12]. However, the global c-KitWv/+ mice model may 
not be sufficient to reveal whether c-Kit plays a primary or secondary role in beta-cell 
survival and function. In this study, we describe a novel mouse model, c-KitβTg, with 
specific c-KIT overexpression in beta-cells to further delineate the physiological role of c-
Kit in normal, HFD-induced diabetic and c-KitWv/+ mice. 
5.2 Materials and methods 
Mouse model: transgenic mice (c-KitβTg) with the human c-KIT gene insertion 
specifically in beta-cells was the experimental group, while the wild type (WT) 
littermates without the human c-KIT gene were designated as the control group. Both c-
KitβTg and WT mice were kept for 4 to 40 weeks of age with normal diet at which point, 
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metabolic studies, and subsequent islet morphological studies, islet qRT-PCR, and islet 
protein analyses were performed. For the HFD study, c-KitβTg and WT mice at 6 weeks 
of age were fed HFD for 4 weeks, at which point metabolic studies, and islet 
morphological studies were performed. For a rescue study in c-KitWv/+ mice, the c-
KitβTg;Wv mouse model was generated by crossbreeding c-KitβTg with c-KitWv/+ mice, 
yielding mice with four different genotypes including: wild type (WT), c-KitβTg, c-
KitWv/+ (Wv), and c-KitβTg;c-KitWv/+ (c-KitβTg;Wv), that were kept until 8 weeks of age, 
at which point metabolic studies were performed. Only male mice were used for this 
study. Generation of animal models was detailed in section 2.1.3, and genotyping was 
detailed in section 2.2.  
Metabolic studies, in vivo, and ex vivo GSIS analyses: Body weight, blood glucose levels 
(non-fasting, 4-hour and overnight fasting (16-hour)), IPGTT and IPITT analyses were 
performed throughout the study. In vivo GSIS, and ex vivo GSIS on isolated islets, were 
performed on mice in the normal diet, the HFD, and the rescued study. Food intake was 
monitored at 6 weeks of age for a 2-week period in the HFD study. See description in 
sections 2.3, 2.4 and 2.5. 
Immunofluorescence and morphometric analyses: Pancreatic tissue sections from mice 
were prepared and double-stained with appropriate antibodies listed in Appendix 5. Islet 
number, islet size, alpha and beta-cell mass were measured. Proliferation (Ki67+ 
labeling), Pdx-1, Pax6, Nkx2.2, Nkx.6.1, c-Kit, SCF, eGFP, Glut2, Glp1R (Glucagon-like 
peptide 1 receptor) positive staining in beta-cell nuclear was determined by double 
immunofluorescence staining. MafA+ staining on pancreatic islets was determined by 
immunohistochemical, as detailed in section 2.7.  
Protein extraction and western blot analyses: protein levels of Pdx-1, c-Kit, SCF, eGFP, 
phospho-AktS473, total Akt, phospho-Gsk3βS9, total Gsk3β, cyclin D1, and correspond 
housekeeping proteins including calnexin and β-actin from isolated mouse islets was 
analyzed (Appendix 6), as detailed in section 2.8. 
RNA extraction and real-time RT-PCR analyses: RNA was extracted from isolated mouse 
islets. mRNA expression of c-Kit, Glp1r (Glucagon-like peptide 1 receptor), Gcg 
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(Glucagon), Slc2a2 (Glut2), Insulin, MafA, Neurod1, Nkx2.2, Nkx6.1, Pax4, Pax6, Pdx-1, 
Kitl (SCF) was measured and normalized to 18S rRNA (Appendix 7), as detailed in 
section 2.9.  
5.3 Results 
5.3.1 Generation of transgenic mouse model with c-KIT overexpression 
specifically in beta-cells 
We generated c-KitβTg mice on a C57BL/6J background using the RIP to direct 
overexpression of the human c-KIT gene specifically in beta-cells. Human c-KIT was also 
linked with an IRES-eGFP to facilitate monitoring of transgene expression. Immunoblot 
analysis of eGFP in pancreas, liver, muscle, brain and isolated islet protein lysates 
showed positive signals in the pancreas and islets of c-KitβTg mice (Figure 5-1A). The 
RIP did not lead to any aberrant transgene expression. Fluorescence microscopy showed 
that eGFP was present in islets freshly isolated from c-KitβTg, but not in those from WT 
littermates (Figure 5-1B). This was further confirmed by immunofluorescence staining 
for eGFP and insulin (Figure 5-1B). The human c-KIT mRNA was only detected in c-
KitβTg mouse islets (Figure 5-1C), a finding corroborated by elevated islet c-Kit levels 
(Figure 5-1D) and c-Kit immunofluorescence staining (Figure 5-1E). We also examined 
the abundance of SCF, a ligand of c-Kit, in c-KitβTg mouse islets (Figure 5-2A). A 
significant increase of SCF (also known as Kitl) mRNA was noted in c-KitβTg islets 
compared with WT islets (Figure 5-2A); however, protein levels of SCF were not 
statistically different between c-KitβTg and WT islets (Figure 5-2B). Taken together, 
these results indicate that overexpression of human c-KIT under the transcriptional 
control of the RIP in c-KitβTg mice is specific to beta-cells. 
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Figure 5-1. Generation of C57BL/6J transgenic mice with c-KIT overexpression 
specifically in beta-cells (c-KitβTg). 
A) Western blot analysis of eGFP abundance in tissues as indicated and isolated 
islets. Representative blots are shown. (B) Abundance of eGFP on freshly isolated 
islets and pancreatic sections of 4-week-old WT and c-KitβTg mice by double 
immunofluorescence staining for eGFP (green) with insulin (red). (C) qRT-PCR 
analysis of the human c-KIT mRNA in isolated islets of WT and c-KitβTg mice at 
4 weeks of age. (D) Western blot analysis of c-Kit levels in isolated islets of WT and 
c-KitβTg mice at 8 weeks of age. Data are expressed as mean  ±  SEM (n=3), 
**p<0.01 analyzed by unpaired student’s t-test. (E) Immunofluorescence staining for 
c-Kit (green) and insulin (red) on pancreatic sections from 4-week-old WT and c-
KitβTg mice. Nuclei were stained with DAPI (blue). Representative images are 
shown. Scale bars (B, E), 25 µm. eGFP: enhanced green fluorescent protein. 
142 
 
 
  
143 
 
  
Figure 5-2. Expression of SCF levels in C57BL/6J transgenic mice with c-KIT 
overexpression specifically in beta-cells (c-KitβTg). 
(A) qRT-PCR and (B) western blot analysis of SCF in isolated islets of WT and c-
KitβTg mice at 8 weeks of age. Representative blots are shown. Data are normalized 
to loading control (β-actin). Data (A and B) are expressed as mean  ±  SEM (n  =4), 
***p<0.001 analyzed by unpaired student’s t-test.  
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5.3.2 Improved glucose tolerance and insulin secretion in c-KitβTg mice 
There were no significant differences in body weight during the 40 weeks of observation 
(Figure 5-3A), with no changes in food intake at 8 weeks of age, between c-KitβTg and 
WT mice (Figure 5-3B). No significant differences in 4-hour fasting plasma insulin and 
blood glucose levels (Figure 5-3C and D) were detected between c-KitβTg and WT mice 
at 8 weeks of age; however, the overnight fasting blood glucose levels were significantly 
lower in c-KitβTg mice than in WT littermates (Figure 5-3D). The IPGTT showed a 
relatively similar response capacity in c-KitβTg and WT mice at 4 weeks of age (Figure 5-
4A). However, significantly improved glucose tolerance was observed in c-KitβTg mice 
at 8 and 20 weeks of age, along with significant decreases in the AUC during the IPGTT 
(Figure 5-4B and C). No changes were observed in insulin tolerance between the 
experimental groups (Figure 5-4D). Furthermore, the effect of c-KIT overexpression on 
beta-cell insulin secretion was significant, with isolated islets from c-KitβTg mice 
releasing significantly more insulin than WT littermates in response to 22 mmol/L 
glucose (Figure 5-4E). This was associated with higher insulin content in c-KitβTg islets 
(Figure 5-4F).  
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Figure 5-3. Body weight, food intake and blood glucose level in c-KitβTg mice. 
(A) Body weight of c-KitβTg and WT mice from 4 to 40 weeks of age. (B) Food 
intake, (C) Fasting (4-hour) plasma insulin and (D) blood glucose levels in c-KitβTg 
and WT mice at 8 weeks of age. Data (A-D) are expressed as mean ± SEM (n=5-18). 
**p<0.01 analyzed by unpaired student’s t-test. FBG: fasting blood glucose; ON: 
overnight  
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Figure 5-4. Glucose tolerance, GSIS, and insulin content in c-KitβTg mice. 
IPGTT at 4 (A), 8 (B), and 20 (C) weeks of age, and (D) IPITT at 8 weeks of age on 
c-KitβTg and WT mice. Glucose responsiveness of the corresponding experimental 
groups is shown as a measurement of AUC of the IPGTT or IPITT graphs expressed 
as (mmol/L x minutes). (E) Ex vivo GSIS on isolated islets from c-KitβTg and WT 
mice at 8 weeks of age. Data are expressed as fold change normalized to basal (2.2 
mM glucose) secretion. (F) Insulin content in isolated islets from c-KitβTg and WT 
mice at 8 weeks of age where data are normalized to DNA content. Data (A-F) are 
expressed as mean ± SEM (n=3-18). *p<0.05, **p<0.01, ***p<0.001 analyzed by 
unpaired student’s t-test.  
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5.3.3 Increased islet transcription factors, beta-cell mass and 
proliferation in c-KitβTg mice 
To further characterize the functional role of c-Kit in beta-cells, we examined levels of 
transcription factors essential for islet growth, function and morphology in c-KitβTg and 
WT mice. At 8 weeks of age, we observed a slightly increased islet number (Figure 5-
5A), with a significant increase in the number of small (<500 µm2) and large islets 
(>10,000 µm2; Figure 5-5B) in c-KitβTg mice. No significant alterations in alpha-cell 
mass were detected between c-KitβTg and WT mice (Figure 5-5C). However, beta-cell 
mass in c-KitβTg mice was increased by 1.6-fold compared with WT (Figure 5-5D). 
Increased beta-cell mass was associated with an increase in beta-cell proliferation in c-
KitβTg mice (Figure 5-5E and F). qRT-PCR analyses of Pdx-1, Neurod1, MafA, Pax6, 
Nkx2.2 and Nkx6.1 showed significantly increased mRNA levels in c-KitβTg mice 
(Figure 5-6A), with elevated intensity of the corresponding signals in the islets of c-
KitβTg mice (Figure 5-6B). The expression of Glut2, Ins1 and Ins2, Gcg and Glp1r 
mRNA in isolated c-KitβTg islets was also significantly increased (Figure 5-7A) with 
relatively enhanced Glut2 and Glp1R staining (Figure 5-7B). 
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Figure 5-5. Islet morphology in c-KitβTg mice at 8 weeks of age. 
Morphometric analyses of islet number (A), islet size (B), alpha-cell mass (C), beta-
cell mass (D), and percentage of Ki67+ beta-cells (E) in c-KitβTg and WT mice at 
8 weeks of age. Data (A-E) are expressed as mean  ±  SEM (n=4–8), *p<0.05, 
**p<0.01 analyzed by unpaired student’s t-test. (F) Double immunofluorescence 
staining of Ki67 (green), with insulin (red) on pancreatic sections from 8-week-old c-
KitβTg and WT mice. Nuclei were stained with DAPI (blue). Arrows indicate 
Ki67+/insulin+ cells. Representative images are shown. Scale bar, 25 µm. 
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Figure 5-6. Expression of islet transcription factors in c-KitβTg mice at 8 weeks 
of age. 
(A) Islet transcription factors in c-KitβTg and WT mice at 8 weeks of age, as 
analyzed by qRT-PCR. Data are expressed as mean  ±  SEM (n=4–8), *p<0.05, 
**p<0.01, and ***p<0.001 analyzed by unpaired student’s t-test. (B) Double 
immunofluorescence staining for transcription factors (green) with insulin (red), with 
nuclei stained with DAPI (blue), with immunohistochemistry staining for MafA (red 
in nuclei) on pancreatic sections from 8-week-old c-KitβTg and WT mice. 
Representative images are shown. Scale bar, 50 µm. 
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Figure 5-7. Expression of islet endocrine genes, Glut2, and Glp1 receptors in c-
KitβTg mice at 8 weeks of age. 
(A) Islet gene expression in c-KitβTg and WT mice at 8 weeks of age, as analyzed by 
qRT-PCR. Data are expressed as mean  ±  SEM (n=4–8), *p<0.05, **p<0.01 analyzed 
by unpaired student’s t-test, (B) double immunofluorescence staining for Glut2 and 
Glp1R (green) with insulin (red), with nuclei stained with DAPI (blue) on pancreatic 
sections from 8-week-old c-KitβTg and WT mice. Representative images are shown. 
Scale bar, 50 µm. 
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5.3.4 Increased PI3K/Gsk3β/cyclin D1 signaling pathway in c-KitβTg 
mouse islets 
Our previous study showed that the c-Kit Wv mutation caused beta-cell dysfunction [12], 
and that this mutation was associated with down-regulation of the Akt/Gsk3β/cyclin D1 
pathway [13]. We therefore examined whether signaling molecules up- and downstream 
of the PI3K/Akt pathway or cell survival signals are altered in c-KitβTg islets. We found 
that protein levels of S473 phospho-Akt (Figure 5-8A), S9 phospho-Gsk3β (Figure 5-
8B), cyclin D1 (Figure 5-8C) and Pdx-1 (Figure 5-8D) were significantly increased in c-
KitβTg islets compared with islets isolated from WT littermates.  
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Figure 5-8. Levels of phosphorylated Akt/Gsk3β/cyclin D1 signaling and 
downstream signaling molecules in c-KitβTg mice at 8 weeks of age. 
Western blot analyses of (A) S473-phosphorylated (P) and total (T) Akt, (B) Ser9 P-
Gsk3β and T-Gsk3β, (C) cyclin D1 and (D) Pdx-1 abundance in isolated islets of c-
KitβTg and WT mice at 8 weeks of age. Representative blots are shown. Data (A-D) 
are normalized to total protein or loading control (β-actin) and expressed as 
mean  ±  SEM (n=4-5), *p<0.05, **p<0.01 and ***p<0.001 analyzed by unpaired 
student’s t-test. 
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5.3.5 c-KitβTg mice tolerate HFD-induced diabetes  
To investigate how beta-cell-specific c-KIT overexpression would affect glucose 
homeostasis of mice under diabetic conditions, c-KitβTg and WT littermates were 
subjected to a HFD. Similar body weight gains were observed in both experimental 
groups (Figure 5-9A). Interestingly, after 4 weeks of HFD, the 4-hour fasting glucose 
level was lower in c-KitβTg-HFD mice than in WT-HFD mice (Figure 5-9B). Glucose 
intolerance was noted in WT-HFD littermates, but was significantly improved in c-
KitβTg-HFD mice (Figure 5-9C), with similar results for insulin response in WT-HFD as 
determined by the IPITT (Figure 5-9D). In vivo GSIS assays revealed slightly higher 
basal and 5-minute plasma insulin levels in c-KitβTg-HFD mice (Figure 5-9E); moreover, 
at 35 minutes after glucose stimulation, the plasma insulin release was significantly 
reduced in WT-HFD compared with c-KitβTg-HFD mice (Figure 5-9E). GSIS on isolated 
islets further demonstrated that c-KitβTg-HFD islet insulin secretion was significantly 
increased in response to 22 mmol/L glucose compared with WT-HFD islets (Figure 5-
9F). The insulin content was also significantly increased in c-KitβTg-HFD islets (Figure 
5-9G). The improved metabolic phenotype of c-KitβTg-HFD mice was associated with a 
significant increase in the number of pancreatic islets and beta-cell mass compared with 
WT-HFD mice (Figure 5-10A and C). A slightly increased alpha-cell mass was observed 
in c-KitβTg-HFD mice; however, the increase was not statistically significant (Figure 5-
10B). Nevertheless, a significant increase in beta-cell mass was detected, with increased 
beta-cell proliferation in c-KitβTg-HFD mice compared with WT-HFD group (Figure 5-
10D).  
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Figure 5-9. Effect of a HFD on c-KitβTg mice. 
(A) Weight gained per food intake, and (B) 4-hour fasting blood glucose levels in 
WT-HFD and c-KitβTg-HFD mice. (C) IPGTT and (D) IPITT in WT-HFD and c-
KitβTg-HFD mice. Glucose responsiveness of the corresponding experimental 
groups is shown as the AUC of the IPGTT (C, insert) or IPITT (D, insert) graphs 
with units of (mmol/L x minutes). (E) In vivo GSIS of WT-HFD and c-KitβTg-HFD 
mice (Lighted bars, WT-HFD insulin; darken bars, c-KitβTg-HFD insulin; black 
circles, WT-HFD glucose; black squares, c-KitβTg-HFD glucose). (F) Ex vivo GSIS 
on isolated islets from WT-HFD and c-KitβTg-HFD mice. Data are expressed as fold 
change normalized to basal (2.2 mM glucose) secretion as mean  ±  SEM. (G) Insulin 
content in isolated islets from WT-HFD and c-KitβTg-HFD mice where data are 
normalized to DNA content and expressed as mean  ±  SEM. Data (A-G) are 
expressed as mean  ±  SEM (n  =5-10), *p<0.05 and ***p<0.001 analyzed by unpaired 
student’s t-test. 
 
162 
 
 
  
163 
 
  
Figure 5-10. Effect of a HFD on islet morphology of c-KitβTg mice. 
Morphometric analyses of islet number (A), alpha-cell mass (B), beta-cell mass (C), 
and percentage of Ki67+ beta-cells (D) in WT-HFD and c-KitβTg-HFD mice. Data 
(A-D) are expressed as mean  ±  SEM (n=6-7), *p<0.05, **p<0.01 analyzed by 
unpaired student’s t-test. 
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5.3.6 c-KitWv/+ mice with specific overexpression of c-KIT in beta-cells 
display normal glucose metabolism  
c-KitWv/+ mice were bred with c-KitβTg mice to determine whether c-KIT overexpression 
in beta-cells could rescue animals with the c-Kit Wv mutation from early onset of 
diabetes. WT, c-KitβTg and c-KitβTg;Wv mice exhibited similar fasting blood glucose 
levels, with a significant improvement in fasting blood glucose levels being noted in c-
KitβTg;Wv compared with c-KitWv/+ mice (Figure 5-11A). c-KitβTg;Wv mice also had a 
similar glucose tolerance capacity to that of WT and c-KitβTg groups, and also displayed 
significant decreases in the AUC (Figure 5-11B). The IPITT revealed no differences 
between the experimental groups (Figure 5-11C). Significantly improved GSIS was 
observed at 5 and 35 minutes in c-KitβTg;Wv mice compared with c-KitWv/+ mice (Figure 
5-11D). To further confirm islet function, an ex vivo GSIS study was conducted. Insulin 
secretion in response to a 22 mmol/L glucose challenge in c-KitβTg;Wv islets was similar 
to that in WT and c-KitβTg islets (Figure 5-11E), but significantly higher than that of c-
KitWv/+ islets (Figure 5-11E). These results indicate that the c-Kit point mutation is 
directly responsible for defective beta-cell function in c-KitWv/+ mice and that c-KIT 
overexpression was able to preserve beta-cell function in c-KitWv/+ mice. 
  
165 
 
 
  
166 
 
Figure 5-11. Glucose tolerance and insulin secretion in c-KitβTg;Wv mice. 
(A) 4-hour fasting blood glucose levels, (B) IPGTT, and (C) IPITT in WT, c-KitβTg,  
c-KitWv/+ and c-KitβTg;Wv mice at 8 weeks of age. Glucose responsiveness of the 
corresponding experimental groups is shown as the AUC of the IPGTT (B, insert) or 
IPITT (C, insert) graphs with units of (mmol/L x minutes). (D) In vivo GSIS of WT 
(white bars), c-KitβTg (black bars), c-KitWv/+ (grey bars) and c-KitβTg;Wv (dotted 
bars) mice. (E) Ex vivo GSIS on isolated islets from c-KitβTg;Wv mice are improved 
in response to a 22 mmol/L glucose challenge. Data are expressed as fold change 
normalized to basal (2.2 mM glucose) secretion. Data (A-E) are expressed as 
mean  ±  SEM (n=3-8), *p<0.05, **p<0.01, and ***p<0.001 analyzed by one-way 
ANOVA followed by LSD post-hoc test. 
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Figure 5-12. A proposed model of SCF/c-Kit signaling to mediate beta-cell 
proliferation and function. 
SCF/c-Kit interaction activates the PI3K/Akt/Gskβ pathway. This leads to increased 
cyclin D1, Pdx-1 and MafA expressions which are important to beta-cell 
proliferation, and function. sSCF: soluble SCF; mSCF: membrane-bound SCF. 
Green arrow: positive signaling.  
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5.4 Discussion  
Here, we demonstrated that c-KIT overexpression in beta-cells confers improved glucose 
metabolism by enhancing insulin secretion, and increasing beta-cell mass and 
proliferation, probably through activation of the PI3K/Akt signaling pathway. When c-
KitβTg mice were subjected to a HFD, they displayed resistance to HFD-induced glucose 
intolerance and preserved beta-cell function relative to WT littermates. Moreover, c-
KitβTg mice were protected against early onset of diabetes. These results clearly indicate 
that c-Kit is intrinsic to beta-cell function and proliferation. This effect is mediated by the 
regulation of key beta-cell transcription factors (e.g. Pdx-1 and MafA) and possibly 
through activation of downstream PI3K/Akt signaling (Figure 5-12). 
Compared with WT mice, c-KitβTg mice had significantly lower overnight fasting blood 
glucose levels, improved glucose tolerance and enhanced GSIS. The improvement in 
glucose metabolism of c-KitβTg mice was associated with an increase in beta-cell mass 
and proliferation, as well as in Glut2 and Glp1r expression. These results corroborate our 
previous finding of glucose intolerance in c-KitWv/+ mice [12]. We monitored c-KitβTg 
mice up to 40 weeks of age and did not detect any abnormal cell growth or islet tumors 
(data not shown), indicating that beta-cell specific c-KIT overexpression does not lead to 
malignancy. We detected a significant increase in SCF mRNA, but only a modest 
increase in the corresponding protein. This is likely to be due to our western blotting 
technique, which could only detect membrane-associated, not soluble, SCF. Nevertheless, 
the concentration of SCF may be in excess and is sufficient to interact with the increased 
number of c-Kit (∼25%) to transduce markedly enhanced intracellular signals in c-
KitβTg mice. Our data indicate that c-Kit overabundance in beta-cells enhances glucose 
tolerance and beta-cell function in males. These sex-related differences in glucose 
metabolism are consistent with our previous results using c-KitWv/+ mice and conditional 
β1 integrin knockout mice [12, 14], and have also been described in other mouse models 
indicating that the sex-related differences may involve other pathways, such as the 
contribution of estrogen to glucose homeostasis in female rodents [15, 16].  
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Significantly increased Pdx-1 mRNA and protein abundance was observed in c-KitβTg 
mice. We previously reported that SCF-stimulated c-KIT activity leads to increased PDX-
1 mRNA expression in human fetal islet-epithelial clusters [7], while c-KitWv/+ mice 
showed a significant reduction in Pdx-1 expression in islets [12]. It is well documented 
that Pdx-1 is integral to normal pancreas development and beta-cell function [17]. In 
addition to beta-cell proliferation [18], Pdx-1 expression is also required for modulation 
of insulin gene expression and glucose metabolism [19]. Our results showed that c-
KitβTg islets exhibited high Pdx-1 levels and had increased beta-cell proliferation and 
mass, confirming a correlation between Pdx-1 and islet beta-cell replication. Indeed, the 
enhanced islet insulin secretion in response to a high glucose challenge and the improved 
glucose tolerance observed in c-KitβTg mice may also be due to increased islet Pdx-1 
abundance. Interestingly, significant up-regulation of MafA mRNA was observed in c-
KitβTg mice. MafA binds to the C1 element of the insulin gene to modulate insulin gene 
transcription and enhance beta-cell maturation [20]. MafA-null mice had a defect only in 
adult islet architecture and beta-cell activity, while MafA overproduction enhanced beta-
cell insulin biosynthesis and secretion through up-regulation of important beta-cell genes, 
including Pdx1, Neurod1, Nkx6.1 and Glp1r [21]. Moreover, overexpression of MafA in 
neonatal rat beta-cells led to enhanced glucose-responsive insulin secretion and beta-cell 
maturation [22]. Thus, improved glucose metabolism and insulin secretion in c-KitβTg 
mice may be due to increased c-Kit stimulation of islet Pdx-1 and MafA expression. 
The molecular mechanisms associated with the phenotypic changes observed in c-KitβTg 
mice include significant up-regulation of phospho-Akt and phospho-Gsk3β in beta-cells. 
Our previous in vitro study on human fetal islet-epithelial clusters demonstrated that 
increased SCF/c-KIT interactions resulted in up-regulation of PI3K/AKT, but not of ERK 
pathway signaling [7]. In this study, we also observed significant increases in Akt and 
Gsk3β phosphorylation together with up-regulation of cyclin D1 in islets isolated from c-
KitβTg mice. These results suggest that c-Kit might stimulate beta-cell function and 
proliferation via direct activation of the Akt/Gsk3β/cyclin D1 pathways [7, 23], in 
association with Pdx-1 and MafA-induced insulin secretion. Islets of beta-cell specific 
Gsk3β ablated mice had increased beta-cell mass with lower fasting blood glucose, 
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along with improved glucose tolerance and GSIS [24]. In contrast, the Akt/Gsk3β 
signaling pathway is significantly down-regulated in c-KitWv/+ mouse islets [13]. Taken 
together, these results suggest that Akt/Gsk3β/cyclin D1 signaling downstream of c-Kit is 
essential for beta-cell function. 
HFD treatment is detrimental to beta-cell function and insulin sensitivity in mice [25, 26], 
and leads to impaired glucose tolerance due to insulin resistance and insufficient beta-cell 
insulin secretion [25-28]. c-KitβTg and WT mice maintained on a HFD showed similar 
food intake and weight gain. Importantly, c-KitβTg-HFD mice exhibited significantly 
improved glucose tolerance and GSIS, supporting the notion that c-Kit has a direct effect 
on beta-cell function via up-regulation the PI3K/Akt signaling pathway, which enables c-
KitβTg-HFD mice to tolerate HFD-induced diabetes. 
Finally, we bred c-KitβTg with c-KitWv/+ mice to determine whether c-KIT overexpression 
could prevent beta-cell dysfunction in c-KitWv/+ mice. Our results showed that c-
KitβTg;Wv mice displayed normal fasting glycaemia and glucose tolerance, as well as 
enhanced glucose-induced insulin secretion. This marked improvement in glucose 
metabolism in c-KitβTg;Wv mice provided direct evidence of a primary effect of c-Kit on 
beta-cell function. 
In summary, we showed that c-KIT overexpression in beta-cells led to improved beta-cell 
proliferation and function, and protected mice from HFD-induced diabetes. Furthermore, 
beta-cell specific overexpression of c-KIT was able to prevent beta-cell defects in c-
KitWv/+ mice. This study provides direct evidence to support the notion that c-Kit plays a 
primary physiological role in beta-cells, and thus may help efforts to develop gene and 
cell therapeutic schemes for patients with diabetes.  
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Chapter 6  
6 c-Kit-mediated VEGF-A production regulates islet 
microvasculature, beta-cell survival, and function in vivo5 
  
                                                
5
 This chapter has been modified and adapted from the following manuscript: 
v Feng ZC, Popell A, Li J, Silverstein J, Yee SP, Wang R. c-Kit receptor tyrosine regulates islet 
microvasculature, beta-cell survival and function in vivo. Manuscript in submission 2014. 
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6.1 Introduction  
Islet angiogenesis and innervation are required for proper endocrine pancreatic 
organogenesis and function [1-3]. The vascular niche that provides oxygen, exchanges 
nutrients and metabolites to support beta-cell survival [4], also exposes islets to 
inflammatory cytokines in the setting of diabetes [5, 6]. Hence, the precise regulation of 
islet angiogenesis plays a prominent role in the modulation of beta-cell survival and 
insulin production. One pro-angiogenic factor, vascular endothelial growth factor 
(VEGF), is produced by the beta-cell and plays a critical role in promoting and 
maintaining islet vascularization [4, 7, 8].   
SCF/c-Kit interactions are implicated in the regulation of angiogenesis. Past studies 
showed that the high co-expression of c-Kit and SCF is associated with increased 
microvessel density and VEGF expression in multiple neoplasms [9-11]. SCF treatment 
of multiple c-Kit-expressing cancer cell lines revealed a significant stimulatory effect on 
VEGF secretion and, conversely, inhibition of c-Kit signaling by imatinib led to reduced 
VEGF expression [12-14]. Previous studies reported that bone marrow stem/progenitor 
cells expressing c-Kit established a proangiogenic milieu by releasing VEGF [15, 16]; 
however, a mutation in c-Kit prevents angiogenesis, interfering with myocardial repair 
tissue formation [16]. Furthermore, c-Kit activity was implicated in mobilization of 
endothelial progenitor cells required for angiogenesis, and SCF was able to enhance the 
neovascularization of human endothelial progenitor cells [17, 18]. Transplantation of c-
Kit-expressing vascular endothelial progenitor cells could generate functional blood 
vessels in vivo, but inactivation of c-Kit resulted in impaired endothelial cell proliferation 
and angiogenesis [19]. Taken together, these studies reveal a remarkable correlation 
between c-Kit and VEGF-driven angiogenesis.  
Although c-Kit has been studied in human and murine pancreatic cells, its involvement in 
the regulation of VEGF production in islets has not been evaluated. Of the six identified 
members in the VEGF family, the pancreatic beta-cell produces significant levels of 
VEGF-A, primarily the VEGF-A 120 and VEGF-A 164 isoforms. Prior studies using the 
genetic mouse model with VEGF-A deficit in beta-cells have demonstrated that there is 
causal effect between VEGF-A production and proper islet vascular development: the 
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functional vascular niche is not only required for the assembly of complex coordinated 
islet architecture, but also for normal islet cell function [2, 4, 8]. In this study, we 
hypothesized that c-Kit-dependent regulation of VEGF-A is critical for islet vasculature, 
maintaining islet function and survival. Using the c-Kit Wv mutant (c-KitWv/+) and beta-
cell-specific c-KIT overexpressing (c-KitβTg) mouse models, we aimed to characterize 
the functional role of SCF/c-Kit interactions in mediating VEGF-A production, islet 
angiogenesis, as well as beta-cell function and survival under normal diet, and long-term 
HFD conditions. 
6.2 Materials and methods 
Mouse model: 1) cross-breeding c-KitWv/+ with c-KitβTg mice generated wild-type (WT), 
c-KitWv/+, c-KitβTg, and c-KitβTg;c-KitWv/+ (c-KitβTg;Wv), and these four experimental 
groups under normal diet were maintained until 8 weeks of age at which point, islet 
vascular morphological studies, and islet protein analyses were performed. 2) WT and c-
KitβTg mice were subjected to either normal diet, or HFD for 20 weeks starting at 6 
weeks of age at which point, metabolic studies, islet morphological studies, pancreatic 
vascular morphological studies, and islet protein analyses were performed. Only male 
mice were used for this study. Generation of animal models was detailed in section 2.1.4, 
and genotyping was detailed in section 2.2. 
Metabolic studies: Body weight, blood glucose levels (non-fasting, 4-hour and overnight 
fasting (16-hour)), IPGTT and IPITT analyses were performed on mice in the normal diet 
study, and the HFD study, as detailed in section 2.3.  
Immunofluorescence and morphometric analyses: Pancreatic tissue sections from mice 
were prepared and double-stained with appropriate antibodies listed in Appendix 5. Islet 
number, islet size, alpha and beta-cell mass was measured. Islet capillary density, 
capillary area per islet, average islet capillary size and diameter, and pancreatic exocrine 
vasculature including exocrine capillary density, and exocrine capillary area were 
quantified. Proliferation (Ki67+ labeling), apoptosis (TUNEL+ labeling), Pdx-1, Nkx6.1, 
E-cad (E-cadherin), PECAM-1 positive staining in beta-cell nuclei was determined by 
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double immunofluorescence staining. MafA+ staining in pancreatic islets was determined 
by immunohistochemical staining, as detailed in section 2.7. 
Protein extraction and western blot analyses: protein levels of phospho-AktS473, total 
Akt, phospho-P70S6KT389, total P70S6K, phospho-NFκBp65S536, total NFκBp65, Pdx-1, 
VEGF-A, PECAM-1, E-cad, cleaved-PARPD214 (cleaved-Poly ADP ribose polymerase), 
total PARP, Mac-2 (Galectin-3), IL-1β, TNF-α (Tumor necrosis factor-α), and 
corresponding housekeeping protein GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) from isolated mouse islets was analyzed (Appendix 6), as detailed in 
section 2.8. 
6.3 Results 
6.3.1 c-Kit function is required for maintaining the normal islet 
microvasculature in vivo  
To investigate the role of c-Kit in islet microvasculature in vivo, we examined endothelial 
cells in 8-week-old mouse pancreatic sections using an immunostaining approach. We 
observed a reduced staining for PECAM-1+ (specific label for endothelial cells) (Figure 
6-1A) but no substantial change in islet capillary number (Figure 6-1B) in c-KitWv/+ 
mouse islets compared to WT group. However, significantly decreased blood vessel area 
over islet area was found in c-KitWv/+ mouse islets, compared to WT by 8 weeks of age 
(Figure 6-1C). Intra-islet vessels were also significantly smaller in c-KitWv/+ mouse islets, 
as reflected by a 50% reduction in the average islet capillary size (vs. WT islets, Figure 6-
1D). This was confirmed by measurement of the internal capillary diameter that showed 
~30% reduction in c-KitWv/+ mouse islets when compared to WT (Figure 6-1E). In 
contrast to c-KitWv/+ mice, there was a significant improvement in islet capillary density 
and area in c-KitβTg;Wv mouse islets (vs. c-KitWv/+ islets, Figure 6-1B and C). 
Furthermore, there was ~30% relative increase in average islet capillary size in c-
KitβTg;Wv mouse islets (vs. c-KitWv/+ islet, Figure 6-1D) along with significantly 
increased capillary diameter (vs. c-KitWv/+ islet, Figure 6-1E). No signficiant changes in 
islet vasculature were observed in c-KitβTg mice. These data indicate that c-Kit function 
is required for maintaining the normal islet vasculature.  
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Figure 6-1. Overexpressing c-KIT in beta-cells rescues loss of islet 
microvasculature in c-KitWv/+ mice. 
(Α) Representative images of PECAM-1 (green) co-stained with insulin (red), and 
nuclei stain DAPI (blue) of 8-week-old WT, c-KitWv/+, c-KitβTg, and c-KitβTg;Wv 
pancreatic sections. Scale bar, 25 µm. Magnified images are shown in insets. Arrows: 
PECAM-1+ cells in the islets. Quantitative analyses between all experimental groups 
of islet capillary density (Β), capillary area per islet (C), average islet capillary size 
(D), and average islet capillary diameter (E). Data (B-E) are expressed as mean ± 
SEM (n=5), *p<0.05, **p<0.01 and ***p<0.001 analyzed by one-way ANOVA 
followed by LSD post-hoc test. 
 
181 
 
6.3.2 Beta-cell specific c-Kit maintains islet microvasculature via the 
PI3K/Akt/mTOR pathway and VEGF-A production in vivo 
We next sought to determine the underlying mechanisms by which c-Kit regulates islet 
microvasculature in vivo. Using isolated islets from pancreata of 8-week-old WT, c-
KitWv/+, c-KitβTg, and c-KitβTg;Wv mice, we found a significant decrease in 
phosphorylation of Akt, P70S6K, and p65NF-κB in c-KitWv/+ mouse islets (Figure 6-2A), 
which were associated with a reduced level of Pdx-1 protein (Figure 6-2B). However, 
when c-Kit function was restored in c-KitWv/+ beta-cells, the Akt/mTOR/p65NF-κB 
pathway was restored in parallel with increased Pdx-1 protein levels (Figure 6-2B). These 
findings were supported by immunostaining demonstrating that Pdx-1+, Nkx6.1+ and 
MafA+ staining was lower in c-KitWv/+ islets when compared to WT and c-KitβTg, as well 
as c-KitβTg;Wv groups (Figure 6-3). VEGF-A protein levels were also lower in c-KitWv/+ 
islets than in WT, c-KitβTg or c-KitβTg;Wv islets, but this only reached significance for 
c-KitβTg mice (Figure 6-2B). 
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Figure 6-2. Rescued islet microvasculature is associated with increased c-Kit-
mediated VEGF-A production via the PI3K/mTOR pathway in c-KitβTg;Wv 
mice. 
(A) Western blot analyses of S473-phosphorylated (P) and total (T) Akt, T389 P-
P70S6K and T-P70S6K, S536 P-NFκBp65 and T-NFκBp65, and (B) VEGF-A and 
Pdx-1 abundance in islets isolated from 8-week-old WT, c-KitWv/+, c-KitβTg, and c-
KitβTg;Wv mice. Representative blots are shown. Data (A and B) are expressed as 
mean ± SEM (n=4-5), *p<0.05, **p<0.01 and ***p<0.001 analyzed by one-way 
ANOVA followed by LSD post-hoc test. 
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Figure 6-3. Expression of islet transcription factors in c-KitβTg;Wv mice. 
Double immunofluorescence staining of 8-week-old WT, c-KitWv/+, c-KitβTg and c-
KitβTg;Wv pancreatic sections for transcription factors Pdx-1 or Nkx6.1 (green) with 
insulin (red) and nuclei stained with DAPI (blue). Immunohistochemistry staining for 
MafA (red in nuclei). Representative images are shown. Scale bar 25 µm. 
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6.3.3 c-KIT overexpression in beta-cell promotes islet angiogenesis in 
vivo 
We further examined the role of c-Kit in islet vasculature in aged (28-week-old) WT and 
c-KitβTg mice. Double immunofluorescence for PECAM-1 and insulin showed an 
increased number of PECAM-1+ cells in c-KitβTg mouse islets (Figure 6-4A), which was 
correlated with an increase in capillary density and vessel area-to-islet area ratio (Figure 
6-4B and C) when compared to WT mouse islets. However, no changes in average islet 
capillary size or diameter (Figure 6-4D and E), and no differences in the vasculature of 
pancreatic exocrine tissue were observed in c-KitβTg mice as compared to WT group 
(Figure 6-4F and G). The observed changes in islet vasculature were supported by 
western blot analyses showing ~40% increase in islet VEGF-A content, with a similar 
increase in PECAM-1 protein levels (Figure 6-4H).  
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Figure 6-4. Beta-cell specific c-KIT overexpression promotes islet angiogenesis 
in vivo. 
Islet microvasculature morphology was analyzed in 28-week-old WT and c-KitβTg 
mice. (A) Representative images of PECAM-1 (green) co-stained with insulin (red). 
Nuclei were stained with DAPI (blue). Scale bar 25µm. Magnified images are shown 
in insets. Arrows: PECAM-1+ cells in the islets. Quantitative analyses of islet 
capillary density (B), islet capillary area per islet (C), average islet capillary size (D), 
average islet capillary diameter (E), exocrine capillary density (F), and exocrine 
capillary area (G), and western blot analyses of VEGF-A, and PECAM-1 protein 
expression in aged c-KitβTg mouse islets (H). Representative blots are shown. Data  
(B-H) are expressed as mean ± SEM (n=3-5), *p<0.05 analyzed by unpaired 
student’s t-test. 
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6.3.4 c-KIT overexpression exaggerates islet hyper-vasculature in 28-
week-old c-KitβTg mice under long-term HFD. 
To determine whether the enhanced islet microvasculature resulting from overexpression 
of c-KIT in beta-cell could preserve beta-cell function and survival under long-term (20-
22 week) HFD, we first assessed the islet vasculature changes in WT-HFD and c-KitβTg-
HFD mice. Immunostaining for PECAM-1 and insulin showed more dilated capillaries 
with accumulated red blood cells in c-KitβTg-HFD islets (Figure 6-5A). There were no 
observed differences in islet capillary density between the two experimental groups 
(Figure 6-5B). However, there was a significant increase in the overall blood vessel area-
to-islet area ratio (Figure 6-5C), average islet capillary size (Figure 6-5D) and intra-islet 
capillary diameter found in c-KitβTg-HFD islets (Figure 6-5E). These results clearly 
demonstrated that there was an intra-islet capillary enlargement in c-KitβTg-HFD islets 
as compared to WT-HFD group. In contrast to the endocrine compartments, the 
vasculature of pancreatic exocrine tissue was unchanged (Figure 6-5F and G). 
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Figure 6-5. Increased vessel dilation in 28-week-old c-KitβTg mice under long-
term HFD. 
(A) Representative images of PECAM-1 (green) co-stained with insulin (red) in 28-
week-old WT-HFD and c-KitβTg-HFD pancreatic sections. Scale bar 25 µm. 
Magnified images are shown in insets. Arrows: PECAM-1+ cells in islets; asterisk: 
red blood cells. Quantitative analyses of vasculature in endocrine (B-E), and 
exocrine compartment (F-G) in 28-week-old WT-HFD and c-KitβTg-HFD mice. 
Data (B-G) are expressed as mean ± SEM (n=5), *p<0.05, **p<0.01 analyzed by 
unpaired student’s t-test. 
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6.3.5 c-KIT overexpression-induced hyper-vasculature impairs beta-cell 
function in 28-week-old c-KitβTg mice under long-term HFD 
It was noted that 28-week-old c-KitβTg mice displayed persistently lower overnight 
fasting blood glucose, improved glucose tolerance and significant decreases in AUC 
when IPGTT was performed (Figure 6-6A and B), with no changes in insulin tolerance 
(Figure 6-6C). In addition, morphological analysis revealed significantly increased islet 
number (Figure 6-6D) with increased beta-cell proliferative activity (Figure 6-6E) in c-
KitβTg mice. An increase in Pdx-1 and Nkx6.1 staining intensity was also noted in c-
KitβTg mouse islets as compared to WT group (Figure 6-7).  
However, these protective effects were diminished after long-term HFD challenge. There 
were no significant differences in body, pancreatic or fat pad weights between c-KitβTg-
HFD and WT-HFD groups (Figure 6-8A-C). In contrast, the overnight fasting blood 
glucose was significantly higher in c-KitβTg-HFD mice as compared to WT-HFD group 
(Figure 6-8D). Glucose tolerance was progressively impaired and there were significant 
increases in AUC when IPGTT was performed after 20-22 weeks (Figure 6-8E and F). 
Although c-KitβTg-HFD mice showed a slight insulin resistance, no significant changes 
in the IPITT AUC were observed between groups (Figure 6-8G). In vivo GSIS assays 
showed significantly decreased plasma insulin levels at 35 minutes following glucose 
stimulation in c-KitβTg-HFD mice as compared to WT-HFD mice (Figure 6-8H). The 
impaired glucose tolerance of c-KitβTg-HFD mice was associated with a significant 
decrease in islet density (Figure 6-9A), alpha and beta-cell mass (Figure 6-9B and C). 
Loss of E-cadherin expression on the beta-cell surface (Figure 6-9D) and reduced total E-
cadherin protein levels were observed in c-KitβTg-HFD islets when compared to WT-
HFD group (Figure 6-9E).   
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Figure 6-6. Glucose tolerance and islet morphology in 28-week-old c-KitβTg 
mice. 
Overnight fasting blood glucose levels (A), IPGTT (B), and IPITT (C) in WT and c-
KitβTg mice at 28 weeks of age. Glucose responsiveness of the corresponding 
experimental groups is shown as a measurement of AUC of the graphs with units of 
(mmol/L x minutes). Morphometric analyses of islet number (D), and quantification 
of Ki67+ beta-cells (E) in WT and c-KitβTg mice at 28 weeks of age. Data (A-E) are 
expressed as mean ± SEM (n=5-9), *p<0.05 analyzed by unpaired student’s t-test.  
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Figure 6-7. Expression of islet transcription factors in 28-week-old c-KitβTg 
mice. 
Double immunofluorescence staining for Pdx-1 or Nkx6.1 (green) and insulin (red), 
and nuclei stained with DAPI (blue) in 28-week-old WT and c-KitβTg pancreatic 
sections. Representative images are shown. Scale bar 25 µm. 
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Figure 6-8. Islet hypervascularization results in impaired glucose tolerance in 
28-week-old c-KitβTg mice under long-term HFD. 
Body (A), pancreatic (B), and fat pad weight (C), overnight fasting blood glucose 
levels (D); measurement of IPGTT AUC after 4, 10, 16 and 20-22 weeks of HFD 
(E); IPGTT (F), IPITT (G) and in vivo GSIS (H) at 20 weeks of HFD performed on 
WT-HFD and c-KitβTg-HFD mice. Data (A-H) are expressed as mean ± SEM (n=7-
12). *p<0.05, **p<0.01, ***p<0.001 analyzed by unpaired student’s t-test. 
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Figure 6-9. Altered islet morphology is observed in 28-week-old c-KitβTg mice 
under long-term HFD. 
Quantitative analyses of islet number (A), alpha-cell (B), and beta-cell mass (C) in 
28-week-old WT-HFD and c-KitβTg-HFD mice. (D) Representative images of E-
cadherin (green) co-stained with insulin (red), and nuclei stained with DAPI (blue) in 
WT-HFD and c-KitβTg-HFD pancreatic sections. Scale bar 25 µm. (E) Western blot 
analysis of E-cadherin in isolated WT-HFD and c-KitβTg-HFD islets. Representative 
blots are shown. Data are normalized to loading control (GAPDH). Data (A-C, and 
E) are expressed as mean ± SEM (n=4-8), *p<0.05, **p<0.01 analyzed by unpaired 
student’s t-test.  
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6.3.6 c-KIT overexpression-induced hyper-vasculature is associated with 
islet inflammatory response and cytokine production in 28-week-
old c-KitβTg mice under long-term HFD 
We further investigated the mechanisms of beta-cell dysfunction in c-KitβTg-HFD mouse 
islets. Total VEGF-A protein levels were significantly higher in c-KitβTg-HFD mouse 
islets (vs. WT-HFD, Figure 6-10A). Cleaved PARP protein levels (associated with cell 
apoptosis) were increased (~45%, Figure 6-10B) in parallel with a significant increase in 
the number of beta-cells positive for TUNEL staining (vs. WT-HFD, Figure 6-10C). 
Western blot analyses showed that levels of MAC-2, TNF-α and IL-1β were significantly 
elevated in c-KitβTg-HFD islets (Figure 6-10D), indicating increased inflammatory 
response was observed in c-KitβTg-HFD islets.   
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Figure 6-10. Increased islet inflammation and cytokine production is induced by 
islet hypervascularization in 28-week-old c-KitβTg mice under long-term HFD. 
Western blot analyses of VEGF-A (A) and cleaved-PARP (B) in islets isolated from 
WT-HFD and c-KitβTg-HFD mice. (C) Representative images of TUNEL (green) 
co-stained with insulin (red) and quantitative analysis of TUNEL+/insulin+ cells in 
WT-HFD and c-KitβTg-HFD pancreatic sections. Protein levels of MAC-2, TNF-α, 
and IL-1β (D) in islets isolated from WT-HFD and c-KitβTg-HFD mice. 
Representative blots are shown. Data (A-B, and D) are expressed as mean ± SEM 
(n=4-5), *p<0.05, **p<0.01 analyzed by unpaired student’s t-test. 
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Figure 6-11. Proposed model of c-Kit signaling that mediates VEGF-A 
production and modulates islet vasculature, affecting beta-cell function and 
survival. 
(A) c-Kit mediates VEGF-A production via the PI3K/Akt/mTOR signaling, which is 
essential for islet vascular formation. Subsequently, proper islet vasculature 
facilitates nutrient and oxygen exchange maintaining beta-cell survival and function. 
(B) Constitutive c-Kit-mediated VEGF-A overproduction results in increased islet 
vasculature. Under HFD-induced diabetic conditions, islet hypervascularization 
attracts macrophage infiltration and cytokine production leading to beta-cell 
dysfunction and apoptosis. 
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6.4 Discussion 
The present study demonstrated that c-Kit receptor tyrosine kinase activity regulates 
VEGF-A production to promote islet vascular formation. At age of 8 weeks, mice bearing 
a loss of c-Kit function showed severe developmental defects in islet vasculature, which 
was rescued by c-KIT overexpression in beta-cells. c-KIT overexpression improved 
VEGF-A production through activation of the PI3K/Akt/mTOR signaling pathway, 
which maintained the vascular formation in c-KitβTg:Wv mice (Figure 6-11A). At age of 
28 weeks, mice with beta-cell specific c-KIT overexpression displayed an increase in 
VEGF-A expression and islet vascularization with persistently improved glucose 
tolerance compared to WT mice. Interestingly, enhanced vasculature may expose islets to 
HFD-induced macrophage infiltration leading to increased inflammatory responses and 
elevated beta-cell apoptosis, which subsequently contributed to the development of 
hyperglycemia (Figure 6-11B).  
The relationship between c-Kit and VEGF-A was observed in the mouse models with a 
loss or gain of c-Kit function in beta-cells. A substantial loss of islet vascularization was 
observed in c-KitWv/+ mice, while improved islet vascular formation was found in c-
KitβTg;Wv mice. We previously reported that the severe loss of beta-cell mass and 
function were associated with glucose intolerance in c-KitWv/+ mice [20, 21], but c-
KitβTg;Wv mice showed a significant improvement in glucose homeostasis [22]. It is 
well documented that the vascular niche serves as an inductive signal in pancreatic bud 
branching and islet maturation. In return, islets release VEGF-A to promote islet 
endothelium growth and ultimately increase islet vascularization, and this was essential 
for maintaining beta-cell function and survival [2, 8, 23, 24]. Islet capillaries were not 
only increased in quantity, but also underwent several changes at the ultrastructural level, 
including increased capillary diameter and size in c-KitβTg;Wv mice likely due to c-Kit-
stimulated VEGF-A production. The improved islet capillary structure caused a reversal 
of the nutrient flow into islets, leading to improved beta-cell function, and increased 
insulin exocytosis into the bloodstream [25, 26]. At the cellular level, molecular 
mechanisms associated with the loss of islet vasculature in c-KitWv/+ mice include a 
significant down-regulation in the PI3K/Akt/mTOR pathway. Conversely, c-KIT 
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overexpression stimulates this signaling pathway including an increase in NFκB 
phosphorylation and VEGF-A expression. These findings were not only in agreement 
with previous findings [27-31], but also corroborated by our previous studies showing 
that the Akt-dependent pathway is a key player to mediate mitogenic signaling in human 
fetal islet-epithelial clusters in vitro [32, 33], and beta-cell proliferation and survival in 
genetic mouse models [20, 22]. Taken together, this study suggests that c-Kit-mediates 
VEGF-A production likely via the PI3K/Akt/mTOR pathway, and plays a critical role in 
proper islet vascular formation in maintaining beta-cell health and euglycemia. 
The observation that c-Kit promotes islet vascularization has implications not only in 
maintaining islet function, but could also be considered as a therapeutic target for 
promoting revascularization of transplanted islets. Following islet isolation, the survival 
of transplanted islets depends on the degrees of effective revascularization [25]. Given 
that the endothelial cells residing within isolated islets retained limited angiogenic 
capacity, it is postulated that their proliferative potential can, in part, be stimulated by 
VEGF-A production mediated by c-Kit in the beta-cell [1, 4, 34]. At 28 weeks of age, c-
KitβTg mice showed significantly increased VEGF-A and PECAM-1 expression with 
increase of islet vascular formation when compared to WT mice, suggesting a chronic 
causal relationship between c-KIT overexpression, and increased islet VEGF-A secretion, 
which in turn leads to increased islet angiogenesis in mice. These in vivo observations 
further demonstrated that c-Kit-mediated VEGF-A production has a primary role in 
regulating islet angiogenesis via promoting endothelial cell proliferation and fenestration, 
and may help to create better methods for revascularization of transplanted islets in the 
treatment of diabetes.  
Previous studies using prediabetic Zucker diabetic fatty rats and HFD-fed mice suggested 
that islet vessel dilation is an adaptive biological response in the setting of insulin 
resistance [5, 6, 35]. The fact that intra-islet endothelial cells were in a quiescent state in 
these insulin resistant animals suggested that such vascular change was independent of 
angiogenic processes [4, 6]. Indeed, an islet compensatory mechanism characterized by 
dilation of pre-existing vessels to increased insulin demand was observed in the current 
chronic HFD studies, in contrast to increased angiogenesis observed in 28-week-old c-
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KitβTg mice under normal diet. Interestingly, significantly increased intra-islet capillary 
size with noticeable red blood cell extravasation were observed in c-KitβTg islets, as 
compared to WT mice, under chronic HFD treatment. We noticed that the previously 
reported protective effect against a HFD (4 weeks) in c-KitβTg mice [22], was 
progressively diminished preceding the development of hyperglycaemia after 22 weeks 
of HFD consumption. The observed glucose intolerance was associated with severe loss 
of beta-cell mass, reduced in vivo insulin release and, in particular, loss of E-cadherin 
expression in beta-cells. E-cadherin, an adhesion molecule of the cadherin family, was 
found to be down-regulated in secretory defective beta-cells [36, 37]. Treatment of beta-
cells with an anti-E-cadherin blocking antibody affected intracellular Ca2+ levels and 
insulin secretion [38]. Our data suggested that such pronounced islet vasculature 
remodeling during chronic HFD could be stimulated by severe islet disorganization and 
beta-cell dysfunction while attempting, but failing, to maintain adequate insulin 
fenestration and euglycemia. On the other hand, increased islet apoptosis was probably 
the cause of islet failure in c-KitβTg mice during chronic HFD. Previous studies 
demonstrated that VEGF-A is a potent chemoattractant for inflammatory cytokines and 
macrophages [5]. In a HFD-induced diabetes mouse model, excessive amounts of 
circulating fatty acids and cytokines derived from adipose tissue were able to induce 
beta-cell apoptosis [39], which was consistent with our findings showing that higher 
levels of inflammatory cytokines and macrophage infiltration were observed in c-KitβTg-
HFD islets. Taken together, our results suggested that c-Kit-mediated VEGF-A 
production during a HFD-induced diabetic status lead to undesirable 
hypervascularization, allowing for cytokine and macrophage infiltration, which may 
contribute to beta-cell loss and dysfunction, as is a major hallmark in the development 
and progression of T2D [40]. 
In summary, this study demonstrated that c-KIT overexpression mediated VEGF-A 
production and secretion via the PI3K/Akt/mTOR pathway, which subsequently 
modulated islet vascular formation in vivo. We noted that increased c-Kit, specifically in 
beta-cells, enhanced islet vascular recovery on fibrin culture after an invasive isolation 
procedure (data not shown), and promoted islet angiogenesis in 28-week-old c-KitβTg 
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mice without disturbing glucose homeostasis. Interestingly, 28-week-old c-KitβTg mice 
under chronic HFD displayed dysregulated vascular dilation due to overproduction of 
VEGF-A, and such vascular changes were associated with beta-cell failure exacerbated 
by recruitment of inflammatory cytokines, leading to the development of hyperglycemia. 
This study represents a unique and integrated in vivo approach to unraveling the cellular 
mechanisms by which SCF/c-Kit interactions mediate VEGF-A production to regulate 
beta-cell function in both positive and negative ways. The finely turned and tightly 
regulated c-Kit activity is critical for the control of the microenvironmental VEGF-A 
concentration in islets, maintaining a normal and stable islet vascular network for proper 
beta-cell function and survival.   
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Chapter 7  
7 Summary, limitations and future directions 
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7.1 Summary  
7.1.1 Overall rationale and main objective 
In the previous study using the c-Kit Wv mutant mouse model, our lab showed that 
deficiency of c-Kit signaling resulted in decreased beta-cell mass and proliferation, 
leading to the onset of diabetes in c-KitWv/+ mice. [1]. However, the mechanisms by 
which c-Kit regulates beta-cell function and survival, and specifically, how c-Kit activity 
is coordinated in beta-cells in vivo, has not been determined. Thus, the main objective of 
this work was to dissect the intracellular signaling pathways by which c-Kit regulates 
beta-cell proliferation, survival and function. The central hypothesis of this work was that 
activation of c-Kit downstream PI3K/Akt signaling pathway plays a critical role in 
determining beta-cell growth and beta-cell insulin releasing function under normal and 
diabetic pathophysiological conditions (Figure 7-1).   
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Figure 7-1. Summary of c-Kit signaling in the beta-cell. 
c-Kit downstream signaling pathways in beta-cells. c-Kit regulates beta-cell 
proliferation, survival and function through: 1) via the Akt/Gsk3β pathway, 2) by 
indirectly suppressing the Fas-mediated caspase dependent apoptotic signalling, 3) 
by modulating islet vascular formation through VEGF-A production via the 
Akt/mTOR pathway. 
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7.1.2 The c-Kit Wv mutation causes beta-cell loss and dysfunction via the 
dysregulated Akt/Gsk3β pathway and up-regulated Fas-mediated 
apoptotic signaling in c-KitWv/+ mouse model 
We hypothesized that the dysregulated Akt/Gsk3β pathway contributes to a severe loss of 
beta-cell mass and impaired beta-cell function in c-KitWv/+ mice (Chapter 3). We found 
that reduced c-Kit activity led to a reduction of Akt and Gsk3β phosphorylation, resulting 
in down-regulation of cyclin D1 gene and protein expression [2, 3] in c-KitWv/+ mouse 
islets [4]. Our results suggested that Gsk3β activity plays a key role in affecting beta-cell 
proliferation and function. When given the exogenous Gsk3β inhibitor, 1-AKP, c-KitWv/+ 
mice demonstrated significantly enhanced cyclin D1 and Pdx-1 gene and protein 
expression [4]. This was associated with enhanced beta-cell proliferation and improved 
glucose tolerance in c-KitWv/+ mice that received 1-AKP injections. Overall, the c-Kit 
mutation triggers beta-cell failure via the impaired Akt/Gsk3β pathway in c-KitWv/+ mice 
[4]. While c-Kit positively regulates beta-cell proliferation, c-Kit signalling is also 
involved in the regulation of beta-cell apoptosis. We hypothesized that the balance 
between c-Kit and Fas signaling is essential for maintaining beta-cell mass and function 
in c-KitWv/+ mice (Chapter 4). Deficient c-Kit signaling led to increased beta-cell death 
in c-KitWv/+ mice, which was associated with an up-regulation of both p53 and Fas gene 
and protein expression in c-KitWv/+ islets at 8 weeks of age [5]. p53 is an important 
checkpoint protein that inhibits cyclin D1 expression in multiple cellular contexts [6, 7]. 
p53 was not only involved in cell cycle arrest in the absence of c-Kit signaling in beta-
cells, but our in vitro INS-1 cell study further determined that the up-regulation of p53 by 
c-Kit siRNA contributed to increased cell apoptosis via induction of Fas activity. 
p53/Fas-mediated cell apoptosis was reversed by the treatment of PFT-α or Fas siRNA 
[5]. Furthermore, the functional role of Fas was further studied by introducing the lpr 
mutation in c-KitWv/+ mice (a double mutation of c-KitWv/+;Faslpr/lpr mouse model). Lack 
of functional Fas expression in c-KitWv/+ mice prevented beta-cell death via down-
regulation of the caspase 8-mediated extrinsic apoptotic pathway. An increase in beta-cell 
mass and improved insulin releasing function was associated with increased c-FLIP/NF-
κB pro-survival signaling in c-KitWv/+;Faslpr/lpr mice [5]. Taken together, these findings 
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suggested that c-Kit signaling regulates beta-cell turnover and beta-cell insulin secretory 
function. 
7.1.3 c-KIT overexpression positively regulates beta-cell proliferation 
and function via an up-regulation of the Akt/Gsk3β/cyclin D1 
pathway in c-KitβTg mice 
Although the c-KitWv/+ mouse model is an excellent system to study the functional impact 
of c-Kit signaling deficiency in any tissue, the non-specific tissue mutation in this mouse 
model does not allow us to determine whether c-Kit has a primary role in beta-cell 
function and survival. To this end, we generated a transgenic mouse model with beta-cell 
specific c-KIT overexpression (c-KitβTg), which has a 30% increase in c-Kit expression 
on beta-cells (Chapter 5) [5]. c-KitβTg mice displayed improved glucose tolerance 
without showing differences in peripheral insulin sensitivity. Expansion of beta-cell mass 
was due to increased islet number and enhanced beta-cell proliferation. Overexpression 
of c-KIT also led to a profound effect in vivo on insulin secretion in response to glucose 
challenge, and exposure of these islets to an elevated glucose concentration resulted in 
increased insulin release and insulin content in beta-cells compared to controls [8]. c-KIT 
overexpression increased the expression of islet transcriptional factors, including Pdx-1, 
MafA, insulin and glucagon genes in parallel with significantly elevated Glp1r and Glut2 
mRNA levels. The changes in gene expression in c-KitβTg islets revealed that c-Kit 
regulates islet gene transcription via the Akt/Gsk3β/cyclin D1 signalling cascade [8]. 
Interestingly, c-KitβTg mice were able to resist HFD-induced diabetes, and maintained 
beta-cell function and mass. Furthermore, overexpressing c-KIT in beta-cells could 
partially reverse the diabetic phenotype in c-KitWv/+ mice, demonstrating that c-Kit has a 
beneficial effect on beta-cell growth and function [8]. 
7.1.4 c-Kit signaling positively regulates islet vascular formation via the 
Akt/mTOR/VEGF-A pathway 
The relationship between c-Kit signaling and VEGF-A synthesis has been implicated in 
the regulation of tumor angiogenesis in multiple neoplasms [9-11]; however, c-Kit’s role 
function in the regulation of VEGF-A production from islets has not been evaluated. In 
Chapter 6, we hypothesized that c-Kit-dependent regulation of VEGF-A is critical for 
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islet vascular formation and beta-cell survival. Our initial study using INS-1 cell cultures 
(presented by MSc candidate Alexei Popell) demonstrated that the Akt/mTOR pathway 
downstream of c-Kit, in vitro, regulated VEGF-A production. Using the mouse models 
created in Chapter 3 and 5, we observed a substantial loss of islet vasculature in c-KitWv/+ 
mice, which was reversed by beta-cell-specific c-KIT overexpression via an upregulation 
of the Akt/mTOR signaling pathway. These results suggested that c-Kit-mediated VEGF-
A production is critical for normal islet microvasculature. However, endothelial-to-beta-
cell interactions may not always result in a positive outcome: islet endothelial cells have 
been shown to contribute to islet destruction in an inflammatory environment. After 
prolonged exposure to a HFD, c-KitβTg mice exhibited drastic islet hypervascularization 
and beta-cell dysfunction and increased beta-cell apoptosis. This observation was 
explained by the chemoattractant effect that resulted in increased inflammatory factor 
recruitment via hypervasculature in the islets. These experiments demonstrated that c-Kit 
is a potential therapeutic target in promoting revascularization during islet cell 
replacement procedures. However, c-Kit activity must be tightly regulated in order to 
control the microenvironmental VEGF-A concentration, as this is essential for 
maintaining a normal and stable islet vascular network for proper beta-cell function and 
survival.  
7.2 Limitations 
7.2.1 Chapter 3 
Mice homozygous for the c-Kit null mutation (W mutation) die late in gestation or shortly 
after birth, presumably because of the embryo being severely anemic and dying at or near 
parturition. Compared to W mutant mice, the Wv mutation on c-Kit leads to a relatively 
mild anemia in both heterozygotes and homozygotes in rodents. Although fertility is 
affected in Wv homozygotes, heterozygous viable Wv mutants (c-KitWv/+) have normal 
reproductive capabilities. The molecular basis of the W phenotype is different from the 
Wv phenotype as well. The W mutation affects c-Kit gene transcription, resulting in an 
absence of c-Kit in tissues. In contrast, the Wv mutation results in reduced intracellular 
kinase activity of c-Kit due to a point mutation that resides in a highly conserved region 
of the c-Kit intracellular region. Therefore, the nature of the Wv phenotype correlates with 
221 
 
the severity of c-Kit signaling deficiency, whereas the mRNA level, protein size, cell 
surface expression, and binding affinity of c-Kit to SCF is not altered. Although the c-
KitWv/+ mouse model is suitable for examining the functional role of c-Kit signaling on 
tissue, there are limitations. The c-KitWv/+ model is a global mutation model wherein 
multiple cell types are affected by the c-Kit mutation. For instance, the Wv mutation 
causes a loss of coat pigmentation due to mast cell defects. Moreover, an extensive loss 
of gastrointestinal cells of Cajal vagal intramuscular arrays results in increased sensitivity 
to exogenous cholecystokinin in c-Kit Wv mutant mice. Previous studies demonstrated 
that cholecystokinin acts on the afferent vagal nerve leading back to the nucleus tractus 
solitarii in the brain, which decreases appetite, and subsequently lowers glucose 
production from the liver [12, 13]. Whether such metabolic changes may affect the 
interpretation of our findings in c-Kit Wv mutant mice remains to be studied. Thus, a 
mouse model with beta-cell specific c-Kit manipulation would be useful to dissect the 
primary functional role of c-Kit in the beta-cell. 
c-KitWv/+ male mice displayed glucose intolerance at 8 weeks of age, whereas such 
symptoms were not observed in c-KitWv/+ females until 40 weeks of age [1]. In 
accordance with our findings, a higher incidence of diabetes in males is also found in 
other diabetic models [14-16]. The reason for this sexual dimorphism remains to be 
investigated, but multiple underlying mechanisms have been proposed. First, the male 
gonadectomy with additional estradiol treatment showed a protective effect against 
diabetes in mice [17]. Second, the rise of androgens at puberty is associated with a more 
severe diabetic state in male rats than in females, since during the neonatal period the 
effect of streptozotocin was not influenced by gender [18, 19]. Third, the genetic 
susceptibility represented by inbred mouse strains could be another contributing factor. 
For example, the inbred cohen diabetic rat males have a more severe glucose intolerance 
pattern compared to females [20], and spontaneous onset of diabetes with a high 
cumulative incidence is observed in male inbred insectivore musk shrews compared to 
females [21]. In addition, gender differences could be related to mitochondrial function 
[22] or the redox state of beta-cells [23]. More interestingly, sexual dimorphism exists in 
counter-regulatory responses to different stressors including fasting, hypoglycemia, and 
exercise [24]. Therefore, underlying mechanisms contributing to the gender bias in c-
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KitWv/+ mice remain to be elucidated. For furture studies, gonadectomy and estradiol 
treatment may be performed to examine whether the onset of diabetes is delayed in c-
KitWv/+ males. Furthermore, genes involved in mitochondrial dysfunction and oxidative 
stress, as well as the responses of neural systems to hunger and satiety, deserve additional 
study between genders. 
Phylogenetically, Gsk3 is closely related to cyclin dependent kinases. Therefore, it is not 
surprising that Gsk3 inhibitors not only inhibit both α and β forms, but also act on 
selective cyclin dependent kinases. Compared to previously used Gsk3 inhibitors, 1-AKP 
has a high potency and selectivity to Gsk3β over the α form and other cyclin dependent 
kinases [25]. The difference in charge distribution throughout the molecule confers the 
ability to distinguish between the ATP cavities of Gsk3β and others on 1-AKP [25]. This 
warrants the use of 1-AKP to inhibit Gsk3β in our studies. However, Gsk3β is a 
ubiquitously expressed, highly conserved serine/threonine protein kinase found in all 
eukaryotes. Therefore, the 1-AKP injection that globally inhibits Gsk3β, and may have 
unknown effects in other tissue. A c-KitWv/+ mouse model with beta-cell specific Gsk3β 
ablation will be useful to circumvent this challenge. Nevertheless, since we combined in 
vitro and in vivo approaches to assess the effect of Gsk3β inhibition on beta-cell function 
and survival, we are confident that active Gsk3β is the molecular switch leading to beta-
cell failure in c-KitWv/+ mice. Gsk3β and Gsk3α share almost identical sequence 
homology, they overlap in function and compensate for each other, but also have distinct 
roles and pathways that they regulate in different tissue [26-28]. The role of Gsk3α has 
largely been ignored, therefore the role of Gsk3α in beta-cells warrants substantial 
attention in future diabetes research.  
7.2.2 Chapter 4 
A c-KitWv/+;Faslpr/lpr mouse model was used to study the relationship between c-Kit and 
Fas in beta-cell turnover and function. The gene coding Fas is located near the lpr locus 
of chromosome 19 in rodents [29]. The lpr mutation leads to the production of non-
functional truncated Fas mRNA due to an early transposable element, similar to an 
endogenous retrovirus inserted into intron 2. Thus, the Faslpr/lpr mouse is an excellent 
system to study the effect of a Fas signaling deficiency in any given tissue. A concern is 
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raised by the global mutation in Fas, which leads to additional effects in the Faslpr/lpr 
mouse model, whereby these mice develop lymphadenopathy and splenomegaly due to 
the accumulation of lymphocytes. In contrast to the apoptotic role of Fas signaling in 
some tissues, Fas also triggers pro-survival cellular processes in other cell types under 
specific conditions. Thus, any phenotype observed in c-KitWv/+;Faslpr/lpr mice cannot be 
attributed with complete certainty to  the Fas lpr mutation in beta-cells. However, given 
that the percentage of the Fas-expressing beta-cell population was increased, and was 
correlated with the onset of diabetes in c-KitWv/+ mice at 8 weeks of age, we are confident 
that the improved beta-cell mass and function was at least partly due to the beneficial 
effect from the Fas lpr mutation in beta-cells of c-KitWv/+;Faslpr/lpr mice. Furthermore, our 
findings showed that the Fas lpr mutation only partially restored beta-cell survival and 
function in c-KitWv/+;Faslpr/lpr mice, indicating that there are other potential mechanisms 
underlying beta-cell destruction that may be triggered by the c-Kit mutation. These 
findings open new avenues for research directed at other apoptotic mediators of cell 
death, such as tumor necrosis factor receptor and tumor necrosis factor-related apoptosis-
inducing ligand receptor. In addition, further research may examine whether beta-cell 
specific c-KIT overexpression is able to block these apoptotic receptors signaling in beta-
cells. 
7.2.3 Chapter 5 
A particular concern is the use of transgene constructs to generate beta-cell-specific gene 
overexpression in vivo. Multiple transgenic lines indicate that the gene directed by RIP is 
not only expressed in beta-cells, but also in regions of the brain, as revealed by the 
presence of fluorescent reporters [30-32]. The brain and islets are linked through the 
neural-entero-islet axis. The brain regulates insulin production from beta-cells, while 
circulating insulin may influence energy balance and metabolism due to its action in the 
hypothalamus. Therefore, targeting gene expression via RIP may yield overlapping 
metabolic phenotypes. In this study, the human c-KIT gene followed by IRES2eGFP 
sequence was inserted into the pKS/RIP plasmid, therefore tissue specificity is achieved 
through the use of RIP allowing for de novo induction of the human c-KIT gene in beta-
cells of c-KitβTg mice. No eGFP signal in the brain was detected using western blot and 
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fluorescence microscopy, but we cannot ignore the potential limitations these methods 
may have. That being said, given that c-KitβTg mice had no changes in body weight, food 
intake or peripheral insulin sensitivity compared to controls, we are confident that 
improved glucose tolerance is associated with the specific overexpression of human c-
KIT genes in beta-cells of c-KitβTg mice. 
Human c-KIT is not structurally identical to mouse c-Kit. Although the C-terminal 
intracellular signaling domain of mouse c-Kit and human c-KIT are 93% homologous, 
their extracellular domains share only 74% homology [33, 34]. For this reason, mouse 
and human c-KIT do not possess identical ligand binding capabilities. This is due to the 
fact that the ligand recognition site of human c-KIT, which is located in the second Ig-
like domain, whereas the binding site of mouse c-Kit lies in the adjacent but 
noncontiguous region of the receptor [33, 34]. Furthermore, mouse SCF has high affinity 
for mouse c-Kit (Kd = 1-5 x 10-9 M), but it has reduced affinity for human c-KIT as 
compared with human SCF [35]. Since c-KitβTg mice contain the human c-KIT gene in 
beta-cells, this approach may raise the question of species specificity of ligand-receptor 
interaction. Nevertheless, c-KitβTg mouse islets showed an up-regulation of the PI3K/Akt 
pathway, which is directly regulated by c-Kit. Our findings indicated that mouse SCF 
was able to activate human c-KIT and exert its biological function, which is consistent 
with previous studies showing that the monovalent binding of mouse SCF to mouse c-Kit 
could induce the formation of human-mouse c-Kit heterodimers through a dimerization 
site in the receptor itself [35].  
Our unpublished data showed that in vitro exposure of INS-1 cells to SCF resulted in 
increased co-localization of c-Kit with insulin receptor, as revealed by double 
immunofluorescence and co-immunoprecipitation. SCF not only stimulated INS-1 cell 
proliferation, but also significantly augmented the protein levels of insulin receptor, 
phospho-insulin receptor substrate 1/2 and Pdx-1. Increased insulin receptor signaling 
was suppressed by wortmannin (PI3K inhibitor) but not U0126 (MEK inhibitor). These 
unpublished findings indicate that there is a potential signaling crosstalk between c-Kit 
and insulin receptor, and this deserves a closer examination for its implication in 
regulating insulin secretion from beta-cells.   
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7.2.4 Chapter 6 
The limitations of this study are similar to those of the studies discussed in Chapter 3 and 
5, specifically in regard to the non-tissue-specific c-Kit Wv mutation or the potential leaky 
expression inherent to the RIP-transgene construct employed in our mouse models. 
Furthermore, the c-KitβTg mouse model is insufficient to determine the direct correlation 
among c-Kit, VEGF-A, and the subsequent islet vascular formation in vivo. A possible 
future study in this line of work is to examine whether changes in VEGF-A concentration 
alter islet endothelial cell growth in an ex vivo model (e.g. stimulation of isolated c-
KitWv/+ mouse islets with VEGF-A) and an in vivo model (e.g. knockdown of VEGF-A 
expression in c-KitβTg mouse islets). 
In this study one interesting observation was that c-KIT overexpression in beta-cells 
enhanced islet angiogenesis in aged 28-week-old c-KitβTg mice. Although the ability of 
isolated c-KitβTg islets to undergo revascularization in vivo is unknown. Therefore, it 
would be interesting to assess the angiogenic capacity of isolated c-KitβTg islets 
following transplantation of these islets in a NOD-SCID mouse model. Another possible 
study is to examine whether a VEGF-A blocker is able to rescue the 
hypervascularization-mediated islet inflammatory response seen in c-KitβTg mice under 
HFD conditions. Findings from these future studies will provide a more comprehensive 
picture of the function of c-Kit in modulating islet vasculature in vivo.   
7.3 Concluding remarks 
In conclusion, the work presented in this thesis has uncovered the mechanisms by which 
c-Kit modulates beta-cell differentiation, survival, and function in vivo. Using the c-
KitWv/+ mouse model, we demonstrated that c-Kit through regulation of the downstream 
Akt/Gsk3β pathway and negatively regulates Fas apoptotic signaling in beta-cells. More 
convincing evidence showing c-Kit has a primary role in beta-cell survival and function 
comes from the beta-cell specific c-Kit overexpressing transgenic mouse model (c-KitβTg 
mice). c-KIT overexpression not only positively influenced beta-cell proliferation and 
insulin secretory function under basal and glucose-stimulated conditions in c-KitβTg mice, 
it also improved beta-cell survival and function protecting beta-cells from the detrimental 
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effects of a HFD. Furthermore, restored c-Kit expression corrected beta-cell failure in c-
KitWv/+ mice. The connection between c-Kit and VEGF-A production in beta-cells was 
also uncovered. Our findings explained the autocrine regulation of islet vascular 
formation by beta-cells and that it is at least partly regulated by c-Kit-mediated VEGF-A 
production through the Akt/mTOR pathway. Taken together, the information provided in 
this work is particularly valuable for advancing our understanding of receptor signaling 
that regulates beta-cell survival and function, and for the future development of effective 
therapies against diabetes. 
7.4 Future directions 
Building on the foundation of this work, further research must be conducted to provide a 
better understanding of SCF/c-Kit signaling in the beta-cells of normal and diabetic 
individuals. Some thoughts regarding the future directions in this line of research are as 
follows: First, multiple c-Kit isoforms that result from alternative splicing. They vary in 
their ability to control the duration, efficiency, and targets of c-Kit signal transduction. 
Moreover, it is important to determine the role of mSCF versus sSCF with respect to c-
Kit signaling and to see if they are distinct qualitatively as well as quantitatively. Future 
work must characterize the distinct functional role of these alternative isoforms of c-Kit 
and SCF in vivo. Second, although highly proliferative c-Kit expressing beta-cells may 
contain a pool of islet progenitors, it should be noted that c-Kit serves as a universal 
marker for the identification and isolation of stem cells from tissue and multiple types of 
cancers. With this in mind, it is necessary to identify these unique islet progenitors 
precisely. Thus, research efforts to develop a specific cocktail of multiple cell surface 
markers would be an asset in identifying these cell populations with greater specificity. 
Third, oncogenic c-Kit mutants promote tumorigenesis in contrast to normal c-Kit. Thus, 
it is important to obtain a complete understanding of the segregation of molecular 
mechanisms underlying mutant and normal c-Kit. This information can be useful in 
uncovering the potential downstream signaling targets necessary to maximize the positive 
effects of c-Kit on islet viability and function, while minimizing the oncogenic effects of 
c-Kit in other normal and neoplastic tissues. Fourth, the propensity of c-Kit-mediated 
insulin release and islet angiogenesis presents several potential long-term adverse effects. 
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For instance, excess insulin release triggered by chronic c-Kit activation on beta-cells 
may lead to hypoglycemia [36]. Additionally, in obese adults with insulin resistance, c-
Kit-mediated islet hypervascularization stimulates an inflammatory response within 
islets, which contributes to a progressive reduction of beta-cell mass and function leading 
to T2D. Therefore, it is essential to optimize the time-dependent effect of c-Kit function 
in preclinical applications when aiming to restore beta-cell survival and function.  
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